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 Mice pretreated with a mild toxic dose of acetaminophen (APAP) 
acquire resistance to a second, higher APAP dose. This phenomenon is 
termed APAP autoprotection and the exact mechanism by which such 
resistance develops is not clearly known. Given the prevalence of APAP-
hepatotoxicity and the human health impact of this potentially hepatotoxic 
agent, a further understanding of the mechanism(s) involved in such 
protection are of considerable significance and could lead to new modalities 
of treatment of acute drug-induced liver injury. The work presented in this 
thesis investigates FMO3 gene expression during APAP-induced liver injury 
as well as the functional significance of FMO3 over-expression during APAP-
induced liver injury. Furthermore, FMO3 gene regulation during oxidative 
stress conditions is also examined.  
 Acetaminophen treatment resulted in up-regulation of liver Fmo3 
protein in male mice. Female mice express higher liver Fmo3 than males and 
are highly resistant to APAP hepatotoxicity. Inhibition of Fmo3, by 
methimazole, renders female mice susceptible to APAP-induced liver injury. 
These findings are suggestive of a protective function for Fmo3. In addition to  
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APAP, ANIT and BDL also increase Fmo3 gene expression in mice. Because 
these hepatotoxicants also induce oxidative stress, we also investigated the 
potential role of the oxidative stress sensor and transcription factor, NRF2, in 
FMO3 gene regulation. Both in vivo and in vitro results show that 
transcriptional regulation of FMO3 might not involve the NRF2-KEAP1 
regulatory pathway.  
 Human liver can adapt to APAP-induced hepatotoxicity similar to our 
APAP autoprotection mouse model. The last part of this dissertation 
examined FMO3 gene induction in a human hepatoma cell line, HepaRG. 
APAP induced FMO3 gene expression in HepaRG cells, and over-expression 
of FMO3 protects cells against APAP-induced cytotoxicity.  The unexpected 
observation of a faster differentiation phenotype in HepaRG cells over-
expressing FMO3 suggests that FMO3 may play an important role in cellular 
differentiation.  
 Collectively, data presented in this thesis provide evidence for Fmo3 
as a novel genetic determinant of APAP-induced liver injury. Furthermore, this 
thesis describes a novel protective function for FMO3. Findings from HepaRG 
cells suggest that FMO3 over-expression in response to APAP may be a 
driving force for differentiation in regenerating hepatocytes.  
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CHAPTER 1 
Review of Literature 
1.1 Liver Function and Structure 
 The structure and function of the liver is well understood. The 
description that follows is adapted from Casarett and Doull’s Toxicology: The 
Basic Science of Poison (Klaassen, 2008), Guyton and Hall: Textbook of 
Medical Physiology (Hall, 2011), and Wheater’s Functional Histology (Young, 
Lowe, Stevens and Heath, 2006). 
Liver Function. The liver’s strategic location between the gastrointestinal 
tract and the rest of the body helps to serve as a checkpoint for substances 
arriving in portal veins. The liver has multiple functions involving nutrient 
homeostasis (processing of carbohydrates, amino acids and lipids); storage 
of glycogen, vitamins and iron; filtration of particulates like bacterial 
endotoxins; protein synthesis including albumin, clotting factors and transport 
proteins; bioactivation and detoxification of xenobiotics; and synthesis and 
secretion of bile and cholesterol. Importantly, the liver is the main organ 
where xenobiotics and endogenous compounds are metabolized into more 
polar, water-soluble derivatives that can be easily excreted into urine and/or 
bile.  
Structural Organization of the Liver. The liver is the largest visceral organ, 
as well as the largest gland in the body, representing 2.5 % of total body 
weight. Blood flow into the liver sinusoids comes from the hepatic portal vein 
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(60-70 %) and hepatic artery (30-40 %). The liver is therefore unusual in 
having both arterial and venous blood supplies as well as a separate venous 
drainage. The liver consists of various cell types: hepatocytes (parenchymal 
cells), sinusoidal lining cells (endothelial cells, Kupffer cells, Ito cells and pit 
cells), hematopoietic cells, nerve cells, and blood and lymphatic vessel cells. 
Hepatocytes are the main functional cells in the liver. The majority of cells 
lining the hepatic sinusoids are endothelial cells that are fenestrated and have 
contractile and metabolic functions. Kupffer cells, which are resident 
macrophages that form part of the monocyte-macrophage defense system, 
phagocytize particles, detoxify endotoxin, secrete mediators of inflammation, 
process antigens, and catabolize lipids and glycoproteins. Ito cells have dual 
functions of vitamin A storage and production of extracellular matrix and 
collagen. Lastly, pit cells are liver-specific natural killer (NK) cells that reside 
mostly near portal veins.  
 The liver is structurally organized into polygon-shaped lobules 
surrounded by connective tissue (Figure 1.1). Each lobule consists of a 
central vein. Cords of hepatocytes and the intervening sinusoids extend 
radially between the central vein and the periphery of the lobule. At the 
corners of the lobule are the portal triads that are made up of a hepatic 
arteriole, portal vein and bile duct. This lobular organization is most easily 
appreciated in sections of pig liver. In human liver, lobules are not as well 
defined by connective tissue although they still contain a central vein and are 
surrounded by portal triads. Blood entering the portal tract via the portal vein 
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and hepatic artery mixes as it enters the sinusoids, percolates along the cords 
of hepatocytes and eventually flows into central veins, and exits the liver via 
the hepatic vein. The lobule is thus divided into three regions known as 
centrilobular, midzonal, and periportal. Even though the structural unit of the 
liver can be considered as a conceptually simple hepatic lobule, the 
physiology of the liver is more precisely represented by a unit structure known 
as the hepatic acinus. The acinus is a roughly berry-shaped liver 
parenchymal unit centered on the portal tract (comprising the terminal 
branches of the portal vein and hepatic artery). The acinus is divided into 
zone 1, 2, and 3. Zone 1 is closest to the portal tract (similar to the periportal 
area) and receives blood rich in oxygen (9-13 %) and nutrients, while Zone 3 
abuts the central vein (coincides with the centrilobular region) and receives 
the least oxygen (4-5 %). Zone 2 is intermediate between Zone 1 and Zone 3 
and coincides with the midzonal region. 
 In addition to the gradient in oxygen concentrations along the hepatic 
sinus, there are gradients in blood bile acid concentrations and 
heterogeneities in protein levels within hepatocytes that generate gradients of 
metabolic functions. For example, mitochondria-rich Zone 1 has high levels of 
oxidative enzymes (fatty acid oxidation), gluconeogenesis and ammonia 
detoxification to urea. Hepatocytes in Zone 3 contain high levels of esterases 
and low levels of oxidative enzymes. Gradients of enzymes involved in the 
bioactivation and detoxification of xenobiotics is seen along the acinus. For 
example, greater amounts of cytochrome P450 proteins (CYP), particularly 
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CYP2E1, are higher in Zone 3, and glutathione (GSH) levels are higher in 
Zone 1. Hepatocytes in different zones exhibit differences in sensitivity to 
chemical toxicity, which are dictated by zonal gradients in GSH, nutrients, 
oxygen, and bioactivation enzymes.  
 Cords of hepatocytes are arranged radially around the central vein with 
bile canaliculi between adjacent hepatocytes. The canaliculi are separated 
from the intercellular space between hepatocytes by tight junctions that are 
permeable to water, electrolytes, and some small organic cations. These tight 
junctions are impermeable to anions such as bile acids (BA), glutathione, and 
bilirubin-diglucuronide resulting in their high concentrations in bile. Canaliculi 
form channels between hepatocytes that connect to a series of ducts in the 
liver. The large extrahepatic bile ducts merge into the common bile duct. Bile 
is modified and stored in the gall bladder before it is released into the 
duodenum. It is important to note that several species including rats do not 
have gall bladders.  
1.2 Hepatic Metabolizing Systems. The liver is the main organ where a 
majority of the xenobiotics are metabolized and eventually excreted. Blood 
from the stomach and the intestine carrying ingested nutrients along with 
drugs and environmental toxicants flow into the portal vein and then through 
the liver before entering the systemic circulation. Hence, the liver is exposed 
to high concentrations of these absorbed compounds. The goal of hepatic 
metabolism is to eliminate endogenous intermediates and exogenous 
chemicals by making it more polar and readily excreted through urine. The 
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mammalian liver is equipped with enzyme systems that perform this function. 
During the past six decades, a large body of knowledge has accumulated 
documenting the role of xenobiotic-metabolizing enzyme systems in the 
mediation of the toxic effects of drugs, environmental pollutants, and some 
endogenous compounds. Here, some of these enzyme systems are briefly 
discussed. 
 Conceptually, the drug metabolizing enzymes involved in xenobiotic-
metabolism or -biotransformation fall into three groups: Phase I, Phase II, and 
Phase III reactions.  Phase I metabolism involves enzymes that catalyze 
hydrolysis, reduction, or oxidation reactions by introducing functional groups 
such as ‐OH, ‐NH2, ‐SH, or ‐COOH. Phase I metabolism usually results in 
a small increase in water solubility. One of the most important enzyme 
systems involved in Phase I metabolism is the microsomal CYP superfamily, 
which to date includes fifty-seven identified enzymes in humans. Other Phase 
I enzymes include flavin-containing monooxygenases (microsomal), 
carboxylesterases, epoxide hydrolases, etc. 
 Phase II conjugation reactions require cofactors (except acetylation 
and methylation reactions) that react with functional groups that are either 
already present on the molecule or are introduced/exposed during Phase I 
metabolism. The Phase II drug metabolizing enzymes catalyze the coupling 
of endogenous small molecules to xenobiotics that usually result in large 
increases in water solubility so that they are more readily excreted. Phase two 
enzymes include members of the UDP-glucuronysltransferase (microsomal), 
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sulfotransferase (cytosolic), and GSH transferase (cytosolic, microsomal and 
mitochondrial).  
 Phase III reactions result in the cellular efflux of polar xenobiotics by 
membrane-bound transporters to either blood or bile. For the purposes of this 
thesis, only three members of the ABCC transport family will be discussed: 
multidrug resistance-associated proteins (Mrp) 2, 3, and 4. Mrp2 is 
predominantly expressed at the hepatocyte canalicular membrane and is 
responsible for the efflux of chemicals and metabolites into bile. Substrates 
for Mrp2 include glucuronide and GSH conjugates. Mrp 3 and 4, on the other 
hand, are basolateral efflux transporters that transport metabolites into the 
blood. Transporters commonly exhibit broad and overlapping substrate 
specificities. 
 The result of xenobiotic biotransformation is typically a reduction in 
lipophilicity and toxicity. However, in some cases, metabolism can produce 
reactive intermediates that can result in an enhancement of toxicity. Some of 
these intermediate metabolites covalently bind to cellular macromolecules 
(proteins and lipids) resulting in oxidative stress and eventually cellular death. 
Examples of xenobiotic activation by CYP enzymes include acetaminophen 
(APAP), carbon tetrachloride, benzene, and benzo[a]pyrene.  
1.3 APAP Hepatotoxicity 
Incidence. Acetaminophen, currently one of the most commonly used 
analgesic and antipyretic agents in the U.S. and Great Britain, was first 
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described more than a century ago. However, APAP-poisoning and APAP-
hepatotoxicity was first recognized in Great Britain (Davidson & Eastham, 
1966) and later in the U.S. (McJunkin et al., 1976). APAP usage increased 
after aspirin was implicated in over 80 % of Reye’s syndrome cases in 
children. As APAP usage increased, the incidence of APAP-induced 
hepatotoxicity also increased. In a retrospective study from 1994 to 1996, 
APAP-induced hepatotoxicity comprised 20 % of acute liver failure (ALF) 
cases in the U.S. (Schiodt et al., 1999). These numbers increased over time 
and by the early 2000s nearly 50 % of ALF cases were due to APAP. Even 
though this fraction has remained fairly constant over the past decade, it is 
still a very prominent leading cause of acute liver failure accounting for more 
that 50 % of all acute liver failure cases from all etiologies (Larson et al., 
2005; W. M. Lee, 2010). The potential for drug-related morbidity and 
mortality, and the popularity of this drug, make it a significant human health 
problem.  
Metabolism. Upon administration of a therapeutic dose of APAP, a majority 
of the parent compound (~90 %) undergoes Phase II metabolism in the liver 
by glucuronidation and sulfation, and the metabolites (APAP-GLUC and 
APAP-SUL) are safely excreted in urine or bile (Nelson, 1990). A small 
portion of APAP (5-15 %) undergoes Phase I metabolism by several 
members of the CYP superfamily including CYP2E1, 1A2, and 3A4. This 
reaction results in the formation of a reactive metabolite, N-acetyl-p-
benzoquinone imine (NAPQI), which by GSH conjugation is effluxed out into 
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the bile (Mitchell et al., 1973; Mitchell et al., 1973; Zaher et al., 1998). The 
GSH conjugate can further undergo cleavage to form a cysteine conjugate 
(APAP-CYS) and subsequent acetylation to the mercapturic acid conjugate 
(APAP-NAC). However, during APAP overdose, the Phase II pathways are 
saturated and a large fraction of the drug undergoes metabolism by CYP 
enzymes, generating more NAPQI. Once GSH stores are depleted, 
unconjugated NAPQI can then exert it’s cytotoxic effect by causing oxidative 
stress, covalent binding to thiol groups on macromolecules and/or lipid 
peroxidation and mitochondrial dysfunction. (Cohen et al., 1997; Jaeschke & 
Bajt, 2006; Patten et al., 1993). 
 Phase III metabolism of APAP includes transport of APAP-metabolites 
into bile or urine for excretion and there is an overlap in metabolite transport 
between transporters. While Mrp2 is responsible for the excretion of APAP-
GLUC conjugate into bile (Chen et al., 2003), Mrp3 is involved in the efflux of 
APAP-GLUC into plasma. Mrp3 has a higher affinity for APAP-GLUC 
compared to Mrp2 (Manautou et al., 2005). Mrp4 and the Breast cancer 
resistance protein (Bcrp) are responsible for the transport of APAP-SUL 
conjugate into plasma and bile, respectively (Zamek-Gliszczynski et al., 2005; 
Zamek-Gliszczynski et al., 2006).  
Protein Covalent Binding in APAP-Induced Cell Injury. As previously 
mentioned, the CYP oxidative metabolite of APAP, NAPQI, is responsible for 
cytotoxic effects of APAP. The earliest effect of NAPQI generation is profound 
depletion of hepatocellular GSH (Mitchell et al., 1973). Once hepatocellular 
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GSH levels are depleted, NAPQI reacts with thiol groups of protein leading to 
protein adducts (Jollow et al., 1973; Potter et al., 1973). Using radioactively 
labeled APAP, studies demonstrated that APAP binds irreversibly to hepatic 
proteins in multiple subcellular compartments, including nucleus, 
mitochondria, endoplasmic reticulum, and cytosol (Jollow et al., 1973; Potter 
et al., 1973). Immunohistochemical studies further identified some of these 
covalently modified proteins that are implicated in APAP-induced liver injury 
(Cohen et al., 1997). Studies also demonstrated that APAP could inhibit 
mitochondrial respiration and increase mitochondrial oxidative stress by 
modifying mitochondrial proteins (Jaeschke, 1990; Meyers et al., 1988). 
Although the covalent binding of proteins and APAP hepatotoxicity occur 
concurrently, APAP-bound proteins are detectable in mice given non-toxic 
doses of APAP. Conversely, antioxidant treatment that prevents APAP 
hepatotoxicity does not alter covalent protein binding. These data suggest 
that covalent binding is required but not sufficient for APAP-induced 
hepatotoxicity.  
Mechanism of Oxidative Stress Mediated Liver Pathophysiology. 
Reactive Oxygen Species (ROS) are produced during metabolism. Under 
normal physiological conditions, these pro-oxidants are detoxified by cellular 
antioxidant systems. When the balance between pro-oxidants and 
antioxidants is disturbed, in favor of ROS generation to the cell’s capacity to 
detoxify them, a state of oxidative stress ensues. During APAP overdose, 
there is a significant elevation of GSH disulphide (GSSG) in cellular as well as 
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mitochondrial compartments of hepatocytes (Jaeschke, 1990; Jaeschke et al., 
2012). Studies show that oxidative stress is an initiating event in APAP 
hepatotoxicity (Bajt et al., 2004; Jaeschke, 2003). Mitochondrial dysfunction 
generates superoxide that reacts with nitric oxide to form a potent oxidant and 
nitrating species, peroxynitrite. Immunohistochemical analysis shows 
formation of lipid peroxide and nitrotyrosine adducts in liver during APAP 
overdose. The oxidative stress caused by ROS and nitrogen species 
increases intracellular calcium levels resulting in the opening of mitochondrial 
membrane permeability transition (MPT) pores (Jaeschke & Bajt, 2006). ROS 
also activates JNK MAPKinase pathway. Activated c-Jun N-terminal Kinase 
(JNK) inactivates anti-apoptotic proteins Bcl-2 and Bcl-xL by phosphorylation. 
The resulting increase in pro-apoptotic proteins results in an increase in 
permeability of the mitochondrial membrane and triggers the release of 
cytochrome C from mitrochondria to cytosol (El-Hassan et al., 2003; Ghosh et 
al., 2010). This combination ultimately results in reduction of cellular 
adenosine-tri-phosphate (ATP) and necrosis of the liver.   
Transporter Expression During APAP-induced Liver Injury. Rodent 
models are extensively used to investigate the mechanisms of APAP-induced 
hepatotoxicity and the effect of APAP on hepatic transport protein expression. 
Mrp2 and P-glycoprotein (Pgp) protein expression increases during APAP-
induced liver injury in rat livers. This increased expression resulted in 
increased biliary elimination of substrates such as dinitrophenyl- S-
glutathione, oxidized glutathione, and digoxin. While the first two are 
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substrates for Mrp2, the latter is a substrate for Pgp (Ghanem et al., 2004). A 
comprehensive analysis of transporter expression performed previously in our 
lab shows that APAP at toxic doses in mice increased expression of 
basolateral (Mrp3, Mrp4) and canalicular (Mrp2) efflux transporters. 
Simultaneously, APAP also decreased expression of basolateral uptake 
transporters such as organic anion transporter polypeptide (Oatp)1a1 and 
1b2 and sodium taurocholate-cotransporting polypeptide (Ntcp) (Aleksunes et 
al., 2006; Campion et al., 2008). Additionally, it was also shown that the 
increased Mrp3 and Mrp4 expression was localized to hepatocytes 
surrounding the central vein, the region where APAP-induced damage is 
localized (Aleksunes et al., 2006). Increases in hepatic efflux transporter 
expression (MRP2, BCRP, MRP4 and MRP5) are also evidenced in human 
liver samples obtained during liver transplantation after APAP overdose 
(Barnes et al., 2007). APAP-GLUC is a substrate for Mrp3 (Manautou et al., 
2005; Slitt et al., 2003) and its altered expression due to toxic APAP pre-
treatment in rats alters the elimination of APAP-GLUC from bile to urine 
(Ghanem et al., 2005). Although the impact of hepatic transport protein 
induction during APAP hepatotoxicity is not clearly known, Aleksunes et al. 
have demonstrated that in a mouse model of resistance to APAP-induced 
hepatotoxicity termed “APAP autoprotection”, there is a significant induction 
of the Mrp4 protein (Aleksunes et al., 2008). Mrp4 induction is localized to the 
hepatocytes surrounding the central vein where proliferation following a mildly 
toxic dose of APAP is confined. Further, colchicine (antimitotic agent) 
	   12	  
treatment blocked the hepatocelluar proliferation around the central vein as 
well as induction of the Mrp4 protein, thus supporting the role of Mrp4 in 
protection from APAP hepatotoxicity (Aleksunes et al., 2008).  
1.4 Liver Injury Models and Mechanisms of Hepatotoxicity 
Allyl Alcohol Hepatotoxicity 
Mechanism of Allyl Alcohol-induced Liver Injury. Allyl alcohol (AlOH) is an 
unsaturated alcohol used in the production of food flavoring agents, fire 
retardants, organic chemicals, drugs, plastics, pesticides, and herbicides. 
Exposure to AlOH occurs primarily in industries where AlOH is produced or 
used. Since exposure to AlOH is limited, it does not pose a significant health 
problem in humans. Today, AlOH serves as a useful experimental tool for 
studying chemical-induced periportal hepatic necrosis (Reid, 1972). AlOH is 
metabolized in the liver by alcohol dehydrogenase to its reactive metabolite, 
acrolein (Badr, 1991). Humans are exposed to acrolein through cigarette 
smoke, automobile exhaust, and oil burning. Acrolein is detoxified by 
aldehyde dehydrogenase to acrylic acid or conjugated to glutathione. The 
glutathione adducts can potentially be converted by CYP enzymes to 
glycidaldehyde, a mutagen & carcinogen that produces oxidative stress and 
lipid peroxidation in periportal hepatocytes. Glycidaldehyde also binds 
covalently to cellular macromolecules leading to hepatocellular injury and 
death (Burcham & Fontaine, 2001; Ohno et al., 1985). While some studies 
suggest that alkylation of cellular proteins by acrolein is the initiating event in 
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hepatotoxicity, some studies also suggest that AlOH-induced hepatotoxicity is 
mediated by lipid peroxidation. The exact mechanisms of AlOH-induced 
hepatotoxicity are not clearly known. However, it is believed that the periportal 
necrosis induced by AlOH targets is due to high oxygen tension in these 
regions, which allows for increased superoxide anion formation and lipid 
peroxidation (Badr, 1991).  
Transporter Expression During AlOH-induced Liver Injury. Our laboratory 
has demonstrated that AlOH treatment decreases expression of uptake 
transporters Oatp1a1 and 1b2 and Ntcp in mice. The reduction is 
accompanied by increases in efflux transporters Mrp1, 2, 4 and 5 (Campion et 
al., 2009). In this study, kupffer cell depletion enhanced AlOH-induced 
hepatotoxicity, while there were no changes in hepatic transporter expression 
(Campion et al., 2009).  
Alpha-naphthylisothiocyanate Hepatotoxicity 
Mechanism of Alpha-Naphthylisothiocyanate-induced Liver Injury. 
Alpha-naphthylisothiocyanate (ANIT) is a hepatotoxicant used to model 
intrahepatic cholestasis in rodents. It produces intrahepatic cholestasis dose 
dependently (Capizzo & Roberts, 1971).  Following oral administration, ANIT 
reaches the liver through the portal vein. In the hepatocytes, ANIT is 
conjugated with glutathione and transported into bile by the canalicular efflux 
transporter, Mrp2. Upon crossing the canalicular membrane, the ANIT‐GSH 
conjugate dissociates, yielding free GSH and ANIT in the bile. ANIT 
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selectively causes damage to the bile duct epithelial cells leading to 
cholestasis (Dietrich et al., 2001).   
Transporter Expression During ANIT-induced Liver Injury. In mice, ANIT 
decreases the expression of uptake transporters Ntcp, Oatp1a1, and 
Oatp1b2, and increases expression of efflux transporter Mrp3, Organic solute 
transporter β (Ostβ), Multidrug resistance protein 2 (Mdr2), Mrp2 and 
ATPase, aminophospholipid transporter, class I, type 8B, member 1 (Atp8b1) 
(Cui et al., 2009). Nuclear receptors, farnesoid X receptor (FXR) and 
pregnane X receptor (PXR) regulate expression of hepatic uptake 
transporters, basolateral, as well as canalicular transporters during ANIT 
treatment. Nuclear receptor FXR regulates the canalicular and basolateral 
transporters bile salt export pump (Bsep), Mdr2, Mrp2, Atp8b1, and Ostβ, 
while PXR regulates Mrp2 (Cui et al., 2009). While Mrp3 expression in 
response to ANIT treatment is regulated by oxidative stress responsive 
transcription factor Nrf2 alone, Bsep mRNA expression is regulated by both 
Nrf2 and FXR (Cui et al., 2009; Tanaka et al., 2009).  
Biliary Obstruction Cholestasis  
Mechanism of Bile Duct Ligation-induced Liver Injury. Obstructive 
cholestasis is a complex disease characterized by decreased or impaired bile 
flow resulting in increased biliary pressure, impaired excretion or 
accumulation of bile salts and various other organic anions within 
hepatocytes, oxidative stress and subsequent activation of proinflammatory 
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cytokines. Common bile-duct ligation (BDL) is used to model extrahepatic 
obstructive cholestasis in rodents. After BDL, the liver accumulates BAs and 
other compounds such as bilirubin and bilirubin-glucuronide leading to liver 
injury. Eventually, bile acid levels increase in liver, plasma, and urine.  
Transporter Expression During BDL-induced Liver Injury. Transporters 
transport BAs both from blood into liver and from liver into bile. Ntcp and 
Oatps (Oatp1a1, 1a4 and 1b2) transport BAs into the liver, while transporters 
such as Mrp2 and Bsep transport BAs out of the liver into bile, and Mrp3, 
Mrp4 and Ostα/β transport BAs from liver into blood. BDL decreases 
expression of hepatic uptake transporters such as Ntcp and Oatp1a1 and the 
reduction corresponds to lower uptake of taurocholate in rat hepatocytes 
(Gartung et al., 1996; Geier et al., 2005). In mice similar to rats, BDL 
decreases expression of uptake transporters Ntcp, Oatp1a1, and 1b2 as well 
as increases expression of efflux transporters Mrp1, 3, 4, and 5 (Slitt et al., 
2007). It is suggested that a decrease in uptake transporters is an adaptive 
mechanism that will extract less BA from blood into liver thus reducing BA 
levels in the hepatocytes. Similarly, up-regulation of efflux transporters during 
BDL decrease BA levels in hepatocytes by enhancing clearance of bile acids 
into the blood and urine.  
Carbon Tetrachloride Hepatotoxicity  
Mechanism of Carbon Tetrachloride-induced Liver Injury. Carbon 
tetrachloride (CCl4), a non-polar solvent, was used for industrial and home 
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use as a cleaning agent, degreasing agent, fire extinguisher, etc. Exposure to 
CCl4 results in severe hepatotoxicity or nephrotoxicity, hence it is banned or 
severely restricted from usage. Currently, CCl4 is used as a model 
hepatotoxicant to study the mechanisms of liver injury such as fatty 
degeneration, fibrosis, hepatocellular death, and carcinogenicity (Weber et 
al., 2003). In the liver, CCl4 is bioactivated into tricholoromethyl radical (˙CCl3) 
by Cyp (Cyp2e1, Cyp2b1 and Cyp2b2) dependent systems (Gruebele et al., 
1996). This ˙CCl3 radical readily reacts with oxygen to form a more reactive 
free radical, trichloromethylperoxyl radical (CCl3OO˙). Free radicals generated 
can also bind covalently to Cyp2e1 resulting in suicide inhibition. The toxic 
effect mediated by CCl3OO˙ includes oxidation of membrane polyunsaturated 
fatty acids resulting in lipid peroxidation. CCl3OO˙ can also covalently bind to 
microsomal proteins, nucleic acids, and lipids resulting in generation of 
superoxide and hydroxyl radicals (Tom et al., 1984). Lipid peroxidation alters 
membrane permeability of cellular and subcellular structures resulting in loss 
of cellular calcium and uncoupling of oxidative phosphorylation leading to 
cellular degeneration and necrosis. The antioxidant defense machinery is also 
affected following exposure to this toxin.  
Transporter Expression During CCl4-induced Liver Injury. Similar to drug 
metabolizing enzymes, transporters exhibit zonal distribution patterns. In rats, 
basal expressions of Mdr mRNA and protein levels are higher in zone 1 and 
lowest in zone 3. Following exposure to CCl4, Mdr1b and Mdr2 expression 
increases in zone 1 and gradually extends to zone 3 (Nakatsukasa et al., 
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1993). Expression of some basolateral transporters such as Oatp1, 4, and 
Ntcp decreases in rats exposed to CCl4 (Geier et al., 2002). Blockage of 
TNFα signaling using the inhibitor etanercept inhibits CCl4-induced 
downregulation of Oatp1a1, Oatp1a4, and Ntcp mRNA supporting the 
concept that proinflammatory cytokines are one of the key regulators of 
organic anion transporters (Geier et al., 2003). Previous work in our 
laboratory reported a simultaneous increase in expression of sinusoidal efflux 
(Mrp1 and Mrp4) and canalicular transport proteins (Mrp2) as well as a 
decrease in expression of Ntcp and Mrp3 proteins in mice in response to CCl4 
treatment (Aleksunes et al., 2006). This coordinated induction of efflux 
transport proteins and reduction of uptake carriers suggests an adaptive 
response by the liver for elimination of xenobiotics and oxidative stress 
products that are generated during CCl4-induced liver injury.  
1.5 Nrf2 Signaling Pathway 
 Oxidative stress is a steady-state level of oxidative damage in a cell, 
tissue, or organ caused by reactive oxygen species (ROS). ROS are 
transiently formed during the normal course of cellular metabolism, and 
elevated levels damage cellular macromolecules including proteins, lipids, 
mitochondrial, and nuclear DNA. Cells possess defense systems that protect 
against oxidative stress. In prokaryotes, the transcription factors oxygen 
response (OxyR) and superoxide response (SoxRS) sense the redox status 
of the cell and during oxidative stress induce expression of defensive genes 
(Zheng & Storz, 2000). Eukaryotic cells have similar mechanisms to protect 
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against oxidative stress. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2 or 
NFE2L2), heat shock protein (Hsp) activator protein 1 and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) promote cell survival, 
whereas activation of JNK, p38 kinase, and tumor protein-53 (TP53) lead to 
cell cycle arrest and apoptosis.  
 Nrf2 belongs to the cap ‘n’ collar family of transcription factors that 
share a conserved basic region-leucine zipper (bZIP) structure. Nrf2 was 
identified during a screen for proteins that bind to the control region of the β-
globin gene (Moi et al., 1994). Unlike p45-NF-E2 that is expressed only in 
blood cells such as megakaryocyte, erythroid, and mast cells, Nrf2 is present 
in a wide variety of tissues including liver, lung, intestine, and kidney.  
Negative Regulation of Nrf2 Mediated by Keap1. Under basal conditions, 
Nrf2 is largely bound to the cytoskeletal anchoring protein Kelch-like ECH-
associated protein 1 (Keap1), also known as cytosolic Nrf2 inhibitor (INrf2) in 
the cytoplasm. Keap1 exists as a dimer and retains Nrf2 in the cytoplasm.  
Serine 104 of Keap1 is required for dimerization of Keap1, and mutations in 
serine 104 leads to disruption of the Keap1 dimer and release of Nrf2 (Zipper 
& Mulcahy, 2002). Amino acid sequence and domain structure-function 
analyses show that Keap1 has broad-complex, tramtrack, bric-a-brac (BTB) / 
poxvirus, zinc finger (POZ) domain, Kelch domain also known as the double 
glycine repeat (DGR) domain, N-terminal region (NTR), Intervening region, 
and C-terminal region (CTR) (Figure 1.2). The BTB/POZ domain serves as an 
adapter for the cullin 3/ring box 1(cul3/Rbx1) E3 ubiquitin ligase complex and 
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promotes ubiquitination of Nrf2 (Kaspar et al., 2009). On the other hand, the 
DGR/Kelch domain binds to actin, allowing the scaffolding of Keap1 to the 
actin cytoskeleton, which plays an important role in Nrf2 retention in the 
cytosol. Thus, Keap1 is responsible not only for sequestering Nrf2, but also 
for its normal proteosomal targeting and degradation.  
Cytoplasmic Retention of Nrf2. Two nuclear export signals in the leucine 
zipper and transactivation domains of Nrf2 are responsible for cytoplasmic 
localization of Nrf2. One of these nuclear export signals is redox sensitive and 
can be disabled in the presence of ROS allowing Nrf2 to translocate into the 
nucleus (Aleksunes & Manautou, 2007). Evidence also suggests that 
phosphorylation of Nrf2 is important for dissociation of Nrf2 from Keap1. More 
recently, it has been demonstrated that phosphorylation and 
dephosphorylation of tyrosine 141 in Keap1 regulate its stability and 
degradation, respectively. It is also shown that modification of critical 
cysteines (Cys 151, Cys 273, and Cys 288) in Keap1 lead to a change in the 
conformation of the BTB domain by means of perturbing the 
homodimerization site, disrupting Neh2 ubiquitination and causing 
ubiquitination of Keap1 (Kaspar et al., 2009). The switch of ubiquitination from 
Nrf2 to Keap1 leads to Nrf2 nuclear accumulation.  
Antioxidant Response Element and Nrf2. Ubiquitination of Keap1 occurs in 
response to a variety of stimuli. Following ubiquitination of Keap1, Nrf2 is 
released that translocates into the nucleus. The nuclear localization signal in 
the basic region of Nrf2 stimulates its nuclear translocation. The basic region 
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is also responsible for DNA binding, and the acidic region of Nrf2 is required 
for transcriptional activation (Jaiswal, 2004). In the nucleus, Nrf2 binds to the 
GTGACA***GC core sequence of antioxidant response element (ARE) 
(Rushmore et al., 1991) and regulates ARE-mediated antioxidant gene 
expression (Figure 1.3). ARE-mediated transcriptional activation requires 
heterodimerization of Nrf2 with other bZIP proteins, including Jun (c-Jun, Jun-
D, and Jun-B) and small Maf (MafG, MafK, and MafF) proteins. 
 The aforementioned Keap1:Nrf2 regulatory pathway is generally 
thought to dictate subcellular localization of Nrf2 and activity. However, 
questions regarding how Nrf2 maintains constitutive transcription of drug 
metabolizing enzymes have prompted researchers to put forth alternative 
models of Nrf2 signaling. One hypothesis includes the constitutive targeting of 
de novo Nrf2 protein to the nucleus. In this model, there is continuous 
shuttling of Keap1/cul3/Rbx1 complex into the nucleus, and this nuclear 
import is mediated by Prothymosin- α (Niture & Jaiswal, 2009). This complex 
inside the nucleus exchanges prothymosin-α with Nrf2 resulting in 
degradation of Nrf2 (Kaspar et al., 2009).  
 Other regulatory mediators of Nrf2 include Bach1, which is a 
transcription repressor. Bach1 heterodimerizes with small Maf proteins in the 
absence of cellular stress and represses gene expression. In the presence of 
oxidative stress, Bach1 is released from the Maf proteins and is replaced by 
Nrf2. The activation of a delayed mechanism involving glycogen synthase 
kinase 3β (GSK3β) controls the switching off of gene transcription by Nrf2 
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activation. GSK3β is a serine/threonine kinase that phosphorylates Fyn (a 
tyrosine kinase) leading to nuclear localization of Fyn. Fyn phosphorylates 
Nrf2 resulting in nuclear export of Nrf2, binding with Keap1, and degradation 
of Nrf2 (Kaspar et al., 2009).  
Activation of Nrf2-Keap1 Regulatory Pathway in Liver Injury Models 
Nrf2 and APAP-induced Hepatotoxicity. Nrf2 knockout mice are more 
susceptible to APAP-induced liver injury compared to their wild-type 
counterparts (Chan et al., 2001; Enomoto et al., 2001). This susceptibility of 
Nrf2 knockout mice to APAP hepatoxicity is attributed to altered phase1 and 
phase 2 metabolism of APAP in the liver, where Nrf2 knockout livers exhibit 
lower Ugt1a6 activity, which is a detoxification pathway for APAP (Enomoto et 
al., 2001). It is also demonstrated that Nrf2 knockout mice have an 85 % 
lower Nqo1 activity compared to wild-type mice (Reisman et al., 2009). On 
the other hand, mice with Keap1 deficient livers exhibit resistance to APAP-
induced hepatotoxicity compared to Nrf2 knockout mice as well as their wild-
type counterparts (Okawa et al., 2006; Reisman et al., 2009). Higher nuclear 
accumulation of Nrf2 in Keap1 knockout livers markedly enhances the 
constitutive expression of genes regulated by Nrf2 such as NAD(P)H:quinone 
oxidoreductase-1 (Nqo1) (about 415 % compared to wild-type), glutathione S-
transferase (Gst), and glutamate cysteine ligase catalytic subunit (Gclc) 
(Okawa et al., 2006; Reisman et al., 2009).  
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 A low toxic APAP dose causes nuclear accumulation of Nrf2 in CD-1 
mouse livers (Goldring et al., 2004). Nrf2 nuclear translocation in these mice 
is accompanied by increased expression of Nrf2 dependent genes such as 
heme oxygenase-1 (Hmox1) and Gclc. Similar studies confirmed the 
induction of Nrf2 dependent genes Nqo1 and Hmox1 in liver (Aleksunes et al., 
2005; Aleksunes et al., 2006; Bauer et al., 2000; Chiu et al., 2002). NQO1 
induction is also reported in human liver samples obtained from patients 
during transplantation following APAP overdose (Aleksunes et al., 2006). 
Taken together, Nrf2 not only regulates expression of enzymes that 
metabolize APAP, but also alters the detoxification mechanism involved 
during APAP-induced hepatotoxicity. 
Nrf2 and AlOH-induced Hepatotoxicity. Liu et al. have demonstrated the 
Nrf2 role in protection against AlOH-induced liver injury using Nrf2-null, 
Keap1-knockdown (Keap1-KD), and Keap1-hepatocyte knockout (Keap1-
HKO) mice called “graded Nrf2 activation” model (Liu et al., 2013). While 
there was lower plasma ALT activity in Keap1-HKO mice following AlOH 
treatment, plasma ALT activity was not detectable in Keap1-KD mice. 
Furthermore, Nrf2-null mice showed increased plasma ALT activity compared 
to wild-type controls. Collectively, it can be concluded from this study that 
Nrf2 activation confers moderate protection against AlOH-induced 
hepatotoxicity in mice (Liu et al., 2013).   
Nrf2 and ANIT-induced hepatotoxicity. ANIT causes intrahepatic 
cholestasis and activates Nrf2 (Tanaka et al., 2009). This is evidenced by 
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Nrf2 translocation and Nqo1 mRNA and protein induction. Surprisingly, the 
authors did not see any difference in degree of liver injury in both wild-type 
and Nrf2-null mice following ANIT treatment. This response was attributed to 
compensatory alteration in Shp and Hnf1α signaling in Nrf2 knockout mice. 
Activation of Nrf2 by oltipraz in Nrf2 knockout mice protected against ANIT-
induced liver injury (Tanaka et al., 2009).  
Nrf2 and BDL-induced Hepatotoxicity. Cholestasis resulting from BDL 
increased Nqo1 gene expression in mouse liver, and this increase is Nrf2-
dependent (Aleksunes et al., 2006). Consistent with this, Yamamoto’s group 
showed that Nrf2 activation protects against BDL-induced liver injury in 
Keap1-knockout mice, an animal model for Nrf2-activation (Okada et al., 
2009). In spite of the lack of Nqo1 induction in Nrf2 knockout mice liver, BDL 
in Nrf2 knockout mice did not result in significant elevations of ALT activity 
(Aleksunes et al., 2006; Weerachayaphorn et al., 2012). This discrepancy is 
attributed to the adaptive compensatory changes involving nuclear 
transcription factors, including Fxr, Shp, Pxr, efflux bile acid transporters, 
altered GSH levels, and bile flow rates in Nrf2 knockout mice 
(Weerachayaphorn et al., 2012). These multiple adaptations lessen the 
susceptibility of Nrf2 knockout mice to BDL-induced liver injury. While the 
levels of various isoforms of Gst’s, Gclc, and Gclm increase from day 1 to day 
7 after BDL (Aleksunes et al., 2006; Yang et al., 2009), this transient increase 
is followed by a fall to below baseline by day 14 that persists up to day 28 
(Yang et al., 2009). This lack of expression of GSH synthetic enzymes during 
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the later stages of cholestasis was shown to be due to the fall in Nrf2 nuclear 
binding activity to ARE (Yang et al., 2009). Collectively, these studies 
demonstrate the influence of Nrf2 on the regulation of bile acid homeostasis 
in the liver as well as protection against BDL-induced liver injury.  
Nrf2 and CCl4-induced Hepatotoxicity. CCl4 treatment results in induction of 
oxidative stress (Ho-1) and detoxification (Nqo1) genes at 6 h and 24 h, 
respectively (Aleksunes et al., 2005). A later report by Randle et al. 
demonstrated that CCl4 administration results in Nrf2 nuclear translocation at 
1 h, while severe hepatic necrosis was evident 24 h later (Randle et al., 
2008). As expected, in this study Nrf2 nuclear translocation was accompanied 
by induction of Hmox1 24 h after CCl4 administration (Randle et al., 2008). 
The Nrf2 role in CCl4-induced liver injury is further supported by the CCl4 
study in Nrf2-null mice (Liu et al., 2013). In this study, Nrf2-null mice are more 
susceptible to CCl4-induced hepatotoxicity compared to Keap1-KD or Keap1-
HKO mice. The Nrf2-mediated protection is attributed to induction of 
antioxidant genes, suppression of inflammatory responses, and attenuation of 
oxidative stress in the livers (Liu et al., 2013).  
1.6 APAP Autoprotection 
 An experimental approach to modulate APAP hepatotoxicity in rodents 
is through auto/heteroprotection. Autoprotection is resistance to toxicant re-
exposure following acute, mild injury with the same toxicant, whereas in 
heteroprotection, the initial toxicant used is different from the second.  
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Mehendale and his colleagues first demonstrated autoprotection in rats in the 
early 1990’s with carbon tetrachloride (CCl4) (Thakore & Mehendale, 1991). 
Previous studies conducted in our laboratory have demonstrated both 
auto/heteroprotection in mice and that pre-treatment with various chemicals 
reduce the severity of APAP toxicity in mice (Aleksunes et al., 2008; 
Manautou et al., 1994). For instance, Manautou et al. show that peroxisome 
proliferators such as clofibrate at subtoxic doses protect rodents from APAP 
toxicity (APAP heteroprotection) (Manautou et al., 1994). Alternatively, APAP 
at a mild toxic dose protects mice against hepatotoxicity from higher doses of 
APAP (APAP autoprotection) (Aleksunes et al., 2008). This model of APAP 
autoprotection was used to investigate the role of hepatobiliary drug 
transporters during the development of resistance to APAP hepatotoxicity. In 
this study, an increased expression of the sinusoidal efflux transporter Mrp4 is 
evidenced in the hepatocytes localized to centrilobular areas where 
compensatory hepatocellular proliferation following pre-treatment with mildly 
toxic doses of APAP is confined. The protection occurs independently of 
changes in bioactivation or detoxification of APAP.  
 The phenomenon of autoprotection is also seen in patients who are 
repeatedly exposed to supratherapeutic doses of APAP. Shayiq et al., while 
describing the incremental dose model of APAP autoprotection in mice, 
introduced a clinical case where a physician addicted to prescription pain 
medication reported tolerance to the combination product (containing opiod 
and APAP) (Shayiq et al., 1999). The physician claimed to have consumed 
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200 tablets per day in the later stages of his addiction (about 65 g APAP) with 
no apparent liver damage. Another later study demonstrated a similar 
phenomenon, where healthy adults given 4 g APAP per day over a period of 
14 days showed elevations in plasma ALT activity around day 7 to 8 that 
decreased by day 14 (Watkins et al., 2006). This shows an adaptation to 
hepatocyte injury during repeated exposure to APAP. These clinical evidence 
supports evaluation of mechanisms underlying APAP autoprotection.  
Gene Expression Profiling in APAP Autoprotection Model 
 The utility of gene array analysis to address mechanistic toxicology 
questions has been demonstrated in our lab (Moffit et al., 2007). Even though 
our previous study demonstrated the role of the drug transporter Mrp4 in 
APAP autoprotection (Aleksunes et al., 2008), a gene array analysis was 
performed to identify any other differentially expressed genes resulting from 
APAP pre-treatment that might also contribute to the development of 
resistance to APAP hepatotoxicity upon re-exposure to this toxicant. A gene 
array analysis revealed statistically significant genes unique to the APAP 
autoprotection mouse model (mice pretreated and re-exposed to APAP) and 
further analysis of these genes using the causal reasoning engine (CRE) 
provided insights into the signaling pathways involving autoprotection 
(O'Connor et al., 2014). Out of several noteworthy genes that were identified 
to be differentially expressed in APAP autoprotected mice, Fmo3 was one of 
them.  
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1.7 Flavin-containing Monooxygenase-3 
 Flavin-containing monooxygenase (FMO) is one of the major 
microsomal monooxygenase enzyme systems located in the membrane of 
the endoplasmic reticulum. Mammalian FMO is an NADPH-dependent and 
oxygen-dependent microsomal FAD-containing enzyme system that functions 
as a nitrogen, sulfur, and phosphorus oxygenase (Rettie & Fisher, 1999).  
Discovery of FMO Enzymes. Miller and his co-workers in the 1960’s 
reported that liver microsomes contained enzymes that catalyzed the 
NADPH- and O2-dependent oxidation of butter yellow and a number of other 
azo dyes (Miller et al., 1960). Later, Ziegler studied the nature of enzymes 
catalyzing the mixed function oxidation reactions. N-oxidation of N, N-
dimethylaniline was selected as a model reaction to characterize enzymes in 
liver microsomes and a high activity was observed in microsomes isolated 
from pig liver. The Ziegler lab further purified the enzyme that catalysed the 
NADPH- and O2-dependent N-oxidation of N, N-dimethylaniline in 1972 from 
pig liver (Ziegler & Mitchell, 1972). This enzyme was called “mixed-function 
amine N-oxidase” or “Ziegler’s enzyme” until 1979. Shortly after the isolation 
of the enzyme from pig liver, Jollow and Cook demonstrated that it catalyzed 
oxygenation of a wide range of xenobiotics that had no common structural 
features (Ziegler et al., 1971; Ziegler & Poulsen, 1998). The list includes 
inorganic and organic compounds and some of these compounds contain 
functional groups bearing sulfur or selenium instead of nitrogen. Since the 
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name “mixed-function amine N-oxidase” was restrictive, the enzyme was 
given the name flavin-containing monooxygenase, abbreviated as FMO. 
Biochemical Properties Unique to FMOs. 
Thermal Stability and NADPH. With the exception of FMO2, placement of 
microsomes in an argon environment at 55°C for 1 min in the absence of 
NADPH decreases FMO activity by 85 % or more, while CYP activity is 
reduced by 15 % or less (Cashman, 1999). NADPH stabilizes FMO activity 
(Cashman, 1999).  
Effect of Detergent. The FMO activity increases at Triton X-100 
concentrations between 0.05-0.5 %. At concentrations above 0.5 %, the 
enzyme activity decreases (Brunelle et al., 1997). Sodium cholate and fatty 
acid at a low concentration inhibit FMO1 and FMO3, while sodium cholate at 
a high concentation (1 %) does not inhibit FMO2 function (Krueger & 
Williams, 2005).  
Effect of pH. The optimal pH for animal and human FMO-mediated N- and S-
oxygenation is generally equal to or above pH 9.0. On the other hand, 
maximum CYP activity is seen at pH 7.4 (Cashman, 1999).   
Formation of a Relatively Stable Hydroperoxyflavoprotein Intermediate. 
Among the flavoproteins that exist, FMO is distinct in its ability to form a 
relatively stable hydroperoxyflavin intermediate. This is because the protein 
environment of the FMO and the presence of NADPH protect the hydroperoxy 
species from decomposing, reacting with apoprotein or disproportionating into 
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reactive oxygen species. Thus, it does not expose the cell to the untoward 
effects of oxidative stress. However, in the absence of NADPH, peroxyflavin 
can decompose to hydrogen peroxide resulting in significant loss of enzyme 
activity (Cashman, 1999).  
Metabolite Prediction. Barring steric constraints, the metabolite produced by 
an FMO of a particular substrate can be predicted based on the oxidation 
product produced from the treatment of substrate with alkyl hydroperoxides or 
peracids (Cashman, 1999).  
Approaches to Distinguish Between FMO- and CYP-mediated 
Metabolism.  
 The similarities and differences between the FMO and CYP enzymes 
are summarized in Table 1.1. FMO and CYP have overlapping substrate-
specificity. There are a number of in vitro approaches to distinguish CYP 
activity from that of FMO. 
Thermal Inactivation. Heating the enzyme up to 50°C for 1 min in the 
absence of NADPH results in the loss of 85 % of FMO activity, while retaining 
85 % of CYP activity (Cashman, 2005). 
pH of Incubation Mixture and Detergents. Performing microsomal 
incubations at pH 8.4 to 9.4 generally abrogates CYP activity (Cashman, 
2005). The presence of high concentrations of Emulgent 911 also abrogates 
CYP activity (Cashman, 2005). Thus, solubilization of microsomes using 
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detergents at elevated pH is another approach to selectively examine FMO 
activity (Cashman, 1999).   
NADPH and Enzyme-mediated Reactions. FMO-dependent reactions are 
initiated by the addition of substrate to a previously pre-equilibrated 
microsomal preparation containing NADPH, while CYP-dependent reactions 
are initiated by the addition of NADPH (Cashman, 1999).  
Metal Ions. FMO is relatively sensitive to metal ions, thus incubations should 
be carried out in the absence of MgCl2 and in the presence of a chelating 
agent (Cashman, 1999).  
Inactivation of prosthetic group. While CYPs can be inactivated via 
saturation of heme prosthetic group by carbon monoxide, FMOs are 
unaffected by carbon monoxide (Krueger & Williams, 2005). 
Inhibitors.  
• Chemical inhibitors: FMO inhibitors include methimazole (MMI), 
thiourea and indole-3-carbinol (I3C), whereas CYP inhibitors include N-
benzylimidazole, aminobenzotriazole, and proadifen hydrochloride 
(SKF-525). 
• Immunological inhibitors: Antibodies directed against FMOs and 
NADPH-P450 reductase. 
Molecular Biology Tools. Recombinant FMO and CYP enzymes. 
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The Potential of Chemical Inhibitors in vivo and Knockout Mouse Lines. 
In rodents, pretreatment with MMI or I3C has been demonstrated to block 
FMO-mediated conversion of various compounds (Nace et al., 1997). MMI is 
not a specific inhibitor, and inhibits thyroid peroxidase along with FMO. The 
reactive intermediate of MMI metabolism, sulfenic acid, also inhibits CYP 
activity. On the contrary, I3C induces CYP enzymes (Katchamart & Williams, 
2001). These problems associated with FMO-inhibitor usage for evaluating 
the FMO role in drug metabolism in vivo can be overcome by use of 
engineered knockout mouse lines. To date, only one Fmo knockout mouse 
line has been produced and this knockout mouse line lacks genes encoding 
Fmo1, Fmo2, and Fmo4. Because the expression of Fmo3 in male mouse 
liver is switched off during development, male mice are essentially void of the 
Fmo3 protein. In the absence of functional Fmo3 protein in normal male mice, 
there has been no need for developing a knockout model (Hernandez et al., 
2009; Shephard & Phillips, 2010).  
The Mechanism of Catalysis. FMO and CYP both require NADPH and O2 as 
cofactors for its catalytic activity. The mechanism of reactions catalysed by 
FMO is different from that of the CYP-mediated metabolism. In CYP-mediated 
metabolism, the first step is the addition of substrate to the enzyme, and 
electron transfer follows this from the flavoprotein NADPH-CYP reductase to 
the substrate-bound CYP. The catalytic cycle of FMO is shown in Figure 1.4. 
In contrast to CYP, the first step in FMO-mediated metabolism is reduction of 
the FAD by NADPH. This step is followed by the formation of a relatively 
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stable intermediate, C4α-hydroperoxyflavin, by the addition of a molecular 
oxygen to the reduced FAD. Therefore, when substrate is accepted by FMO, 
the enzyme is in an active form (i.e. a cocked gun) ready to effect 
oxygenations. CYP forms an unstable ferrous-O2 complex that is capable of 
decomposing to generate superoxide anion or hydrogen peroxide. 
Oxygenation by FMO proceeds through an attack of the nitrogen atom (or any 
other nucleophilic heteroatom) on the terminal hydroperoxyflavin oxygen atom 
to produce the N-oxygenated substrate and the hydroxyflavo enzyme 
species. Thus, one atom of molecular oxygen is transferred to the substrate 
and the second to form water. The rate-limiting step of the catalytic cycle is 
thought to be the breakdown of the FADOH pseudobase or the release of 
NADP+. As this occurs after the substrate transformation, substrate binding 
has no influence on Vmax (Cashman, 1999; Cashman, 2005).  
FMO Ontogeny and Tissue Specificity in the Mouse and Humans. FMO 
enzymes exhibit tissue-, species-, gender- and age-specificity in expression. 
FMOs are expressed in the liver, lung, kidney, intestine, and brain. For the 
purpose of this thesis, FMO expression in mouse liver will be discussed in 
comparison to human liver. Cherrington et al. examined hepatic Fmo1, Fmo3, 
and Fmo5 ontogeny in CD-1 mouse liver by western blotting and this was 
quantified in a review by Hines (Cherrington et al., 1998; Hines, 2006). 
Hepatic Fmo3 is undetectable at day 2 after birth in both male and female 
mice. By day 14 after birth, the Fmo3 protein is detectable in both sexes and 
is approximately about 50 % of adult female levels. On day 42 (young adult 
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age), there is a gender-dependent dimorphism apparent, where male mice 
express undetectable levels and female mice express very high levels of 
hepatic Fmo3. This is consistent with other reports that show gender-
dependent dimorphism with respect to liver Fmo3 levels in B6C3F1 mice 
(Ripp et al., 1999) as well as 129/SV mice (Janmohamed et al., 2004). Fmo5 
on the other hand is expressed at very low levels in the fetus at gestation day 
17, and by day 2, the levels are at adult values. Unlike Fmo3, no gender-
dependent dimorphism is seen with Fmo5. Fmo1 is detectable on gestation 
day 15, and by day 17 of gestation, the levels reach adult values. By young 
adult age, a gender-dependent dimorphism in liver Fmo1 expression is 
evident, where male mice express detectable but lower Fmo1 compared to 
females (Cherrington et al., 1998; Hines, 2006). Janmohamed et al. reported 
tissue specificity and ontogeny of liver FMO mRNA levels in the 129/SV 
mouse strain, measured by RNase protection assay and in situ hybridization 
(Janmohamed et al., 2004). In this study, it was demonstrated that Fmo5 
expression in female mouse liver is about 2- to 3-fold higher than Fmo3, 
which in turn is 2-fold higher than Fmo1. On the contrary, hepatic Fmo3 is 
expressed at undetectable levels in adult male mice. Little or no Fmo2 and 
Fmo4 expression is seen in both sexes (Janmohamed et al., 2004). There is 
a gradient for FMO expression in liver where Fmo1 and Fmo5 show a 
decreasing concentration gradient from central vein to periportal areas. 
Conversely, Fmo3 mRNA in female liver is localized to the periportal region. 
Consistent with this, our results from immunohistochemical staining for the 
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Fmo3 protein in female C57BL/6J mice livers also show a similar staining 
pattern (Rudraiah et al., 2014).  
 FMO1 is the predominant FMO in fetal human liver, whereas FMO3 is 
predominant in adults (Koukouritaki et al., 2002). Dolphin et al. provided the 
first evidence of a developmental switch from FMO1 to FMO3 in human liver 
(Dolphin et al., 1996). Although this study was the first to suggest a hepatic 
FMO developmental switch in humans, Koukouritaki et al. demonstrated a 
detailed ontogeny in FMO enzyme expression, and also that the FMO1 and 
FMO3 are independently regulated during development (Koukouritaki et al., 
2002).   
FMO Substrates Specificity. Different FMO enzymes exhibit broad and 
overlapping substrate specificity. This property is in part attributed to the 
formation of C4α-hydroperoxyflavin intermediate in the absence of the 
substrate. Substrate specificity is determined more by access to the activated 
flavin as opposed to specific binding at the active site (Hines, 2006; Poulsen 
& Ziegler, 1995).  
 FMO1, 2, and 3 oxygenate a wide variety of nucleophilic tertiary and 
secondary amines as well as sulfur-containing compounds compared to 
FMO4 and FMO5. FMO5 has restricted substrate-specificity because it does 
not form a stable intermediate (Ziegler, 2002). The substrate-specificity of 
FMO5 is poorly defined, although is apparently distinct from FMO3. Because 
of their limited substrate specificity and low expression levels in most tissues 
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in humans, FMO4 and FMO5 currently are not thought to play an important 
role in drug metabolism (Krueger & Williams, 2005).  
In general, structural requirements for FMO substrates are as follows 
(Krueger & Williams, 2005): 
• Any compound that contains a soft nucleophile and that is accessible 
to the C4α-hydroperoxyflavin intermediate can be a substrate. 
• Compounds containing a single positive charge are excellent 
substrates (e.g., cationic tertiary amines). 
• Negatively charged compounds are poor substrates with a few 
exceptions, such as sulindac sulfide and lipoic acid. 
• Zwitterions and compounds with more than one positive charge are 
typically not substrates.  
Few examples for FMO substrates are presented in Table 1.2. 
Transcriptional Regulation of FMO. Mammalian FMOs were considered 
non-inducible by xenobiotics (Cashman & Zhang, 2002; Krueger & Williams, 
2005). Thus, the transcriptional regulation of FMO involving stress activated 
transcription factors or a receptor that binds ligand and interacts with DNA 
was not studied as other forms of regulation. However, recent studies by 
Celius et al. show that activation of the Aryl hydrocarbon (Ah) receptor by 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces Fmo3 mRNA in mice, 
with marginal changes in protein levels (Celius et al., 2008; Celius et al., 
2010). Authors also show that the Fmo3 mRNA up-regulation by 3-
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methylcholanthrene (3MC) and benzo(a)pyrene (BaP) but not TCDD in Hepa-
1 cells is mediated by p53 and its binding to a p53-response element in the 
promoter region of Fmo3 (Celius et al., 2010).  
 The hormonal effects on FMO activity have been described. Adult 
female mice livers exhibit higher Fmo3 activity compared to male mice. 
Gender-related differences in mouse liver Fmo3 activity are shown to be due 
primarily to testosterone-dependent repression of the enzyme in male mice 
(Duffel et al., 1981). Rat liver FMO is positively regulated by testosterone and 
repressed by estradiol (Cashman & Williams, 1990; Cashman & Zhang, 2006; 
Lemoine et al., 1991). Diurnal cortisol secretion also regulates FMO activity in 
female mice (Dixit & Roche, 1984). In pregnant rabbits, plasma concentration 
of progesterone and corticosterone is shown to regulate lung Fmo2 mRNA 
and protein levels at day 15 and 28-31 (Hines et al., 1994). In cultured rat 
hepatocytes, lipopolysaccharide and proinflammatory cytokines treatment 
decreased FMO1 mRNA levels via a cGMP-independent destabilizing effect 
of nitric oxide rather than decreased transcription (Ryu et al., 2004). 
 In humans, Lou and Hines demonstrated that hepatocyte nuclear 
factor (HNF) 1α and HNF4α positively regulate, while Yin yang (YY1) 
negatively regulate FMO1 expression (Luo & Hines, 2001). An upstream SNP 
was also identified within the conserved core binding sequence for the YY1. 
Transient expression assays showed that this SNP in YY1 could account for 
two- to three-fold loss of FMO1 promoter activity, and genotype analysis 
showed individuals of Caucasian, African, and Hispanic descent had 11 %, 13 
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% and 30 % frequency, respectively (Hines et al., 2003). Klick and Hines also 
demonstrated that binding of transcription factors such as nuclear factor-Y 
(NF-Y), upstream stimulatory factor 1 (USF1), YYI and an unidentified GC 
box to the regulatory domains upstream of the transcription start site are 
important for constitutive FMO3 transcription regulation (Klick & Hines, 2007). 
The pre-B-cell leukemia factor 2 (Pbx2) as a heterodimer with an unidentified 
homeobox (Hox) isoform contributes to FMO3 developmental- and tissue-
specific regulation (Klick & Hines, 2007). A later study by the same group 
identified another element, CCAAT enhancer-binding protein β (C/EBPβ), as 
being more distal to the transcription start site and this is shown to be 
important for FMO3 developmental expression pattern (Klick et al., 2008). 
Shimuzu et al. reported that HNF-4 and NF-Y could play crucial roles in 
modulating the activity of the FMO3 expression in the Japanese population 
(Shimizu et al., 2008).  
Post-transcriptional Regulation of FMO. Post-transcriptional regulation of 
FMO is not well understood. For example, not much is known about 
enhancement of FMO mRNA stability or mechanisms regulating the stability 
of FMO mRNA transcripts. Recent reports by Celius et al. showed an 
increase in miRNA following TCDD treatment in C57BL/6J mice livers (Celius 
et al., 2008). In silico analysis further predicted binding sites on mouse Fmo3 
mRNA for the up-regulated miRNAs (mmu-miR203 and mmu-148a). The 
authors concluded that a modest increase in FMO catalytic activity evidenced 
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following TCDD treatment, in spite of a large increase in Fmo3 mRNA, is due 
to targeted degradation of mRNAs by miRNAs (Celius et al., 2008).  
 FMOs have a consensus sequence for N-glycosylation, and mass 
spectrometry studies have shown that FMO1 is selectively N-glycosylated at 
Asn 120 (Korsmeyer et al., 1998). The highly conserved nature of this site 
suggests that this region could be important in a structural or functional role in 
enzyme action, but cDNA expression of FMOs in bacterial expression 
systems show that enzyme activity does not require N-glycosylation 
(Cashman & Zhang, 2006).  
Physiological functions of FMO. The function of FMO is described 
previously and is involved in the oxygenation of endogenous compounds and 
xenobiotics. The importance of mammalian FMO in xenobiotic metabolism is 
known, while its physiological role has not yet been identified, except for TMA 
N-oxygenation. Trimethylamine (TMA) is an odorous compound formed by 
gut bacteria and is responsible for a fish odor. In humans, a mutation in the 
FMO3 results in failure to efficiently N-oxygenate TMA, leading to a genetic 
disease known as trimethylaminuria.  
 FMO is involved in oxygenation of sulphur-containing endogenous 
substrates such as cysteamine (reduced form) to cystamine (disulfide form) 
(Poulsen, 1981).  Although the physiological role of cysteamine S-
oxygenation by Fmo3 is not clear, in the 1970s, Ziegler and Poulsen 
suggested a role for FMO in protein disulphide bond formation through 
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oxidation of cysteamine. It was also proposed that oxygenation of cysteamine 
may be a significant source of disulphide, maintaining the cellular 
thiol:disulphide potential in a cell (Ziegler et al., 1979). Further, Suh and 
Robertus showed that yeast FMO serves as a modulator of cellular thiols and 
maintains optimum redox potential within the endoplasmic reticulum, allowing 
for proper folding of disulfide bond- containing proteins (Suh & Robertus, 
2002).  
 The cytoprotective functions of Fmo3 and its possible involvement in 
APAP autoprotection are summarized below. However, this is entirely 
speculative at this point. The relationship between cellular thiol:disulphide 
ratios and the regulation of metabolic reactions has been recognized for a 
long time (Barron, 1953). Oxygenation of cysteamine during APAP 
hepatotoxicity may serve to help control the overall thiol:disulphide redox 
state of the cell, which in turn may modulate cellular metabolism and/or 
activate signal transduction pathways leading to altered susceptibility to 
APAP (or protection). It is also possible that oxygenation of cysteamine to 
cystamine by Fmo3 and transport out of the cell may represent a detoxication 
mechanism or protective function, since cysteamine is toxic to cells at 
concentrations as low as 39 µM through the transition metal-dependent 
formation of hydrogen peroxide (Jeitner & Lawrence, 2001).  
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1.8 Summary 
 The project described in this thesis originated from a gene array 
analysis on the APAP autoprotected mice livers performed previously. One of 
the differentially expressed genes identified during analysis is Fmo3. For a 
long time, Fmo3 was considered non-inducible by xenobiotics. Thus, the 
mechanism(s) underlying Fmo3 gene induction by a xenobiotic is not well 
studied. Apart from its role in drug metabolism and fish odor syndrome, the 
physiological functions of Fmo3 are not currently known. The goal of this 
project was to investigate the mechanistic role of Fmo3 gene expression 
during APAP-induced hepatotoxicity. The results presented in this dissertation 
show Fmo3 mRNA and protein induction during APAP hepatotoxicity in mice. 
To verify that Fmo3 gene induction is not model-specific, Fmo3 gene 
expression in other mouse models of hepatic injury was also investigated. 
Since a common event for all hepatotoxicants tested is oxidative stress, the 
oxidative stress transcription factor Nrf2 role in FMO3 gene expression was 
examined. Similar to APAP autoprotection mouse model, human liver 
acquires resistance to supratherapeutic doses of APAP. HepaRG cells were 
employed to evaluate whether APAP-induced cytotoxicity induces FMO3 
gene expression. The functional significance of FMO3 over-expression during 
APAP hepatotoxicity was also evaluated both in vivo and in vitro. 
 In conclusion, this thesis clearly demonstrates Fmo3 as a genetic 
determinant of APAP toxicity. Although many hepatotoxicants that result in 
oxidative stress induces Fmo3 gene expression, both in vitro and in vivo 
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studies demonstrate that FMO3 gene expression does not involve activation 
of the NRF2-KEAP1 regulatory pathway. Results from human cell line studies 
show that FMO3 over-expression alters susceptibility to APAP-induced 
hepatotoxicity and that FMO3 may play an important role in cellular 
differentiation. The cellular differentiation phenotype appears to be important 
because the only gene altered in this cell line is FMO3 and differentiation is 
happening in the absence of multiple gene expression changes that would 
result in response to APAP (as in the autoprotection mouse model). With the 
recent advancements showing a relationship between FMO3 gene expression 
in humans, and the risk of atherosclerosis as well as ischemic stroke, a 
complete understanding of the FMO3 over-expression function appear to be 
important. This work not only emphasizes FMO3’s novel protective function, 
but also its unexplored facets of function.  
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Figure 1.1. Scheme showing structural organization of the liver lobule.  
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Figure 1.2. Schematic drawing of various domains of Nrf (Nrf1, Nrf2, Nrf3) 
and Keap1/INrf2 (Kaspar et al., 2009).  
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Figure 1.3. A schematic representation of Nrf2-mediated gene transcription 
(Bataille & Manautou, 2012). 
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Figure 1.4. A schematic representation of catalytic cycle of FMO. S: 
Substrate, S-O: Oxygenated substrate, Enz(Flox): Oxidized flavoprotein, 
Enz(FlH2): Enzyme in reduced form, Enz(FlOOH): C4α-hydroperoxyflavin of 
FAD, Enz(FlHOH): Hydroxyflavin of FAD (Cashman, 1995).  
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Table 1.1 Similarities and differences between the FMO and CYP (Cashman, 
2005; Hodgson et al., 1999).  
 
  
FMO 
 
CYP 
 
Co-substrates NADPH, O2 NADPH, O2 
Coupled enzymes None 
NADPH-P450 reductase 
Cytochrome b5 * 
Cellular location Microsomes Microsomes, mitochondria 
Xenobiotic inducers 
AhR activators 
(TCDD)** 
(Celius et al., 2008 and 
2010).  
 
Many, e.g. Phenobarbital, 
TCDD 
 
Inhibitors 
Competitive substrates, 
only 
Competitive substrates and 
mechanism based inhibitors, 
e.g.SKF525A, piperonyl 
butoxide 
Isoforms 
Few, only 11 known 
currently. FMO6 to 
FMO11 are 
pseudogenes in humans 
(Hines, 2006). 
Many, over 3000 known 
currently 
Substrates 
Some inorganics, 
organic compounds with 
N, S, Se, P heteroatoms 
Organic compounds with 
and without N, S, Se, P 
heteroatoms 
Oxygenation 
FMO oxygenates 
compounds via a two-
electron mechanism 
Oxidizes compounds via a 
sequential one-electron 
processes 
Toxicity of 
metabolites 
Usually non-toxic 
Greater prevalence for 
generation of toxic 
metabolite 
 
* Cytochrome b5 is required only for some CYP isoforms and for 
some substrates 
** Activation of the Aryl hydrocarbon receptor (AhR) induces Fmo3 
mRNA in mice, but with marginal changes in protein levels. 
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Table 1.2 Substrates for FMO. Taken from (Hodgson et al., 1995; Krueger & 
Williams, 2005; Ziegler, 1988).  
 
 
Substrate Example 
Endogenous substrates 
Sulfur-containing Cysteamine, Methionine, Lipoic acid, 
S-farnesylcysteine, S-cysteine 
conjugates, selenocysteine 
conjugates 
Nitrogen-containing Trimethylamine, Tyramine, 
Phenethylamine 
Exogenous substrates 
Sulfur-containing Cimetidine, Albendazole, Sulindac 
sulfide, Methimazole, Ethionamide,  
Nitrogen-containing Imipramine, Clozapine, Tamoxifen, 
Chloro- and Bromo-pheniramine, 
Zimeldine, Ranitidine, Benzydamine, 
Olopatadine, Xanomeline, Pargyline, 
Itopride, Nicotine 
Phosphorus-containing Fonofos, Diethylphenylphosphine, 
Fenthion 
Selenium-containing 2-selenylbenzanilide 
Inorganics HS-, I-, I2 
Boronic acid  
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CHAPTER 2 
Tolerance to Acetaminophen Hepatotoxicity in the Mouse Model of 
Autoprotection is Associated With Induction of Flavin-containing 
Monooxygenase-3 (FMO3) in Hepatocytes 
2.1 Abstract 
 Acetaminophen (APAP) pretreatment with a hepatotoxic dose (400 
mg/kg) in mice results in resistance to a second, higher dose (600 mg/kg) of 
APAP (APAP autoprotection).  Recent microarray work by our group showed 
a drastic induction of liver flavin containing monooxygenase-3 (Fmo3) mRNA 
expression in our mouse model of APAP autoprotection. The role of liver 
Fmo3, which detoxifies xenobiotics, in APAP autoprotection is unknown. The 
purpose of this study was to characterize the gene regulation and protein 
expression of liver Fmo3 during APAP hepatotoxicity. The functional 
consequences of Fmo3 induction were also investigated. Plasma and livers 
were collected from male C57BL/6J mice over a period of 72 h following a 
single dose of APAP (400 mg/kg) to measure Fmo3 mRNA and protein 
expression. Although Fmo3 mRNA levels increased significantly following 
APAP treatment, protein expression changed marginally. In contrast, both 
Fmo3 mRNA and protein expression were significantly higher in APAP 
autoprotected livers. Unlike male C57BL/6J mice, female mice have about 80-
times higher constitutive Fmo3 mRNA levels and are highly resistant to APAP 
hepatotoxicity. Co-administration of APAP with the FMO inhibitor 
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methimazole rendered female mice susceptible to APAP hepatotoxicity, with 
no changes in susceptibility detected in male mice. Furthermore, a human 
hepatocyte cell line (HC-04) clone over-expressing human FMO3 showed 
enhanced resistance to APAP cytotoxicity. Taken together, these findings 
establish for the first time induction of Fmo3 protein expression and function 
by xenobiotic treatment. Our results also indicate that Fmo3 expression and 
function plays a role in protecting the liver from APAP-induced toxicity. 
Although the mechanism(s) of this protection remains to be elucidated, this 
work describes a novel protective function for this enzyme.  
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2.2 Introduction 
 Acetaminophen (APAP) overdose is a leading cause of acute liver 
failure in the U.S. and Great Britain, accounting for more than 50 % of all 
acute liver failure cases from all etiologies (Larson et al., 2005; W. M. Lee, 
2010). APAP is safe at therapeutic doses, where the majority of APAP 
administered is glucuronidated or sulfated and the metabolites are safely 
excreted into the urine and bile. Under these conditions, a small amount of 
APAP also undergoes bioactivation by cytochrome P450 metabolism to 
generate N-acetyl-p-benzoquinone imine (NAPQI), a reactive metabolite that 
can be detoxified by hepatic glutathione (GSH). However, when NAPQI is 
produced in large amounts, as in the case of APAP overdose, GSH stores are 
depleted and NAPQI reacts with intracellular thiols, binds covalently to cellular 
macromolecules, and produces oxidative stress, which ultimately results in 
necrosis of centrilobular hepatocytes (Cohen et al., 1997; Hinson et al., 
2010). The growing concern over APAP-induced hepatotoxicity has prompted 
extensive research aimed at devising measures to reduce the risk of APAP 
heptotoxicity.  
 An experimental approach to modulate APAP hepatotoxicity in rodents 
is through auto/heteroprotection. Autoprotection is resistance to toxicant re-
exposure following acute, mild injury with the same toxicant, whereas in 
heteroprotection, the initial toxicant used is different from the second.  
Mehendale and his colleagues first demonstrated autoprotection in rats in 
early 1990’s with carbon tetrachloride (CCl4) (Thakore & Mehendale, 1991). 
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Previous studies conducted in our laboratory have demonstrated both 
auto/heteroprotection in mice and that pre-treatment with various chemicals 
can reduce the severity of APAP toxicity in mice (Aleksunes et al., 2008; 
Manautou et al., 1994). For instance, Manautou et al. showed that 
peroxisome proliferators such as clofibrate at subtoxic doses protect rodents 
from APAP toxicity (APAP heteroprotection) (Manautou et al., 1994). 
Alternatively, APAP at a mild toxic dose protects mice against hepatotoxicity 
from higher doses of APAP (APAP autoprotection) (Aleksunes et al., 2008). 
This model of APAP autoprotection was used to investigate the role of 
hepatobiliary drug transporters during the development of resistance to APAP 
hepatotoxicity. In this study, an increased expression of the sinusoidal efflux 
transporter Mrp4 (Multidrug resistance-associated protein 4) is evidenced in 
the hepatocytes localized to centrilobular areas where compensatory 
hepatocellular proliferation following pre-treatment with mildly toxic doses of 
APAP is confined. The protection is shown to occur independently of changes 
in bioactivation or detoxification of APAP.  
 The utility of gene array analysis to address mechanistic toxicology 
questions has been demonstrated in our lab (Moffit et al., 2007). Even though 
our previous study demonstrated the role of the drug transporter Mrp4 in 
APAP autoprotection (Aleksunes et al., 2008), a gene array analysis was 
performed to identify any other differentially expressed genes resulting from 
APAP pre-treatment that might also contribute to the development of 
resistance to APAP hepatotoxicity upon re-exposure to this toxicant. Gene 
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array analysis revealed statistically significant gene expression changes 
unique to the APAP autoprotection mouse model (mice pretreated and re-
exposed to APAP) and further analysis of these genes using causal 
reasoning engine (CRE) provided insights into the signaling pathways 
involved in autoprotection (O'Connor et al., 2014). Of several noteworthy 
genes that were identified to be differentially expressed in APAP 
autoprotected mice, Fmo3 is one of them. Fmo3 is unique in a way that it is 
considered non-inducible (Cashman & Zhang, 2002), but Fmo3 mRNA 
expression increased 20- and 7-fold at 4 and 24 h in the autoprotected group, 
respectively (O'Connor et al., 2014). Although a role of Fmo3 in APAP 
hepatotoxicity is not known, it was the most biologically plausible for playing a 
role in autoprotection.  
 Fmo3 is a monooxygenase involved in drug-metabolism somewhat 
similar to cytochrome P450 (CYP) in that it produces many of the same 
metabolites, although its substrate specificity is much more limited. Fmo3 is 
not known to metabolize APAP and most metabolic products of Fmo3 are 
considered to be non-toxic (Krueger & Williams, 2005). Hepatic expression of 
the Fmo3 gene is highly variable showing cell-, tissue-, gender- and 
developmental stage-specific expression patterns (Hines, 2006; Janmohamed 
et al., 2004; Koukouritaki et al., 2002). Mammalian Fmo3 is also considered 
to be non-inducible (Cashman & Zhang, 2002). However, recent studies by 
Celius et al. showed that activation of the Aryl hydrocarbon (Ah) receptor 
induces Fmo3 mRNA in mice, with marginal changes in protein levels (Celius 
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et al., 2008; Celius et al., 2010). To our knowledge, the current study is only 
the second to document xenobiotic-dependent Fmo3 induction, the 
importance of which is unknown. Further, the role of Fmo3 in APAP-induced 
hepatotoxicity and/or autoprotection also is not known.  However, it is 
intriguing that female mice, which contain approximately 80-times more 
hepatic Fmo3 mRNA than males (Janmohamed et al., 2004), are much more 
resistant to APAP hepatotoxicity compared to their male counterparts (Dai et 
al., 2006).  
 The initial studies reported herein describe Fmo3 gene expression 
during APAP-induced hepatotoxicity. To better understand an Fmo3 role in 
protection against APAP hepatotoxicity, we further attempted to establish a 
causal relationship between the two, i.e., Fmo3 gene expression and APAP 
hepatotoxicity. Thus, the functional significance of Fmo3 over-expression 
during APAP hepatotoxicity was evaluated. To date, there are no 
commercially available Fmo3-specific knockout mice because the expression 
of this enzyme in male mouse liver is switched off during development and 
male mice are essentially void of Fmo3 protein. In the absence of functional 
Fmo3 protein in normal male mice, there has been no need for developing a 
knockout model (Hernandez et al., 2009; Shephard & Phillips, 2010). As an 
alternative model to low Fmo3 function, inhibition of Fmo3 activity in female 
mice was achieved using the FMO inhibitor, methimazole. Methimazole 
(MMI), an antithyroid drug, is an FMO substrate and also a competitive 
inhibitor that has been used to block FMO-mediated conversion of various 
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compounds in animal models (Nace et al., 1997). Fmo3 and Fmo5 are among 
the most abundant FMO enzymes in female mouse liver and MMI is not a 
substrate for Fmo5 (Cherrington et al., 1998; Hines, 2006; Overby et al., 
1995; Zhang et al., 2007). Thus, with MMI, among all FMO enzymes, Fmo3 
was predominantly inhibited. Taking advantage of this observation, we could 
test the hypothesis that MMI inhibition of Fmo3 renders female mice 
susceptible to APAP-induced hepatotoxicity. In addition to the in vivo Fmo3 
inhibitor study, we also developed an in vitro transgene over-expression 
system. We have established for the first time a stable cell line (Human 
hepatocyte HC-04) that over-expresses human FMO3 protein. Using this 
system, we could test the hypothesis that enhanced expression of FMO3 
confers resistance against APAP-induced cytotoxicity. 
 FMO is involved in the oxygenation of sulphur-containing endogenous 
substrates, e.g., catalyzing the conversion of cysteamine (reduced form) to 
cystamine (disulfide form) (Poulsen, 1981).  Although, the physiological role 
of cysteamine S-oxygenation by Fmo3 is not clear, in the 1970s Zieglar and 
Poulsen proposed that oxygenation of cysteamine may be a significant 
source of disulphide, maintaining the cellular thiol:disulphide potential in a cell 
(Ziegler et al., 1979). Upregulation of Fmo3 during APAP-induced 
hepatotoxicity and oxygenation of cysteamine by Fmo3 may serve to help 
control the overall thiol:disulphide redox state of the cell, which in turn may 
modulate cellular metabolism and/or activate signal transduction pathways 
leading to altered susceptibility to APAP (or protection). To reiterate, the 
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objective of the current investigation was to characterize the gene regulation 
and protein expression of liver Fmo3 during APAP-induced hepatotoxicity. 
The functional consequences of Fmo3 induction were also investigated. To 
our knowledge, this is the first report describing a novel protective function for 
this drug-metabolizing enzyme.  
2.3 Materials and Methods 
Chemicals  
 Acetaminophen, propylene glycol, methimazole and reduced GSH 
were purchased from Sigma-Aldrich (St Louis, MO). All other reagents were 
of reagent grade or better.  
Animals 
 Male and female C57BL/6J mice, 9-10 week old, were obtained from 
Jackson Laboratories (Bar Harbot, ME). Upon arrival, mice were acclimated 
for one week prior to experimentation. Mice were housed in a 12 h dark/light 
cycle in a temperature and humidity controlled environment. Mice were fed 
laboratory rodent diet (Harlan Teklad 2018, Madison, WI) ad libitum.  
 Dosing regimen 1. Following an overnight fast, male mice (n=6) were 
treated with APAP (400 mg/kg, ip) in 50 % propylene glycol (PG) or vehicle. 
Animals were sacrificed 24, 48 and 72 h after APAP treatment. Plasma and 
liver were collected for measuring alanine amino transferase (ALT) activity, 
Fmo3 mRNA and protein levels and enzyme activity.  
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 Dosing regimen 2. Following an overnight fasting male mice (n=6) 
were treated with APAP (400 mg/kg, ip) in 50 % PG or vehicle. Animals were 
treated with APAP (600 mg/kg, ip) in 50 % PG or vehicle, 48 h after the first 
treatment. Animals were sacrificed and plasma and liver were collected after 
24 h for analysis.  
 Dosing regimen 3. Following an overnight fast, female mice (n=6) were 
administered a single dose of methimazole  (MMI) (50 mg/kg, ip) in saline. 
Animals were sacrificed and plasma and livers were collected at 0.5, 4, 12 
and 24 h for analysis of hepatotoxicity and GSH content. A single group of 
mice received a first dose of MMI (50 mg/kg, ip) and 12 h after the first dose, 
mice were treated with a second dose of MMI (50 mg/kg, ip). Plasma and liver 
were collected 12 h later for analysis. 
 Dosing regimen 4. Following an overnight fasting female or male mice 
(n=6) were administered vehicle (saline) or MMI (50 mg/kg, ip). Animals were 
treated with APAP (400 mg/kg, ip), 30 min later. The group receiving two 
doses of MMI along with APAP received the first dose of MMI 30 min prior to 
APAP treatment and the second dose of MMI at 12 h after the first dose. Mice 
in the group receiving only the second MMI dose were treated with MMI 11.5 
h after APAP treatment. At 24 h after APAP treatment, animals were 
sacrificed and plasma and liver were collected for measuring ALT activity and 
GSH levels in this group of mice.   
 All animal studies were performed in accordance with National Institute 
of Health standards and the Guide for the Care and Use of Laboratory 
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Animals. This work was approved by the University of Connecticut’s 
Institutional Animal Care and Use Committee.  
Alanine Aminotransferase (ALT) Assay 
 Plasma ALT activity was determined as a biomarker of hepatocellular 
injury. Infinity ALT Liquid Stable Reagent (Thermo Fisher Scientific Inc., 
Waltham, MA) was used to determine ALT activity. Samples were analyzed 
using a Bio-Tek Power Wave X Spectrophotometer.  
RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR) 
 TRIzol reagent (Life Technologies, Carlsbad, CA) was used to extract 
total mouse liver RNA. cDNA was then made using an M-MLV RT kit 
(Invitrogen, Carlsbad, CA). Fmo3 mRNA expression was quantified by the ΔΔCT method and normalized to two housekeeping genes, β-actin and 
ribosomal protein S18. Data presented in this manuscript were normalized to β-actin. Primer pairs were synthesized by Integrated DNA Technologies 
(Coralville, IA) and are as follow: Fmo3 forward: 5′-GGA AGA GTT GGT 
GAA GAC CG-3′, reverse: 5′-CCC ACA TGC TTT GAG AGG AG-3′. 
Amplification was performed using an Applied Biosystems 7500 Fast Real-
Time PCR System. Amplification was carried out in a 20 μL reaction volume 
containing 8 μL diluted cDNA, Fast SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA) and 1 μM of each primer.   
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Preparation of Crude Membrane and Microsomal Fractions 
 Microsomes were isolated from livers as described previously 
(Cashman & Hanzlik, 1981). Briefly, livers were homogenized in cold 
homogenization buffer (0.1 M potassium phosphate, 0.1 mM dithiothreitol 
(DTT), 2 % sucrose, pH 9.0) and homogenates were centrifuged at 10,000 x 
g for 20 min at 4°C. The supernatant was then centrifuged at 100,000 x g for 
60 minutes. The resulting pellet was washed and resuspended in 0.1 M 
potassium phosphate buffer (pH 9.0) containing 1 mM EDTA and stored at -
80°C. Protease inhibitor was added to all buffers before use. Protein 
concentration was determined by the method of Lowry using Bio-Rad protein 
assay reagents (Bio-Rad Laboratories, Hercules, CA).  
Western Blot Analysis 
 For western blot analysis of Fmo3, microsomal proteins (10 μg) were 
electrophoretically resolved using 10 % polyacrylamide gels and transferred 
onto PVDF-Plus membrane (Micron Separations, Westboro, MA). A custom-
made rabbit anti-mouse Fmo3 primary antibody (GenScript USA Inc., NJ) was 
used to detect Fmo3 with β-Actin as a loading control. Extensive 
characterization of the reactivity and/or specificity of this antibody was carried 
out. The antibody developed was specific for mouse Fmo3 protein.  Blots 
were then incubated with HRP conjugated secondary antibodies against 
rabbit IgG. Protein-antibody complexes were detected using a 
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chemiluminescent kit (Thermo Scientific, IL) followed by exposure to X-ray 
film.  
Enzyme Assay 
 Methimazole (MMI) metabolism was determined 
spectrophotometrically by measuring the rate of MMI S-oxygenation via the 
reaction of the oxidized product with nitro-5-thiobenzoate (TNB) to generate 
5,5’-dithiobis(2-nitrobenzoate) (DTNB). The incubation mixture consisted of 
50 mM sodium phosphate buffer (pH 9.0), 0.5 mM NADP+, 0.5 mM glucose-
6-phosphate, 1.5 IU/mL glucose-6-phosphate dehydrogenase, 0.06 mM 
DTNB, 0.04 mM DTT and 100 to 150 μg/mL liver microsomes isolated from 
mice. Reactions were initiated by the addition of different amounts of MMI 
(substrate) and range of MMI concentrations used were between 1.25 and 
800 μM. Incubations were done in duplicates. The disappearance of the 
yellow color was measured spectrophotometrically at 412 nM and specific 
activity (µM/min/mg) was determined using the molar extinction coefficient of 
NADPH (28.2 mM-1cm-1).  
Immunohistochemistry 
 Immunohistochemical detection of Fmo3 protein was performed on 5 μm liver sections from tissues fixed in 10 % neutral-buffered zinc formalin 
followed by routine processing, paraffin embedding, sectioning and 
rehydration. Antigen retrieval was performed via microwave (950 watt) 
method in 10 mM sodium citrate buffer for 2 minutes at 100 % power and at 
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30 % power for another 8 minutes. Endogenous peroxidase activity was 
blocked with a 10 min incubation in 3 % H2O2, and avidin/biotin blocking was 
performed using a commercially available kit from Vector Laboratories 
(Burlingame, CA). Sections were incubated overnight with the previously 
mentioned anti-mouse Fmo3 primary antibody at a dilution of 1:8000 followed 
by Vector Laboratory’s biotinylated goat anti-rabbit secondary antibody for 30 
min. Protein-antibody complexes were detected with the Vector Elite ABC 
reagent and developed using a Vector ®Nova RED substrate kit for 
peroxidase. Slides were counterstained with hematoxylin, and mounted in 
“Protocol” mounting media (Fisher Scientific, IL). 
GSH Assay  
 Total hepatic GSH concentrations were determined by the recycling 
method as previously described (Rahman et al., 2006). Briefly, 15-25 mg of 
liver tissue was added to 500 μL of 5 mM EDTA disodium salt in 0.1 M 
potassium phosphate buffer containing protease inhibitors. Tissues were kept 
on ice and homogenized by hand in a dounce homogenizer for 5-6 strokes. 
Equal volumes of 0.67 mg/mL 5,5′ -dithio-bis(2-nitrobenzoic acid) (DTNB) 
and 3.33 units/mL glutathione reductase (Sigma Aldrich, St. Louis, MO) in 0.1 
M potassium phosphate buffer containing 5 mM EDTA disodium salt were 
mixed and 120 μL was added to 20 μL of each liver homogenate in a 96 well 
plate. Sixty μL of 0.67 mg/mL β-NADPH (Sigma) in 0.1 M potassium 
phosphate buffer containing 5 mM EDTA disodium salt was then added to 
each well. Absorbance was read immediately at 412 nm, taking 
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measurements every 30 seconds for 2 minutes. The assay was performed in 
duplicate for each sample and compared to a standard curve made from two 
fold serial dilutions (211.2 nmol/mL to 1.65 nmol/mL) of a GSH standard 
(Sigma).  
Histopathology 
 Liver samples were fixed in 10 % neutral-buffered zinc formalin prior to 
processing and paraffin embedding. Liver sections (5 μm) were stained with 
hematoxylin and eosin. Sections were examined by light microscopy for the 
presence and severity of necrosis and degeneration using an established 
grading system (Manautou et al., 1994).  
Lentiviral Vector Construction  
 The FMO3-T2A-luc lentiviral transfer vector was constructed by 
modifying the FUdeltaGW-rtTA (obtained from K. Hochedlinger via Addgene, 
Cambridge, MA, plasmid 19780) to replace the rtTA insert with a polylinker 
designed to accommodate the human FMO3 ORF (Clone ID: 5175615 from 
Open Biosystems, Waltham, MA). To allow for bicistronic expression of FMO3 
and luciferase, sequence encoding the T2A peptide (Szymczak et al., 2004) 
was inserted into the polylinker. The luciferase ORF from pGL4.10 vector 
(Promega, Madison, WI) was cloned in frame with FMO3 and the T2A 
sequence. Luciferase activity was used to normalize levels of FMO3 over-
expression. 
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Cell Culture and Transduction 
 The replication-defective virus was generated in HEK 293T cells and 
concentrated as previously described (Maherali et al., 2008). HC-04 cells 
were seeded 24 h prior to transduction in complete DMEM medium and then 
infected with a series of volumes of untitered concentrate (100 µL, 50 µL, and 
25 µL per well of a 6 well culture dish) overnight. Prior to, during, and after the 
viral transduction, the cells were maintained in complete DMEM containing 
0.05 mM riboflavin. Media was changed daily to prevent riboflavin 
degradation.  
Cell Culture and Treatment 
 HC-04 cells over-expressing human FMO3 (hFMO3-HC-04) and empty 
vector (EV-HC-04) were maintained in DMEM supplemented with 10 mM 
glucose, 10 % FBS, 0.05 mM riboflavin and 1 % antibiotic-antimycotic (100 
units/mL penicillin G sodium, 100 µg/mL streptomycin sulfate, and 0.25 µg/mL 
amphotericin B) in a 5 % CO2 and humidified environment (95 % relative 
humidity) at 37°C. For APAP treatments, cells were seeded at 200,000 cells 
per well in a 24-well plate. The following day, culture media was replaced with 
media containing APAP (1 mM to 15 mM). Twenty-four hours later, 
cytotoxicity was measured by the LDH assay. For MMI treatments, cells were 
seeded at 200,000 cells per well in a 24-well plate. The next day, cells were 
incubated in media containing 1 mM MMI for 30 min at 37°C. Thirty minutes 
following incubation with MMI, culture media containing 15 mM APAP was 
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added to wells. Cytotoxicity was measured using the LDH assay kit 24 h later. 
  
LDH Leakage 
 As a measure of cytotoxicity following APAP treatment, percent lactate 
dehydrogenase (LDH) leakage in all in vitro experiments was determined via 
the Tox-7 kit. The assay was performed according to manufacturer’s 
instructions (Sigma-Aldrich, St. Louis, MO). 
Statistical Analysis 
 Results are expressed as means ± standard error (SE). Data were 
analyzed using the Student’s t-test or ANOVA followed by a post-hoc test. 
While Student’s t-test was used to compare means of two different treatment 
groups, ANOVA was used to compare the means of more than two means of 
different treatment groups that are normally distributed with a common 
variance. Differences were considered significant at p<0.05.   
2.4 Results 
Time Course of Plasma ALT Activity and Fmo3 mRNA Levels After APAP 
Treatment 
 Administration of 400 mg/kg APAP to male C57Bl/6J mice resulted in 
elevation of plasma ALT levels (Figure 2.1A). Plasma ALT activity increased 
to 191±18 and 219±47 IU/L at 24 and 48 h, respectively, following APAP 
treatment (mean plasma ALT activity in control mice was 25±5 IU/L). By 72 h, 
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plasma ALT activity is not statistically different from propylene glycol vehicle 
controls indicating recovery from APAP-induced liver injury. Fmo3 mRNA 
levels were quantified by qRT-PCR. The results in Figure 2.1B show that 
Fmo3 mRNA levels increased by 5±2.6-and 23±5.6-fold, at 24 and 48 h 
respectively, compared to the 0 h control group.  
Time Course of Fmo3 Protein Expression After APAP Treatment 
 To examine the temporal changes in Fmo3 gene expression and 
function following APAP treatment, Fmo3 protein levels were quantified by 
western blotting and by measuring catalytic activity using MMI as substrate. 
Representative blots and associated densitometric analysis are shown in 
Figure 2.2A and 2.2B, respectively. Although the expression of Fmo3 protein 
tended to increase by 1.1±0.3- to 1.6±0.2-fold between 24 and 72 h after 
APAP, these increases are statistically significant only at 72 h. An alternative 
method to quantitate Fmo3 protein induction is by measuring FMO catalytic 
activity using MMI (Zhang et al., 2007). With APAP treatment, FMO specific 
activity increased over time and this increase is statistically significant at 72 h 
only (24±1.5 µM/min/mg)(Fig. 2.2C). Figure 2.2D shows 
immunohistochemical analysis of Fmo3 protein localization. Cellular 
localization of Fmo3 protein and degree of protein expression did not change 
at 24 or 48 h, but marginally increased at 72 h after treatment with a single 
dose APAP (400 mg/kg). Unlike Fmo3 mRNA levels that peaked at 48 h, 
maximum Fmo3 protein expression is observed at 72 h following APAP 
treatment. These data demonstrate that a single dose APAP (400 mg/kg) 
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treatment results in a marginal, yet significant increase in Fmo3 protein levels 
and activity at 72 h, the longest time-point tested.   
Plasma ALT Activity and Fmo3 mRNA Expression in the Mouse Model of 
APAP Autoprotection 
 Previous studies conducted in our laboratory demonstrated the 
phenomenon of APAP autoprotection in mice, where mice receiving an initial 
mild toxic dose of APAP are protected against hepatotoxicity from higher 
doses (Aleksunes et al., 2008). To investigate Fmo3 gene expression in the 
mouse model of APAP autoprotection, male C57BL/6J mice were pretreated 
with either propylene glycol vehicle or 400 mg/kg APAP. Forty-eight hours 
following pretreatment, mice were challenged with vehicle or a higher dose of 
APAP (600 mg/kg). Plasma ALT activity and Fmo3 mRNA levels were 
measured 24 h after the challenge dose (Fig. 2.3A and 2.3B respectively). 
Plasma ALT levels in mice receiving vehicle pretreatment and APAP 
challenge (600 mg/kg; VA) increased significantly to 1600±413 IU/L 
compared to vehicle controls (VV). Likewise, ALT levels in mice pretreated 
and challenged with APAP (AA; autoprotected group) increased significantly 
to 230±69 IU/L compared to VV controls. However, the values are 
significantly lower than in the VA group. Consistent with the single dose 
APAP (400 mg/kg) study, APAP pretreated, vehicle challenged mice (AV) 
have marginal increases in ALT values in comparison to VV controls. The 
results in Figure 2.3B show Fmo3 mRNA levels in the mouse model of APAP 
autoprotection. Fmo3 mRNA transcript levels in the AV and AA groups 
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increased significantly by 39±5- and 70±11-fold, respectively, with APAP 
autoprotected mice showing the greatest (70-fold) induction.  
Fmo3 Protein Expression in the Mouse Model of APAP Autoprotection 
 Fmo3 protein expression is not normally detectable in adult male mice 
livers because the expression of this enzyme is silenced during development  
(Cherrington et al., 1998; Falls et al., 1997; Shephard & Phillips, 2010). To 
determine if Fmo3 protein expression correlates with the mRNA expression 
seen in APAP autoprotected male mouse livers, western blot analysis was 
performed as described in Materials and Methods. Representative blots are 
shown in Figure 2.4A and densitometric analysis of blots are shown in Figure 
2.4B. As expected, no detectable hepatic Fmo3 protein is present in VV 
control livers. Following treatment with APAP (dosing regimen 2) Fmo3 
protein levels increased in both AV (p value 0.0743) and AA group (p value 
0.041). However, the elevation is statistically significant only in APAP 
autoprotected group (15±2-fold change). In agreement with protein 
expression data, the MMI assay used to measure enzyme specific activity 
shows an increase in activity to 16±2 and 42 ±5µM/min/mg in AV and AA 
groups of mice, respectively, compared to vehicle controls 
(3±1µM/min/mg)(Fig. 2.4C). Figure 2.5 shows immunohistochemical analysis 
of Fmo3 protein localization. Protein staining is localized to centrilobular 
regions in both pretreated and autoprotected livers instead of its conventional 
periportal localization seen in non-treated female livers. This distinct zonal 
localization by APAP coincides with the area where damage and/or 
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hepatocellular compensatory repair/proliferation occurs (Figure E/F and G/H, 
respectively).  
Effect of Methimazole Treatment on Liver in Mice  
 Methimazole is a drug used in the treatment of hyperthyroidism and is 
a high affinity substrate and effective competitive inhibitor of the Fmo-
mediated oxidation of various compounds (Nace et al., 1997). Later studies 
described in this manuscript use MMI (50 mg/kg) to inhibit FMO activity in 
female as well as male mice. MMI at higher doses can by itself deplete 
hepatic GSH levels or cause hepatotoxicity in GSH-depleted mice (Mizutani 
et al., 1999; Mizutani et al., 2000). To determine whether administration of 
MMI by itself at doses used in our study results in hepatotoxicity, female mice 
were administered either one or two doses of 50 mg/kg MMI. Animals were 
sacrificed and plasma and livers were collected over a timecourse of 12 h for 
liver toxicity analysis (dosing regimen 3). Plasma ALT activity increased to 
39±4 IU/L at 12 h following a single dose MMI treatment compared to vehicle 
controls (15±3 IU/L)(Fig. 2.6A). Even though the ALT activity increased 
significantly at 12 h, these levels are below the normal physiological range for 
hepatotoxicity (40-43 IU/L, as per the “Physiological Data Summary” provided 
by The Jackson Laboratory for female C57BL/6J mice). Hepatic GSH levels 
are shown in Figure 2.6B. GSH levels in livers from MMI treated mice are not 
different from that in their vehicle treated controls. In support of ALT activity 
data, histopathological analysis of H&E stained liver sections from MMI 
treated mice do not show any signs of liver injury (Fig. 2.6C). Collectively 
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these data suggest that MMI at two doses of 50 mg/kg does not result in 
hepatotoxicity nor does it deplete hepatic GSH levels, one of the key 
detoxification mechanisms involved during APAP exposure. 
Immunohistochemical Analysis of Liver Fmo3 Protein Expression and 
Localization in Naïve C57BL/6J Male and Female Livers 
 Female mice express about eighty times higher Fmo3 mRNA levels 
compared to males (Janmohamed et al., 2004). To examine whether the 
differences in mRNA levels translate to protein levels, an 
immunohistochemical analysis for Fmo3 protein expression was performed in 
naïve livers from male and female mice using our custom-made Fmo3 
primary antibody. Consistent with the literature, Fmo3 protein expression and 
its cellular localization is not detectable in male liver under basal conditions. 
Strikingly, female livers express higher Fmo3 protein levels compared to male 
mice. This Fmo3 expression is restricted to hepatocytes surrounding portal 
veins (Figure 2.7).  
Effect of Methimazole Treatment on APAP-induced Liver Injury in Female and 
Male C57BL/6J Mice 
  As shown in Figure 2.7, female mice express higher Fmo3 protein 
levels compared to their male counterparts. It has also been demonstrated 
that female mice are much more resistant to APAP hepatotoxicity compared 
to male mice (Dai et al., 2006). If Fmo3 plays a role in conferring tolerance to 
APAP-induced hepatotoxicity in female mice, methimazole (FMO inhibitor) 
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treatment should render female mice susceptible to APAP hepatotoxicity. To 
investigate the effect of MMI treatment on APAP-induced hepatotoxicity in 
female mice, groups of mice received APAP along with either one or two 
doses of MMI (dosing regimen 4). Plasma ALT activity in female mice did not 
change compared to vehicle controls following APAP (400 mg/kg) treatment 
(Fig. 2.8A)(mean plasma ALT activity in control mice: 27±2 IU/L). APAP 
treatment along with the first and second dose of MMI (1&2MMI/APAP), 
significantly increased plasma ALT levels to 3343±802 IU/L. APAP treatment 
with only the first dose (1MMI/APAP) of MMI also increased plasma ALT 
values to 473±93 IU/L. Hepatic GSH levels also are shown in Figure 2.8B. 
Liver GSH content measured at 24 h in mice receiving APAP alone show a 
rebound increase to 72±3 nmol/mg protein compared to vehicle controls 
(48±4 nmol/mg protein). On the other hand, all three groups of mice receiving 
APAP and MMI co-treatment show significantly lower GSH levels 
(1&2MMI/APAP: 19±7, 1MMI/APAP: 30±3 and APAP/2MMI: 37±2 nmol/mg 
protein) compared to the group receiving APAP alone. This change correlates 
well with higher plasma ALT activity in these three groups. The severity of 
hepatocellular necrosis by APAP along with MMI was analyzed and graded 
using a scale ranging from 0 to 5. Liver samples with grades greater than 2 
are considered to have significant injury (Manautou et al., 1994). Results of 
histopathological analysis are presented in Figure 2.8C and Table 2.1. 
Examination of liver sections from the control group revealed normal 
histology. Consistent with the plasma ALT activity, APAP (400 mg/kg) 
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treatment resulted in a minimal amount of hepatocellular injury in female 
mice. Even though the severity of APAP-related injury increased with MMI, 
there is greater injury with two doses of MMI. 
 Fmo5 and Fmo3 are abundant FMO enzymes in female adult mouse 
liver (Cherrington et al., 1998; Hines, 2006; Janmohamed et al., 2004). While 
Fmo3 is abundant in female mice, male mice are void of Fmo3 (Cherrington 
et al., 1998; Hines, 2006; Janmohamed et al., 2004). With the exception of 
FMO5, MMI is a substrate for all FMO enzymes (Overby et al., 1995; Zhang 
et al., 2007). Thus, with MMI we presume female hepatic Fmo3 is 
predominantly inhibited. If the susceptibility of female mice to APAP-induced 
hepatotoxicity is due to MMI inhibition of Fmo3 (demonstrated in Fig. 2.8A 
and 2.8B), then we anticipate seeing no alteration in the susceptibility of male 
mice to APAP hepatotoxicity with MMI administration. To investigate the 
effect of MMI treatment on APAP-induced hepatotoxicity in male mice, groups 
of mice received APAP along with either one or two doses of MMI (dosing 
regimen 4). Administration of APAP (400 mg/kg) in saline to male mice 
resulted in elevation of plasma ALT levels to 1794±222 IU/L compared to 
vehicle controls (45±12 IU/L) (Fig. 2.8D). APAP co-administration with MMI 
did not significantly change plasma ALT activity compared to APAP treated 
male mice (1&2MMI/APAP: 1984±592, 1MMI/APAP: 2333±126 and 
APAP/2MMI: 1530±328 IU/L). Hepatic GSH levels are presented in Figure 
2.8E. Consistent with plasma ALT levels, hepatic GSH content following 
APAP (400 mg/kg) treatment decreased significantly to 16±2 nmol/mg protein 
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compared to vehicle controls (61±2 nmol/mg protein). Further, GSH levels did 
not change significantly in all groups of mice that received APAP along with 
one or two doses of MMI compared to the APAP only group (1&2MMI/APAP: 
13±2, 1MMI/APAP: 11±2 and APAP/2MMI: 17±1 nmol/mg protein). These 
data demonstrate that the susceptibility of female mice to APAP-induced 
hepatotoxicity from MMI treatment is due to inhibition of hepatic Fmo3.  
Establishment of Human Hepatocyte Cell Line (HC-04) Over-expressing 
Human FMO3 (hFMO3-HC-04) 
 To further evaluate the functional significance of FMO3 over-
expression during APAP hepatotoxicity, we developed a human hepatocyte 
cell line (HC-04) that over-expresses human FMO3. Unlike HepG2 cells, HC-
04 cells express CYPs that bioactivate APAP to its toxic metabolite NAPQI 
and also are susceptible to APAP-induced cellular toxicity (Lim et al., 2007). 
Thus, this cell line is a good model for studying the protective effects of FMO3 
gene expression during APAP-induced cytotoxicity. FMO3 was incorporated 
into a bicistronic vector driven by the ubiquitin-C promoter, which allowed co-
expression of FMO3 and luciferase (LUC) genes in transduced HC-04 cells. 
We identified five clones that over-expressed human FMO3, of which three 
were maintained as cell lines. Results from luciferase activity assays used to 
measure the efficiency of transduction are presented in Figure 2.9A. The 
clones expressed a 33±1-, 89±2- and 455±8-fold change in luciferase activity 
as compared to the empty vector control (EV-HC-04). For convenience, these 
clones are named Low- Mid-, and High-FMO3 expressing cell lines, 
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respectively. FMO3 protein expression was confirmed by performing western 
blotting using microsomal fractions isolated from EV expressing HC-04 cells 
and all three FMO3-over-expressing HC-04 clones. Representative blots and 
densitometric analysis are shown in Figure 2.9B. Following transduction, 
Fmo3 protein levels increased by 5±0.1-, 10±0.3- and 33±0.5-fold in Low-, 
Mid- and High-FMO3 expressing HC-04 cells, respectively. The specific 
activity of over-expressed FMO3 protein increased to 75±1.2, 80±0.7 and 
80±0.6 µM/min/mg in Low-, Mid- and High-FMO3 expressing HC-04 cells 
respectively compared to EV-HC-04 controls (5 µM/min/mg) (Fig. 2.9C).  
Effect of APAP Treatment in HC-04 Cells Over-expressing Human FMO3 
(hFMO3-HC-04) 
 Cell culture and treatment is described in detail in the Materials and 
Methods. Results are shown in Figure 2.10. The percent LDH leakage into 
the media in Low-FMO3 expressing hFMO3-HC-04 cells in response to 1, 5, 
10 and 15 mM APAP treatment is significantly lower (7, 10, 17and 24 %) 
compared to empty vector controls (8, 13, 23 and 31 %), respectively. The 
amount of LDH leakage does not change in Mid-FMO3 expressing cells and 
is significantly greater (9, 14, 28 and 42 %) in High-FMO3 expressing cells 
following 1, 5, 10 and 15 mM APAP treatment. Taken together, these data 
suggest that over-expression of FMO3 protects against APAP-induced 
cytotoxicity only in Low-FMO3 expressing cells. By contrast, APAP 
cytotoxicity is aggravated in the High-FMO3 expressing clone.  
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Effect of MMI Pretreatment During APAP-induced Cytotoxicity in HC-04 Cells 
Over-expressing Human FMO3 (hFMO3-HC-04) 
 The amount of LDH leakage (%) into the media does not change with 
MMI treatment (Fig. 2.11A). In response to 15 mM APAP treatment, the 
percent LDH leakage into the media in Low-FMO3 expressing cells 
decreased significantly to 25 % compared to EV controls (29 %)(Fig. 2.11B). 
Following pretreatment with 1 mM MMI, the susceptibility of Low-FMO3 
expressing cells to APAP-induced cytotoxicity restored to 29 %. On the 
contrary, Mid- and High-FMO3 expressing cells did not exhibit any protection 
against APAP-induced cytotoxicity. These cell lines also show enhanced 
cytotoxicity during MMI pretreatment.   
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Figure 2.1 
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Figure 2.1 Plasma ALT activity and quantitative RT-PCR analysis of liver 
Fmo3 transcripts following a single dose APAP treatment. Plasma and livers 
were collected from mice 24, 48 and 72 h following APAP (400 mg/kg) or 
vehicle treatments. (A) The data are presented as mean plasma ALT (IU/L) ± 
SE. (B) RNA was isolated from livers and further cDNA was made using a 
commercial MMLV-RT kit. The cDNA samples were analyzed by quantitative 
RT-PCR using Fmo3 mouse-specific primers. Gene expression was 
normalized to housekeeping gene β-Actin. Fmo3 mRNA expression are 
presented as mean Fold Change ± SE. One-way ANOVA was performed 
followed by the Dunnett’s post-test. Asterisks (*) represent a statistical 
difference (p < 0.05) between 0 h vehicle and APAP-treated groups.  
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Figure 2.2 
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Figure 2.2 Analysis of liver Fmo3 protein expression following a single dose 
APAP treatment by western blotting, enzyme activity assay as well as by 
immunohistochemistry. After overnight fasting, mice received a single dose of 
400 mg/kg APAP or vehicle.  Livers were collected at 24, 48 and 72 h 
following APAP or vehicle treatments. Western blots for Fmo3 were 
performed using liver microsomes from control and APAP-treated mice. A 
custom-made rabbit anti-mouse Fmo3 primary antibody, described in 
Materials and Methods section was used to detect Fmo3. Equal protein 
loading (10 μg protein/lane) was confirmed by detection of β-actin. 
Microsomal protein isolated from naïve female mouse liver was used as a 
positive control indicated by “+” sign. The data are presented as blots (A) and 
as mean Fmo3 protein expression (Fold Change) ± SE (B). FMO activity was 
measured in liver microsomes from control and APAP-treated mice using 
methimazole as substrate as described under Materials and Methods. Data 
are presented as mean Specific Activity (μM/min/mg) ± SE (C). Asterisks (*) 
represent a statistical difference (p < 0.05) between 0 h vehicle and APAP-
treated groups. Immunohistochemical staining to detect Fmo3 was conducted 
on zinc formalin fixed, paraffin-embedded liver sections from control and 
APAP-treated mice. Immunochemical staining was performed with the same 
antibody used for Western blotting. Representative images are shown (D). 
Scale bar: 100 μm. (A) Vehicle-treated 0 h; (B) APAP-treated 24 h; (C) 
APAP-treated 48 h; (D) APAP-treated 72 h. 
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Figure 2.3 
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Figure 2.3 Plasma ALT activity in the mouse model of APAP autoprotection. 
Groups of mice were treated with vehicle or APAP 400 mg/kg. 48 h after 
pretreatment, mice were challenged with vehicle or APAP 600 mg/kg. Plasma 
and livers were collected 48 h following APAP challenge. (A) The data are 
presented as mean plasma ALT (IU/L) ± SE. One-way ANOVA was 
performed followed by the Dunnett’s post-test. While asterisks (*) represent a 
statistical difference (p< 0.05) between VV group and VA groups, pound (#) 
represent a statistical difference (p < 0.05) between VA and AA groups. (B) 
RNA was extracted from livers and cDNA was prepared using a commercial 
MMLV-RT kit as described in Materials and Methods. The cDNA samples 
were analyzed for Fmo3 mRNA levels by quantitative RT-PCR using Fmo3 
mouse-specific primers. Gene expression was normalized to housekeeping 
gene β-Actin. Fmo3 mRNA expression are presented as mean Fold Change 
± SE. One-way ANOVA was performed followed by the Dunnett’s post-test. 
Asterisks (*) represent a statistical difference (p < 0.05) from VV groups and 
pound (#) represent a statistical difference (p<0.05) between VA and AA 
groups. 
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Figure 2.4 
 
	   81	  
 
 
 
Figure 2.4 Analysis of liver Fmo3 protein expression in the mouse model of 
APAP autoprotection by western blotting and enzyme activity assay. Dosing 
regimen is described in detail in Materials and Methods section. Briefly, 
groups of mice were administered with vehicle or APAP (400 mg/kg) and 48 h 
later challenged with vehicle or APAP (600 mg/kg). Livers were collected 24 h 
following the last treatment. Western blots for Fmo3 was performed using 
liver microsomes from all groups of mice. A custom-made rabbit anti-mouse 
Fmo3 primary antibody, described before was used to detect Fmo3. Equal 
protein loading (10 μg protein/lane) was confirmed by detection of β-actin. 
Microsomal protein isolated from naïve female mouse liver was used as a 
positive control indicated by “+” sign. The data are presented as blots (A) and 
as mean Fmo3 protein expression (Fold Change) ± SE (B). Liver microsomes 
isolated from all groups of mice were used to measure FMO activity using 
methimazole as substrate. Data are presented as mean Specific Activity 
(μM/min/mg) ± SE (C). Asterisks (*) represent a statistical difference (p < 
0.05) from VV groups. 
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Figure 2.5 
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Figure 2.5 Immunohistochemical analysis of liver Fmo3 protein expression 
and localization in the mouse model of APAP autoprotection. Details of APAP 
autoprotection treatment regimen are described in Materials and Methods. 
Groups of mice were pretreated with vehicle or APAP (400 mg/kg) and 
challenged with vehicle or APAP (600 mg/kg) 48 h later. Twenty-four hours 
after the challenge dose livers were collected and fixed in zinc formalin and 
paraffin embedded. Immunochemical staining to detect Fmo3 was performed 
with the same antibody used for Western blotting. Representative images 
from all groups of mice are shown at two magnifications. Scale bar: 100 and 
500 μm. (A/B) VV – Vehicle pretreated and vehicle challenge group; (C/D) VA 
– Vehicle pretreated and APAP (600 mg/kg) challenge group; (E/F) AV – 
APAP (400 mg/kg) pretreated and Vehicle challenge group; (G/H) AA – APAP 
(400 mg/kg) pretreated and APAP (600 mg/kg) challenge group liver sections.  
	   84	  
 
Figure 2.6 
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Figure 2.6 Plasma ALT activity, hepatic GSH levels and histopathology of 
liver sections after 50 mg/kg methimazole (MMI) treatment in female mice. 
Dosing regimen is described in detail in Materials and Methods section. 
Briefly, groups of mice were administered a single dose of MMI (50 mg/kg) 
and plasma and livers were collected 0.5, 4, 12 and 24 h later.  A single group 
of mice received both the first and the second dose of MMI and 12 h after the 
second dose, plasma and livers were collected for analysis. (A) The data are 
presented as mean plasma ALT (IU/L) ± SE. (B) GSH levels are expressed 
as GSH nmol/mg protein ± SE. One-way ANOVA was performed followed by 
the Dunnett’s post-test. Asterisks (*) represent a statistical difference (p< 
0.05) between vehicle and MMI-treated groups. (C) Histopathology of 
formalin-fixed, paraffin-embedded liver sections from MMI treated mice. 
Representative images are shown. Scale bar: 100 μm. (A) Control; (B) First 
dose MMI-treated 0.5 h; (C) First dose MMI-treated 4 h; (D) First dose MMI-
treated 12 h; (E) First dose MMI-treated 24 h; (F) First and second dose MMI-
treated 12 h.  
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Figure 2.7 
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Figure 2.7 Immunohistochemical analysis of Fmo3 in naïve female and male 
liver. Livers from untreated female and male mice were collected and fixed in 
zinc formalin and paraffin embedded. Immunochemical staining of Fmo3 was 
performed on paraffin sections using the custom-antibody used before. 
Representative images are shown. Scale bar: 100 μm. (A) Female (B) Male 
liver specimens.  
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Figure 2.8 
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Figure 2.8 Plasma ALT activity, hepatic GSH levels and histopathology of 
liver sections after MMI intervention in APAP treated mice. Female or male 
mice were treated with vehicle or APAP (400 mg/kg) or APAP along with MMI 
(50 mg/kg). The first dose of MMI was administered 30 min prior to APAP 
treatment and the second dose 12 h after the first dose. 24 h after APAP 
treatment, plasma and livers were collected for analysis. (A) The data from 
female mice are presented as mean plasma ALT (IU/L) ± SE. (B) GSH levels 
in female mice livers are expressed as GSH nmol/mg protein ± SE. One-way 
ANOVA was performed followed by the Dunnett’s post-test post-test. 
Asterisks (*) represent a statistical difference (p< 0.05) compared to vehicle 
treated group and pound (#) represent a statistical difference (p<0.05) from 
APAP treated group.  (C) Histopathology of formalin-fixed, paraffin-embedded 
liver sections after MMI intervention in APAP treated female mice. 
Representative images are shown. Scale bar: 100 μm. (A) Vehicle – Vehicle 
treated group; (B) APAP – APAP (400 mg/kg) treated group; (C) 1&2 
MMI/APAP – APAP (400 mg/kg) with both the first and second dose MMI (50 
mg/kg) treated group; (D) 1 MMI/APAP – APAP (400 mg/kg) with the first 
dose MMI (50 mg/kg) treated group; (E) APAP/2MMI – APAP (400 mg/kg) 
with the second dose MMI (50 mg/kg) treated group. (D) The data from male 
mice are presented as mean plasma ALT (IU/L) ± SE. (E) GSH levels in male 
mice livers are expressed as GSH nmol/mg protein ± SE. One-way ANOVA 
was performed followed by the Dunnett’s post-test. Asterisks (*) represent a 
statistical difference (p< 0.05) compared to vehicle treated group.  
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Figure 2.9 
 
 
	   91	  
 
 
 
 
 
Figure 2.9 Establishment of HC-04 cells over-expressing human FMO3 
(hFMO3-HC-04). Lentiviral vector construction and transduction are described 
in detail in Materials and Methods section. (A) Luciferase activity to measure 
the efficiency of transduction in hFMO3-HC-04 clones. The data are 
presented as mean luciferase activity/mg protein (Fold Change) ± SE. (B) 
Western blot for Fmo3 was performed using microsomal protein isolated from 
empty vector (EV), Low-, Mid- and High-FMO3 expressing cell lines. Rabbit 
anti-human FMO3 primary antibody was used to detect FMO3 protein 
expression. Equal protein loading (10 μg protein/lane) was confirmed by 
detection of β-actin. The data are presented as blots as well as mean FMO3 
protein expression (Fold Change) ± SE. (C) Microsomes isolated from EV 
expressing HC-04 cells and all three FMO3-over-expressing HC-04 clones 
were used to measure FMO activity using methimazole as substrate. Data are 
presented as mean Specific Activity (μM/min/mg) ± SE Protein. One-way 
ANOVA was performed followed by the Dunnett’s post-test. Asterisks (*) 
represent a statistical difference (p< 0.05) compared to EV controls. 
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Figure 2.10 
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Figure 2.10 Effect of APAP treatment in HC-04 cells over-expressing human 
FMO3 (hFMO3-HC-04). Empty vector, Low-, Mid- and High-FMO3 expressing 
cell lines were treated with a range of APAP concentrations from 1 mM to 15 
mM. 24 h later, percent LDH leakage into the medium was measured using a 
commercial kit. The data are presented as mean LDH leakage (%) ± SE. 
Two-way ANOVA was performed followed by the Bonferroni’s post-test. 
Asterisks (*) represent a significant decrease (p< 0.05) compared to EV 
controls and pound (#) represent a significant increase (p<0.05) compared to 
EV controls. 
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Figure 2.11 
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Figure 2.11 Effect of MMI pretreatment during APAP-induced cytotoxicity in 
HC-04 cells over-expressing human FMO3 (hFMO3-HC-04). Empty vector, 
Low-, Mid- and High-FMO3 expressing cell lines were incubated with MMI (1 
mM) for 30 min before APAP (15 mM) treatment. 24 h after APAP treatment, 
percent LDH leakage into the medium was measured. The data are 
presented as mean LDH leakage (%) ± SE. Two-way ANOVA was performed 
followed by the Bonferroni’s post-test. Asterisks (*) represent a significant 
decrease (p<0.05) compared to APAP treated EV control and pound (#) 
represent a significant increase (p<0.05) compared to respective APAP 
treated EV and hFMO3-HC-04 cell lines.  
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TABLE 2.1 
Histopathological Analysis of Livers after MMI Intervention in APAP Treated 
Mice. Liver sections were examined for severity of degenerative and necrotic 
changes in centrilobular region as described previously (Manautou et al., 
1994). Liver samples with grades greater than 2 are considered to have 
significant injury.  Data were rank ordered prior to statistical analysis. 
Asterisks (*) represent a statistical difference (p<0.05) from vehicle control 
group and pound (#) represent a statistical difference (p<0.05) from APAP 
treated group. 
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Histological Grade 
Treatment Group 
0 1 2 3 4 5 
Percent >2 
Control 5 0 0 0 0 0 0 
APAP 0 5 0 0 0 0 0 
1&2MMI / APAP*# 0 0 0 1 1 2 100 
1MMI / APAP* 0 0 4 1 0 0 20 
APAP / 2MMI 0 5 0 0 0 0 0 
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2.5 Discussion 
 The mechanism of APAP-induced cellular and liver organ toxicity is 
multifactorial and complex (Jaeschke & Bajt, 2006; Jaeschke et al., 2012). 
Examining novel genes and pathways differentially regulated in experimental 
models of xenobiotic hepatotoxicity resistance can provide novel avenues to 
develop new modalities of treatment for liver diseases.  Our laboratory has 
previously developed a mouse model of APAP autoprotection for studying the 
mechanisms of hepatic injury/recovery (Aleksunes et al., 2008). This study 
also elucidated the role of efflux transporter MRP4 and compensatory cellular 
proliferation in protecting against APAP-induced hepatotoxicity in this model 
of APAP autoprotection. However, it is possible that factors other than MRP4 
also can contribute to the development of APAP toxicity tolerance. A gene 
array analysis recently conducted in our lab provided insights into signaling 
pathways potentially involved in APAP autoprotection (O'Connor et al., 2014). 
Fmo3 was among the genes with the most significant change in APAP 
autoprotected mice. Even though a role of Fmo3 expression in APAP 
hepatotoxicity is not known, it was the most biologically plausible for playing a 
role in autoprotection.  
 In this study, we investigated the hepatic expression of Fmo3 protein 
during APAP-induced hepatotoxicity. Historically, Fmo3 was considered to be 
a non-inducible drug-metabolizing enzyme (Cashman & Zhang, 2002; 
Cashman & Zhang, 2006; Hines, 2006; Krueger & Williams, 2005). However, 
recent studies show that activation of the Ah receptor induces Fmo3 mRNA 
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levels (Celius et al., 2008; Celius et al., 2010). In these studies, although 
there is a very large increase in Fmo3 mRNA levels, protein levels measured 
by methimazole oxidation show only modest increases in protein function. 
Similarly, our results show that the dramatic elevation in liver Fmo3 mRNA 
expression following administration of a single APAP dose is accompanied by 
marginal increases in Fmo3 protein expression and catalytic activity. It is 
worth noting that the Fmo3 mRNA expression is variable between studies, 
which is again similar to the observations with ligand dependent activation of 
AhR and Fmo3 mRNA expression (Celius et al., 2008). These differences in 
expression cannot be due to diurnal variation in basal expression because 
animals were dosed and tissue harvested at approximately the same time of 
the day every time we conducted independent studies. Fmo3 is subject to 
hormone regulation (Cherrington et al., 1998; Falls et al., 1997; Janmohamed 
et al., 2004), and such, 9 to 10 weeks old mice were used in the current 
study. Irrespective of the level and degree of increased Fmo3 mRNA 
expression following a single dose APAP treatment, increases in protein 
expression remained marginal.  
 In contrast to what was observed with a single APAP hepatotoxic dose, 
both liver Fmo3 mRNA and protein expression are significantly higher in mice 
treated with the APAP autoprotection regimen (pre- and post-APAP 
treatment). In agreement with greater Fmo3 protein expression, Fmo3 
catalytic activity and centrilobular zonal expression also are significantly 
greater in the APAP autoprotection group. These findings suggest the 
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regulation of Fmo3 gene expression (transcriptional and/or translational) is 
different under the conditions of treatment with a single APAP dose versus an 
autoprotection treatment regimen. Because the level of damage from a mildly 
toxic dose of APAP is minimal, the need for restoration of balance in cellular 
processes may also be less. Thus all mRNA transcribed in response to the 
minimally toxic APAP exposure may not be translated into functional protein. 
In contrast, after an autoprotected dosing regimen, the initial exposure to a 
mildly toxic APAP dose would prime the tissue for faster recovery from re-
exposure to a second toxic insult. Indeed, the possibility exists that at least a 
portion of the dramatic increases in Fmo3 protein observed with the second 
APAP dose results from rapid translation of Fmo3 mRNA stabilized in 
ribonucleoprotein complexes. Such translational control has been well 
documented in other systems where a rapid response to a potentially toxic 
exposure occurs (e.g., translation of stored ferritin mRNA in response to iron 
exposure). This overall concept is well accepted and referred to by some 
scientists as “hormesis”. The precise cellular and molecular events leading to 
this adaptation is not known. Moreover, immunohistochemical analysis of 
APAP autoprotected livers show the Fmo3 expression is localized to the 
hepatic centrilobular regions, where APAP induced damage and/or 
hepatocellular compensatory repair/proliferation occurs, instead of the 
conventional periportal localization seen in female livers. This expression 
pattern is again suggestive of a potential Fmo3 role in the development of 
APAP hepatotoxicity resistance via an unknown cytoprotective function.  
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 Female mice exhibit higher Fmo3 gene expression than male mice 
(Cherrington et al., 1998; Hines, 2006; Janmohamed et al., 2004), and are 
much more resistant to APAP hepatotoxicity compared to males (Dai et al., 
2006). Our findings with the FMO inhibitor methimazole in female mice 
demonstrate that MMI inhibition of Fmo3 makes female mice susceptible to 
APAP-induced hepatotoxicity. The caveats of any inhibitor study are the 
specificity of inhibition as well as potential off target effects exhibiting toxicity 
comparable to that seen in males. Historically, MMI is known to interfere with 
the synthesis of thyroid hormones by inhibiting the enzyme, thyroperoxidase 
and is capable of inhibiting other enzymes involved in oxygenation reactions 
such as FMO and CYP dependent monooxygenases (Hunter & Neal, 1975). If 
MMI was contributing to changing female mice susceptibility to APAP 
hepatotoxicity by inhibiting CYP-dependent metabolism, we would have 
anticipated seeing less liver damage.  Clearly, this is not the case because 
MMI treatment makes female mice sensitive to APAP hepatotoxicity. This is 
quite remarkable since C57BL/6J female mice are quite resilient to APAP 
hepatotoxicity. Undesirable side effects such as cholestasis can develop from 
MMI treatment due to extrathyroidal actions in humans (Schmidt et al., 1986). 
However, a cholestatic liver is less susceptible to APAP-induced 
hepatotoxicity in mice (Silva et al., 2006). Lastly, MMI at higher doses can 
deplete hepatic GSH levels or in GSH-depleted mice induce centrilobular 
necrosis (Mizutani et al., 1999; Mizutani et al., 2000). However, under the 
conditions used in the current study, MMI treatment alone does not result in 
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GSH depletion or hepatotoxicity in mice. Furthermore, MMI treatment in male 
mice did not alter APAP-induced hepatotoxicity negating any potential non-
specific functions of MMI. Collectively, these results suggest that the 
susceptibility of female mice to APAP hepatotoxicity following MMI treatment 
is the result of inhibiting Fmo3 function. 
 To further study the importance of FMO3 over-expression, we 
established an in vitro over-expression system using HC-04 cells. While the 
percent LDH leakage into the media in Low-FMO3 expressing hFMO3-HC-04 
cells in response to APAP treatment is significantly lower compared to empty 
vector controls, the amount of LDH leakage by APAP does not change in the 
Mid-FMO3 expressing clone and is significantly greater in High-FMO3 cells. 
Taken together, these data suggest that over-expression of FMO3 
significantly alters susceptibility to APAP induced cytotoxicity. Even though 
the percent protection from APAP cytotoxicity in the Low-FMO3 expressing 
clone is only about 20 percent, one must keep in mind that FMO3 over-
expressing cells are a mono cell culture. The possible contribution from other 
cell types, such as Kupffer cells and endothelial cells known to play an 
important role in signaling mechanisms should not be overlooked. The data 
also suggest that there is a threshold for FMO3 over-expression in protecting 
against APAP-induced cytotoxicity. This is evidenced by the enhanced APAP 
cytotoxicity in the High-expressing FMO3 cells. MMI treatment did not result 
in elevation of basal LDH leakage into the medium in all FMO3-over-
expressing clones. This suggests that MMI by itself at doses used in vitro did 
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not result in cytotoxicity. Inhibition of FMO3 activity by MMI in all three Low-, 
Mid- and High-FMO3 expressing cell lines resulted in rescue of sensitivity to 
APAP in Low-FMO3 expressing cell line compared to EV controls. Since 
High-FMO3 expressing cells exhibit greater LDH leakage in comparison to EV 
controls following APAP treatment (threshold for FMO3 over-expression), one 
might anticipate seeing lower APAP cytotoxicity following MMI co-treatment. 
Considering this is not the case, it is possible that MMI at 1mM concentration 
results in inhibition of FMO3 activity in Low-FMO3 expressing cell line but is 
metabolized in High-FMO3 expressing cells. To emphasize, MMI is a 
substrate for Fmo3 as well as a competitive inhibitor with IC50 value of 
60.2±16.2 µM (Attar et al., 2003; Rettie & Fisher, 1999).  
 FMO is involved in oxygenation of phosphorus, nitrogen and sulphur-
containing xenobiotics. FMO’s also are involved in the oxidation of 
endogenous substrates such as cysteamine to cystamine (Poulsen, 1981).  
Although, the physiological role of FMO3 cysteamine S-oxygenation is not 
clear, Zieglar and Poulsen proposed in the 1970’s that FMO might be 
involved in protein disulphide bond formation through oxidation of cysteamine. 
It was also proposed that oxygenation of cysteamine may be a significant 
source of disulphide, maintaining the cellular thiol:disulphide potential in a cell 
(Ziegler et al., 1979). Further, Suh and Robertus showed that yeast FMO 
serve as a modulator of cellular thiols and maintains optimum redox potential 
within the endoplasmic reticulum, allowing for proper folding of disulfide bond- 
containing proteins (Suh & Robertus, 2002). The cytoprotective functions of 
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Fmo3 and its possible involvement in APAP autoprotection are summarized 
below. The relationship between cellular thiol:disulphide ratios and the 
regulation of metabolic reactions has been recognized for a long time (Barron, 
1953). Oxygenation of cysteamine during APAP hepatotoxicity may serve to 
help control the overall thiol:disulphide redox state of the cell, which in turn 
may modulate cellular metabolism and/or activate signal transduction 
pathway leading to altered susceptibility to APAP (or protection). Oxygenation 
of cysteamine to cystamine by Fmo3 and transport out of the cell also may 
represent a detoxication mechanism or protective function, because 
cysteamine is toxic to cells at concentrations as low as 39 µM through the 
transition metal-dependent formation of hydrogen peroxide (Jeitner & 
Lawrence, 2001). To investigate whether oxygenation of cysteamine to 
cystamine by Fmo3 is important during APAP hepatotoxicity, follow-up 
studies will measure the total hepatic cysteamine and cystamine 
concentrations in the mouse model of APAP autoprotection.  
 In the present study, up-regulation of Fmo3 gene expression in the 
mouse APAP autoprotection model and its role in protecting against APAP-
induced cytotoxicity or hepatotoxicity has led to the conclusion that Fmo3 is 
important for development of resistance to APAP-induced hepatotoxicity. The 
phenomenon of autoprotection is also seen in patients who are repeatedly 
exposed to supratherapeutic doses of APAP (Shayiq et al., 1999; Watkins et 
al., 2006). These clinical data suggest that human liver can adapt to APAP-
induced hepatotoxicity similar to that seen in our APAP autoprotection mouse 
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model. C57BL/6J wild type mice are commonly used for studies of APAP 
hepatotoxicity and the mechanisms of toxicity in these animals are not 
completely understood. Although, key events such as NAPQI formation, GSH 
depletion, protein arylation, peroxynitrate formation and mitochondrial 
damage play an important role in APAP hepatotoxicity (Cohen et al., 1997; 
Hinson et al., 2010; Jaeschke & Bajt, 2006; Jaeschke et al., 2011; McGill et 
al., 2012). Even though primary human hepatocytes are the gold standard 
tool for studying APAP hepatotoxicity mechanisms, they have major 
drawbacks. The availability of these cells is limited, and the drug response 
can vary significantly due to differences in donors. Most importantly, the 
lifespan of primary human hepatocytes is short and they undergo changes in 
CYP expression levels over time in culture. Hepatoma cell lines like HepG2 
express very low CYP levels compared to primary human hepatocytes or 
human liver especially those that are involved in the metabolism of APAP 
(Rodriguez-Antona et al., 2002). Using the more recently available human 
hepatoma cell line, HepaRG, which expresses a more normal spectrum of 
drug metabolizing enzymes, studies have demonstrated that the mechanistic 
features of APAP-induced hepatotoxicity are the same as reported for human 
hepatocytes and mouse liver in vivo (McGill et al., 2011). Thus, it is very likely 
that the phenomenon of APAP autoprotection seen in human might also 
involve FMO3 over-expression. Although this is a subject of current 
investigation in our laboratory the mere fact that the protein once thought to 
be non-inducible is being induced following treatment with a commonly used, 
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over-the-counter drug like acetaminophen is quite alarming. Importantly, one 
also must be concerned about the number of other drugs that are co-
administered with APAP and are FMO3 substrates.  
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CHAPTER 3 
Differential FMO3 Gene Expression in Various Liver Injury Models 
Involving Hepatic Oxidative Stress in Mice  
3.1 Abstract 
 Flavin-containing monooxygenase-3 (FMO3) catalyzes metabolic 
reactions similar to cytochrome P450 monooxygenase however, most 
metabolites of FMO3 are considered non-toxic. Recent findings in our 
laboratory demonstrated Fmo3 gene induction following toxic acetaminophen 
(APAP) treatment in mice. The goal of this study was to evaluate Fmo3 gene 
expression in diverse other mouse models of hepatic oxidative stress and 
injury. Fmo3 gene regulation by Nrf2 was also investigated using Nrf2 
knockout (Nrf2 KO) mice. In our studies, male C57BL/6J mice were treated 
with toxic doses of hepatotoxicants or underwent bile duct ligation (BDL, 10d). 
Hepatotoxicants included APAP (400 mg/kg, 24 to 48 h), alpha-naphthyl 
isothiocyanate (ANIT; 50 mg/kg, 2 to 48 h), carbon tetrachloride (CCl4; 10 or 
30 µL/kg, 24 and 48 h) and allyl alcohol (AlOH; 30 or 60 mg/kg, 6 and 24 h). 
Because oxidative stress activates nuclear factor (erythroid-derived 2)-like 2 
(Nrf2), additional studies investigated Fmo3 gene regulation by Nrf2 using 
Nrf2 knockout (Nrf2 KO) mice. At appropriate time-points, blood and liver 
samples were collected for assessment of plasma alanine aminotransferase 
(ALT) activity, plasma and hepatic bile acid levels, as well as liver Fmo3 
mRNA and protein expression. Fmo3 mRNA expression increased 
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significantly by 43-fold at 12 h after ANIT treatment, and this increase 
translates to a 4-fold change in protein levels. BDL also increased Fmo3 
mRNA expression by1899-fold, but with no change in protein levels. 
Treatment of mice with CCl4 decreased liver Fmo3 gene expression, while no 
change in expression is detected with AlOH treatment. Nrf2 KO mice are 
more susceptible to APAP (400 mg/kg, 72 h) treatment compared to their 
wild-type (WT) counterparts, which is evidenced by greater plasma ALT 
activity. Fmo3 mRNA and protein expression increased in Nrf2 KO mice after 
APAP treatment. Collectively, not all hepatotoxicants that produce oxidative 
stress alter Fmo3 gene expression. Along with APAP, toxic ANIT treatment in 
mice markedly increases Fmo3 gene expression. While BDL increases Fmo3 
mRNA expression, protein level does not change. The discrepancy with Fmo3 
induction in cholestatic models, ANIT and BDL, is not entirely clear. Results 
from Nrf2 KO mice with APAP suggest that the transcriptional regulation of 
Fmo3 during liver injury may not involve Nrf2. 
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3.2 Introduction 
 Drug-induced liver injury (DILI) is a significant challenge for both drug 
development and clinical care. It accounts for more than 50 % of all acute 
liver failure cases in the U.S. (Larson et al., 2005; W. M. Lee, 2010). Many 
chemicals, such as acetaminophen (APAP), carbon tetrachloride (CCl4) and 
allyl alcohol (AlOH) have been used to model hepatotoxicity relevant to 
human exposure. Alpha-naphthyl isothiocyanate (ANIT) and bile duct ligation 
(BDL) on the other hand are used to model cholestasis, a pathological 
condition caused by impairment of hepatic bile flow. While ANIT produces 
intrahepatic cholestasis, BDL produces extrahepatic cholestasis. With APAP 
and CCl4, the parent compound is metabolized by cytochrome P450 (CYP) to 
generate reactive metabolites, N-acetyl-p-benzoquinone imine (NAPQI) and 
tricholoromethyl radical (˙CCl3), respectively. AlOH in turn is metabolized in 
the liver by alcohol dehydrogenase to its reactive metabolite, acrolein.  The 
glutathione adduct of acrolein is converted by CYPs to glycidaldehyde. 
Toxicity resulting from these reactive metabolites is multifactorial and includes 
lipid peroxidation, generation of oxidative stress, altered cellular redox status 
and protein adduct formation (Burcham & Fontaine, 2001; Cohen et al., 1997; 
Jaeschke et al., 2012; Ohno et al., 1985; Tom et al., 1984). During 
cholestasis resulting from either BDL or ANIT treatment, increase in bile acid 
concentration stimulates production of reactive oxygen species eventually 
leading to hepatocellular necrosis and apoptosis (Sokol et al., 1995; Trauner 
et al., 1998).  
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 The role of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) role as a 
master defense against hepatotoxicity produced by various chemicals has 
been investigated in several studies.  Nrf2 belongs to the cap ‘n’ collar family 
of transcription factors that promotes transcription of a battery of 
cytoprotective genes (Aleksunes & Manautou, 2007; Kensler et al., 2007). 
Under basal conditions, Nrf2 is largely bound to the cytoskeletal anchoring 
protein Kelch-like ECH-associated protein 1 (Keap1) also known as cytosolic 
Nrf2 inhibitor in the cytoplasm. In response to oxidative stress, Nrf2 is 
released from Keap1 and translocates to the nucleus. In the nucleus, Nrf2 
binds to the GTGACA***GC core sequence of the antioxidant response 
element (ARE) (Rushmore et al., 1991) and promotes ARE-mediated 
antioxidant gene expression.  
 A low toxic APAP dose causes nuclear accumulation of Nrf2 in mouse 
liver, which is accompanied by increased expression of Nrf2 dependent 
cytoprotective genes such as heme oxygenase-1 (Hmox1), NAD(P)H:quinone 
oxidoreductase-1 (Nqo1) and glutamate cysteine ligase catalytic subunit 
(Gclc) (Aleksunes et al., 2005; Aleksunes et al., 2006; Bauer et al., 2000; 
Chiu et al., 2002; Goldring et al., 2004). Similar results have been reported 
with ANIT, BDL, CCl4 and AlOH, other models of hepatic oxidative stress 
used in the present study (Aleksunes et al., 2005; Aleksunes et al., 2006; Liu 
et al., 2013; Randle et al., 2008; Tanaka et al., 2009). On the other hand, Nrf2 
KO mice are more susceptible to APAP-induced liver injury compared to their 
wild-type counterparts (Chan et al., 2001; Enomoto et al., 2001). Likewise, 
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Nrf2 KO mice are also more susceptible to CCl4- and AlOH-induced 
hepatoxicity compared to wild-type mice (Liu et al., 2013). However, Nrf2-null 
mice do not exhibit any difference in susceptibility to either BDL or ANIT 
treatment (Tanaka et al., 2009; Weerachayaphorn et al., 2012). This 
response is attributed to the adaptive compensatory changes involving 
nuclear transcription factors, including Fxr, Shp, Pxr and Hnf1α, efflux bile 
acid transporters, altered GSH levels and bile flow rates in Nrf2 KO mice 
(Tanaka et al., 2009; Weerachayaphorn et al., 2012). Collectively, the models 
of hepatic injury selected for the current study not only result in hepatic 
oxidative stress but also activate the Nrf2-Keap1 regulatory pathway. 
 Despite Fmo3 being considered non-inducible, studies with aryl 
hydrocarbon receptor (AhR) agonists in mice show liver Fmo3 gene induction 
(Celius et al., 2008; Celius et al., 2010). A recent gene array analysis 
performed in our laboratory also demonstrated Fmo3 gene induction in the 
APAP autoprotection mouse model (mice receiving a low hepatotoxic APAP 
dose that become resistant to a subsequent higher APAP dose) (O'Connor et 
al., 2014). Unlike with AhR agonists that result in marginal increases in Fmo3 
protein expression in mouse liver, we show significant increases in Fmo3 
protein levels in APAP autoprotected mice (Rudraiah et al., 2014). Fmo3 
induction by other hepatotoxicants that produce oxidative stress is not 
currently known.  
 In human liver, transcription factors regulating constitutive FMO3 
expression as well as those involved in developmental expression pattern are 
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extensively studied (Klick & Hines, 2007; Klick et al., 2008; Shimizu et al., 
2008). Because the mammalian FMOs were considered non-inducible by 
xenobiotics (Cashman & Zhang, 2002; Krueger & Williams, 2005), the 
transcriptional regulation of FMO involving stress-activated transcription 
factors or receptors that bind ligands and interact with DNA was not studied 
as other forms of regulation. Thus, little is known about the transcriptional 
regulation of Fmo3 in response to toxicant exposure. Recently, Celius et al. 
show that the Fmo3 mRNA up-regulation by 3-methylcholanthrene (3MC) and 
benzo(a)pyrene (BaP) but not TCDD in Hepa-1 cells is mediated by p53 and 
its binding to a p53-response element in the promoter region of Fmo3 (Celius 
et al., 2010).  
 Differentially expressed genes in the APAP autoprotection model were 
further analyzed using Causal Reasoning Engine (CRE), a recently 
developed computational platform (O'Connor et al., 2014). CRE analysis 
provides hypotheses on the upstream molecular events that best explain 
gene expression profiles based on prior biological knowledge. CRE analysis 
of differentially expressed genes in APAP autoprotection study supports an 
induction of the Nrf2 pathway (O'Connor et al., 2014). Additionally, the 5'-
flanking region of the mouse Fmo3 contains multiple copies of the ARE 
(Celius et al., 2008). Therefore, the purpose of the present study was to 
investigate liver Fmo3 gene expression under oxidative stress conditions 
involving activation of the Nrf2-Keap1 regulatory pathway. Mice were dosed 
with hepatotoxicants APAP (400 mg/kg, 24 to 48 h), ANIT (50 mg/kg, 2 to 48 
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h), CCl4 (10 or 30 µL/kg, 24 and 48 h) or AlOH (30 or 60 mg/kg, 6 and 24 h) 
or underwent sham surgery or bile duct ligation (10 d). Doses selected for 
hepatotoxicants are based upon previous studies conducted in our laboratory 
resulting in oxidative stress and tissue injury. The inclusion of multiple time-
points following hepatotoxicants exposure enabled comprehensive 
characterization of temporal changes in Fmo3 in relation to injury and 
recovery. Further, in order to investigate whether Nrf2 mediates Fmo3 gene 
expression, Nrf2 KO mice were employed. APAP was used as a model 
toxicant in the Nrf2 KO mice study. From these experiments, it is concluded 
that not all hepatotoxicants that produce oxidative stress in mice induce liver 
Fmo3 gene expression. Toxic ANIT treatment, along with the previously 
demonstrated APAP treatment, markedly increases Fmo3 gene expression. 
While BDL increases Fmo3 mRNA expression, protein levels do not change. 
APAP treatment induces Fmo3 gene expression in Nrf2 KO mice liver 
suggesting that the transcriptional regulation of Fmo3 might not involve Nrf2. 
3.3 Materials and Methods 
Chemicals  
 Acetaminophen, alpha-naphthyl isothiocyanate, carbon tetrachloride, 
allyl alcohol, propylene glycol and corn oil were purchased from Sigma-
Aldrich (St Louis, MO). All other reagents were of reagent grade or better and 
commercially available.  
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Animals 
 Male C57BL/6J mice (9- to 10-week old) were purchased from Jackson 
Laboratories (Bar Harbor, ME) for this study. Upon arrival, mice were 
acclimated for one week prior to experimentation. Mice were housed in a 
temperature-, light- and humidity-controlled environment. Mice were fed 
laboratory rodent diet (Harlan Teklad 2018, Madison, WI) ad libitum.  
 Experimental Design 1. Following an overnight fast, male mice (n=6) 
were treated with APAP (400 mg/kg in 50 % propylene glycol, ip, 24, 48 and 
72 h), ANIT (50 mg/kg in corn oil, po, 2, 4, 8, 12, 24 and 48 h), CCl4 (10 or 30 
µL/kg in corn oil, ip, 24 and 48 h), AlOH (30 or 60 mg/kg in saline, ip, 6 and 24 
h) or vehicle. At the end of each experiment, animals were sacrificed at the 
specified time-points for each hepatotoxicant and plasma and livers were 
collected for analysis. BDL liver samples were obtained from a previously 
described cohort (Donepudi et al., 2012).  Briefly, sham or BDL surgery was 
performed under phenobarbital-induced anesthesia (65 mg/kg, ip). The 
surgeries were performed at the University of Rhode Island, College of 
Pharmacy animal facility with IACUC approval. Serum and liver were 
collected 10 d after surgery for analysis.  
 Experimental Design 2. Following overnight fasting, male Nrf2 KO mice 
and their wild-type counterparts (C57BL/6J) were treated with APAP (400 
mg/kg, ip) in 50 % PG or vehicle. Plasma and livers were collected 72 h after 
APAP treatment for analysis.   
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 All animal studies were performed in accordance with National Institute 
of Health standards and the Guide for the Care and Use of Laboratory 
Animals. This work was approved by the University of Connecticut’s 
Institutional Animal Care and Use Committee.  
Alanine Aminotransferase (ALT) Assay 
 Plasma or serum ALT activity was determined as a biochemical 
indicator of hepatocellular injury. Infinity ALT Liquid Stable Reagent (Thermo 
Fisher Scientific Inc., Waltham, MA) was used to determine ALT activity. 
Briefly, 100 µL of reagent was added to 10 µL serum or plasma samples, and 
absorbance was measured spectrophotometrically at 340 nm using a Bio-Tek 
Power Wave X Spectrophotometer. ALT activity (IU/L) was determined using 
the molar extinction coefficient of NADH (6.3 mM-1cm-1).  
Total Bile acid Assay 
 Total bile acids were extracted from whole liver homogenates using a 
t-butanol extraction method. Briefly, livers were homogenized in extraction 
solution (1:1, water: t-butanol) and bile acids extracted overnight at room 
temperature in the dark. Blood levels of total bile acid and hepatic bile acid 
levels were measured using a spectrophotometric bile acid assay kit 
(Bioquant, San Diego, CA) according to manufacturer’s protocol.  
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RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR) 
 Total RNA was extracted from mouse liver samples using TRIzol 
reagent (Life Technologies, Carlsbad, CA) according to the manufacturer’s 
instructions. Total RNA was then reverse-transcribed into cDNA using an M-
MLV RT kit (Invitrogen, Carlsbad, CA). Fmo3 mRNA expression was 
quantified by the ΔΔCT method and normalized to two housekeeping genes, 
β-actin and ribosomal protein S18. Data presented were normalized to β-
actin. Primer pairs were synthesized by Integrated DNA Technologies 
(Coralville, IA) and are as follow: Fmo3 forward: 5′-GGA AGA GTT GGT 
GAA GAC CG-3′, reverse: 5′-CCC ACA TGC TTT GAG AGG AG-3′. 
Amplification was performed using an Applied Biosystems 7500 Fast Real-
Time PCR System. Amplification was carried out in a 20 μL reaction volume 
containing 8 μL diluted cDNA, Fast SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA) and 1 μM of each primer.    
Preparation of Microsomal Fraction and Western Blot Analysis 
 Microsomes were isolated from livers as described previously 
(Cashman & Hanzlik, 1981; Rudraiah et al., 2014) and stored at -80°C until 
use. Protein concentration was determined by the method of Lowry using Bio-
Rad protein assay reagents (Bio-Rad Laboratories, Hercules, CA). For 
western blot analysis, microsomal proteins (10 μg) were electrophoretically 
resolved using 10 % polyacrylamide gels and transferred onto PVDF-Plus 
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membrane (Micron Separations, Westboro, MA). Membranes were blocked 
with 5 % non-fat powdered milk in tris buffered saline containing 0.05% 
tween-20 (TBS-T) for 8 h. A rabbit anti-mouse Fmo3 primary antibody 
(GenScript USA Inc., NJ) (1:5000) was used to detect Fmo3 with β-actin as a 
loading control. Blots were then incubated with HRP conjugated secondary 
antibodies against rabbit IgG (1:2000) (Sigma-Aldrich, St Louis, MO). Protein-
antibody complexes were detected using a chemiluminescent kit (Thermo 
Scientific, IL) with visualization using GeneMate blue autoradiography film 
(Bioexpress, Kaysville, UT).  
Enzyme Assay 
 Methimazole (MMI) metabolism was determined 
spectrophotometrically by measuring the rate of MMI S-oxygenation via the 
reaction of the oxidized product with nitro-5-thiobenzoate (TNB) to generate 
5,5’-dithiobis(2-nitrobenzoate) (DTNB). The incubation mixture consisted of 
50 mM sodium phosphate buffer (pH 9.0), 0.5 mM NADP+, 0.5 mM glucose-6-
phosphate, 1.5 IU/mL glucose-6-phosphate dehydrogenase, 0.06 mM DTNB, 
0.04 mM dithiothreitol and 100 to 150 μg/mL liver microsomes isolated from 
mice. Reactions were initiated by the addition of different amounts of MMI 
(substrate), with a concentration range from 1.25 to 800 μM. Incubations were 
done in duplicates. The disappearance of the yellow color was measured 
spectrophotometrically at 412 nm and specific activity (μM/min/mg) was 
determined using the molar extinction coefficient of NADPH (28.2 mM-1cm-1).  
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Statistical Analysis 
 The statistical significance between groups was determined using the 
Student’s t-test, one-way ANOVA with Dunnett’s post-hoc test or two-way 
ANOVA followed by the Bonferroni’s post-hoc test. While Student’s t-test was 
used to compare means of two different treatment groups, ANOVA was used 
to compare the means of more than two treatment groups that are normally 
distributed with a common variance. All statistical analysis was performed 
using GraphPad Prism version 4.00 for Macintosh (GraphPad Software, Inc., 
San Diego, CA). Data are presented as mean ± standard error (SE), with 
p<0.05 considered statistically significant.   
3.4 Results 
Plasma ALT Activity in the Mouse Liver Injury Models  
 The hepatotoxicity of APAP (400 mg/kg) at 24, 48 and 72 h as 
assessed by plasma ALT activity has been reported previously (Rudraiah et 
al., 2014). Briefly, APAP increased plasma ALT activity to 191±18 and 
219±47 IU/L at 24 and 48 h, respectively (mean plasma ALT activity in control 
mice was 25±5 IU/L).  Plasma ALT activity is not statistically different from 
vehicle controls by 72 h, indicating recovery from APAP-induced liver injury. 
Plasma ALT activity in all mouse models of liver injury is shown in Figure 3.1. 
ANIT increased ALT activity at 12 h (182±9 IU/L), which continued to increase 
at 24 and 48 h (715±126 IU/L and 781±45 IU/L, respectively) compared to 
vehicle control group (9±1 IU/L). BDL for 10 d results in an elevation of ALT 
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activity to 185±10 IU/L. A high CCl4 dose (30 µL/kg) increased plasma ALT at 
24 and 48 h to 6367±1135 and 397±111 IU/L, respectively. A low CCl4 dose 
(10 µL/kg) also increased plasma ALT activity at 24 and 48 h to 757±106 and 
416±68 IU/L, respectively.  The greatest increase in plasma ALT with both 
doses of CCl4 is observed at 24 h. While AlOH treatment (low dose, 30 
mg/kg) did not result in significant increases in ALT levels at 6 h and 24 h 
(36±4 and 73±24 IU/L, respectively), a high AlOH dose (60 mg/kg) results in 
significantly higher ALT levels at both 6 h and 24 h (153±50 and 4440±2428 
IU/L, respectively). The associated histopathological damage with all 
hepatotoxicants has been reported previously (Aleksunes et al., 2005; 
Aleksunes et al., 2006; Campion et al., 2009; Donepudi et al., 2012; Rudraiah 
et al., 2014). With acute toxicity models, plasma ALT activity lesser than 1000 
IU/L is usually associated with a minimal to mild hepatocellular damage 
(histological grade of 2 or less than 2), and an ALT activity higher than 1000 
IU/L is associated with moderate, marked or severe hepatocellular damage 
(histological grade of 3, 4, or 5) (Aleksunes et al., 2008; Manautou et al., 
1994). Alternatively, a 10 d BDL with an associated ALT activity of less than 
200 IU/L, exhibit a chronic hepatocellular damage involving fibrosis (Donepudi 
et al., 2012).  
Hepatic Fmo3 mRNA Expression in the Mouse Liver Injury Models 
 Fmo3 mRNA levels were quantified by qRT-PCR and the results are 
presented in Figure 3.2. Fmo3 mRNA expression following 400 mg/kg APAP 
treatment has been previously reported (Rudraiah et al., 2014). Briefly, Fmo3 
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mRNA levels increased by 5±2.6-and 23±5.6-fold, at 24 and 48 h after APAP, 
respectively, compared to the 0 h control group. ANIT increased Fmo3 mRNA 
levels as early as 2 h after treatment. This increase peaked and is statistically 
significant only at 12 h (43±10-fold increase), compared to 0 h vehicle control 
group. BDL also increased Fmo3 mRNA expression by 1899±625-fold, 
compared to sham operated mice. Both the low and high dose of CCl4 
decreased Fmo3 mRNA levels at both time points examined, and this 
decrease is statistically significant only at 48 h (10 µL/kg: 0.2±0.06-fold and 
30 µL/kg: 0.2±0.08-fold). No change in liver Fmo3 mRNA levels is observed 
with AlOH treatment.  
Hepatic Bile Acid Concentrations in the Mouse Liver Injury Models  
 To determine the extent of cholestasis induced by different 
hepatotoxicants used in the current study, total hepatic bile acid levels were 
measured (Figure 3.3). As expected ANIT increased hepatic bile acid levels 
to 1.7±0.2 and 1.6±0.4 µmol/g at 24 and 48 h, respectively, compared to 0 h 
vehicle control group (0.2±0.02 µmol/g). BDL also increased hepatic bile acid 
concentrations to 19.49±0.85 µmol/g compared to sham operated group 
(10.61±1.65 µmol/g). No significant changes were observed in mice treated 
with APAP, CCl4 and AlOH.  
Total bile Acid Concentrations in the Blood in the Mouse Liver Injury Models 
 Bile acid concentration in plasma is also a biomarker of cholestasis. In 
order to determine the extent of cholestasis, plasma bile acid levels were also 
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quantified in all mouse models of liver injury (Figure 3.4). Plasma bile acid 
concentration increased in ANIT treated mice at 24 and 48 h to 210±20 and 
330±128 µmol/L, respectively, compared with vehicle treated mice (2±0.2 
µmol/L). Bile duct ligation significantly increased serum bile acid levels to 
1359±142 µmol/L compared to sham operated mice (86±11 µmol/L). 
Significant increases in plasma bile acid concentrations are seen in high dose 
CCl4 treated mice at both 24 and 48 h (112±15 µmol/L and 29±2 µmol/L, 
respectively). Exposure to APAP and AlOH did not result in any significant 
change in plasma bile acid levels.  
Fmo3 Protein Expression in the Mouse Liver Injury Models 
 Temporal expression of the Fmo3 protein following exposure to 
hepatotoxicants and BDL were quantified by western blotting. Representative 
blots and associated densitometric analyses are shown in Figure 3.5. Fmo3 
protein increase following APAP treatment has been previously reported 
(Rudraiah et al., 2014). Although the expression of Fmo3 protein tended to 
increase by 1.1±0.3- to 1.6±0.2-fold between 24 and 72 h after APAP, the 
increase is statistically significant only at 72h. Consistent with Fmo3 mRNA 
changes evidenced with ANIT treatment, Fmo3 protein levels also tend to 
increase as early as 2 h. However, this increase is significant only at 12 h 
(3.5±0.9-fold) compared to 0 h vehicle treated group. Fmo3 protein levels 
decreased to 0.7±0.08- and 0.3±0.1-fold at 24 and 48 h, respectively, after 
exposure to ANIT. Conversely, in spite of the dramatic increase in Fmo3 
mRNA levels after BDL, Fmo3 protein levels did not change.  No significant 
	   122	  
changes in Fmo3 protein expression are observed with CCl4 or AlOH 
treatment.  
Plasma ALT Activity and Fmo3 mRNA Levels After APAP Treatment in Wild-
Type and Nrf2 Knockout Mice 
 All models of hepatic injury used in the current study activate the Nrf2-
Keap1 regulatory pathway. Furthermore, CRE analysis of differentially 
expressed genes in our APAP autoprotection study supported an induction of 
the Nrf2 pathway (O'Connor et al., 2014). To investigate whether Nrf2 
mediates Fmo3 gene expression, APAP was used as a model toxicant for 
Nrf2 activation in Nrf2 KO and WT mice. Mice were administered a 400 mg/kg 
APAP dose for 72 h. Dose and time-point selected were based on our single 
dose APAP study performed previously (Rudraiah et al., 2014), where a 400 
mg/kg APAP treatment increased Fmo3 protein levels at 72 h. Administration 
of 400 mg/kg APAP to male C57BL/6J WT mice did not result in significantly 
different plasma ALT values at 72 h from vehicle controls. This is consistent 
with the previously reported results, indicating recovery from APAP-induced 
liver injury and increased Fmo3 protein expression in WT mice (Rudraiah et 
al., 2014). In contrast, plasma ALT activity is elevated at 72 h in Nrf2 KO mice 
receiving the same dose of APAP (176±12 IU/L) compared to vehicle control 
group (23±5 IU/L) (Figure 3.6A). This is again consistent with the literature 
and confirms that Nrf2 plays an important role not only in the magnitude of 
toxicity, but also in the degree and rate of recovery from APAP-induced liver 
injury. Fmo3 mRNA levels were quantified by qRT-PCR. The results in Figure 
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3.6B show that there is no change in Fmo3 mRNA levels at 72 h in wild-type 
mice administered 400 mg/kg APAP. This is again consistent with previous 
reports, where maximal Fmo3 mRNA expression is seen at 48 h after APAP 
administration and returns to normal by 72 h (Rudraiah et al., 2014). Notably, 
Fmo3 mRNA expression is significantly higher in Nrf2 KO mice 72 h after 
APAP treatment by 140±43-fold change compared to vehicle control group.   
Fmo3 Protein Expression After APAP Treatment in Wild-Type and Nrf2 
Knockout Mice 
 To examine the temporal changes in Fmo3 gene expression following 
APAP treatment in WT and Nrf2 KO mice, Fmo3 protein levels were 
quantified by western blotting and by measuring catalytic activity using MMI 
as substrate. Representative blots and associated densitometric analysis are 
shown in Figure 3.7A. Consistent with increased Fmo3 mRNA expression in 
Nrf2 KO mice administered APAP (400 mg/kg) at 72 h, Fmo3 protein levels 
are also significantly higher (5.1±1.3-fold) compared to vehicle control group. 
Measuring FMO catalytic activity using MMI can also quantitate Fmo3 protein 
induction (Zhang et al., 2007). FMO specific activity increased significantly in 
Nrf2 KO livers (48±6 µM/min/mg) at 72 h after APAP compared to vehicle 
controls of either genotype (Figure 3.7B). 
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Figure 3.1 
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Figure 3.1 Plasma ALT activity in mice treated with hepatotoxicants or BDL. 
Male C57BL/6J mice were treated with ANIT (50 mg/kg, po, 2,4,8,12,24 & 48 
h), CCl4 (10 & 30 µL/kg, ip, 24 & 48 h), AlOH (30 & 60 mg/kg, ip, 6 & 24 h) or 
BDL (10 d). Plasma was collected from mice at various time points following 
hepatotoxicant treatment or the appropriate vehicle. The data are presented 
as mean plasma ALT (IU/L) ± SE. One-way ANOVA, t-test or two-way 
ANOVA was performed, appropriately, followed by the Dunnett’s posttest for 
One-way ANOVA and the Bonferroni posttest for two-way ANOVA. Asterisks 
(*) represent a statistical difference (p < 0.05) between vehicle-treated and 
hepatotoxicant-treated group.  
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Figure 3.2 
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Figure 3.2 Quantitative RT-PCR analysis of liver Fmo3 transcripts after 
hepatotoxicant treatment or BDL. Livers were collected from mice sacrificed 
at respective time-points  (2,4,8,12,24 & 48 h for ANIT; 24 & 48 h for CCl4; 6 
& 24 h for AlOH; and 10 d for BDL). RNA was isolated and cDNA was made 
using a commercial MMLV-RT kit. The cDNA samples were analyzed by 
quantitative RT-PCR using Fmo3 mouse-specific primers. Gene expression 
was normalized to the housekeeping gene β-actin. Fmo3 mRNA expression 
is presented as mean Fold Change ± SE. One-way ANOVA, t-test or two-way 
ANOVA was performed, appropriately, followed by the Dunnett’s posttest for 
One-way ANOVA and the Bonferroni posttest for two-way ANOVA. Asterisks 
(*) represent a statistical difference (p < 0.05) between vehicle-treated and 
hepatotoxicant-treated or BDL group.  
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Figure 3.3 
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Figure 3.3 Hepatic bile acid levels after hepatotoxicant administration or BDL. 
Livers were collected at the end of each study (24, 48 & 72 h for APAP; 
2,4,8,12,24 & 48 h for ANIT; 10 d for BDL; 24 & 48 h for CCl4; and 6 & 24 h 
for AlOH). Liver total bile acids were measured spectrophotometrically using a 
commercial bile acid assay kit. Hepatic total bile acids are expressed as 
mean hepatic bile acids (μmol/g) ± SE. One-way ANOVA, t-test or two-way 
ANOVA was performed, appropriately, followed by the Dunnett’s posttest for 
one-way ANOVA and the Bonferroni posttest for two-way ANOVA. Asterisks 
(*) represent a statistical difference (p < 0.05) between vehicle-treated and 
hepatotoxicant-treated or BDL group.  
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Figure 3.4 
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Figure 3.4 Blood levels of Total Bile acid in the mouse models of liver injury. 
Mice were administered APAP (400 mg/kg, ip, 24, 48 & 72 h), ANIT (50 
mg/kg, po, 2,4,8,12,24 & 48 h), CCl4 (10 & 30 µL/kg, ip, 24 & 48 h), AlOH (30 
& 60 mg/kg, ip, 6 & 24 h) or BDL (10 d). Blood was collected and the plasma 
or serum (for BDL) was isolated by centrifugation. Total bile acid levels were 
measured spectrophotometrically using a commercial bile acid assay kit. 
Total bile acids are expressed as mean total bile acids (μmol/L) ± SE.  
Student’s t-test, one-way ANOVA, or two-way ANOVA was performed, 
appropriately, followed by the Dunnett’s posttest for one-way ANOVA and the 
Bonferroni posttest for two-way ANOVA. Asterisks (*) represent a statistical 
difference (p < 0.05) between vehicle-treated and hepatotoxicant-treated or 
BDL group.  
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Figure 3.5 
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Figure 3.5 Analysis of liver Fmo3 protein expression in the mouse models of 
liver injury by western blotting. Western immunoblots for Fmo3 were 
performed using liver microsomes from control and hepatotoxicant-treated or 
BDL mice. A custom-made rabbit anti-mouse Fmo3 primary antibody, 
described in Materials and Methods was used to detect Fmo3. Fmo3 protein 
levels were normalized to β-actin loading control. Microsomal proteins 
isolated from naïve female mouse liver was used as a positive control 
(indicated by “+” sign). The data are presented as blots and as mean Fmo3 
protein expression (Fold Change) ± SE. One-way ANOVA, t-test or two-way 
ANOVA was performed, appropriately, followed by the Dunnett’s posttest for 
One-way ANOVA and the Bonferroni posttest for two-way ANOVA. Asterisks 
(*) represent a statistical difference (p < 0.05) between vehicle-treated and 
hepatotoxicant-treated or BDL group.  
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Figure 3.6 
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Figure 3.6 Plasma ALT activity and quantitative RT-PCR analysis of liver 
Fmo3 transcripts following a single dose APAP treatment in wild-type and 
Nrf2-knockout mice. Plasma and livers were collected from mice 72 h 
following APAP (400 mg/kg) or vehicle treatment. (A) The data are presented 
as mean plasma ALT (IU/L) ± SE. (B) RNA was isolated from livers and 
cDNA samples were analyzed by quantitative RT-PCR using Fmo3 mouse-
specific primers. Gene expression was normalized to the housekeeping gene 
β-actin. Fmo3 mRNA expression are presented as mean Fold Change ± SE. 
One-way ANOVA was performed followed by the Dunnett’s post-test. 
Asterisks (*) represent a statistical difference (p < 0.05) between vehicle-
treated group and APAP-treated group and pound (#) represent a statistical 
difference (p<0.05) compared with APAP-treated wild-type mice.  
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Figure 3.7 
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Figure 3.7 Analysis of liver Fmo3 protein expression following a single dose 
APAP treatment in wild-type and Nrf2-knockout mice by western blotting and 
enzyme activity assay. After overnight fasting, groups of wild-type and Nrf2 
knockout mice received a single dose of 400 mg/kg APAP or vehicle.  Livers 
were collected 72 h following APAP or vehicle treatments. Western blots for 
Fmo3 was performed using liver microsomes from control and APAP-treated 
mice. Equal protein loading (10 μg protein/lane) was confirmed by detection 
of β-actin. Microsomal proteins isolated from naïve female mouse liver were 
used as a positive control indicated by “+” sign. The data are presented as 
blots and as mean Fmo3 protein expression (Fold Change) ± SE (A). FMO 
activity was measured in liver microsomes from control and APAP-treated 
mice using methimazole as substrate. Data are presented as mean Specific 
Activity (μM/min/mg) ± SE (B). Asterisks (*) represent a statistical difference 
(p<0.05) between vehicle-treated group and APAP-treated group and pound 
(#) represent a statistical difference (p<0.05) compared with APAP-treated 
wild-type mice.  
 
 
 
	   138	  
3.5 Discussion 
 FMO3 is a microsomal enzyme involved in the oxygenation of lipophilic 
substrates to more polar metabolites. Substrates include nitrogen-, sulfur- and 
phosphorous-containing drugs and xenobiotics, and most metabolic products 
of Fmo3 are considered to be non-toxic (Krueger & Williams, 2005). Although 
FMOs were discovered in the 1960s (Miller et al., 1960) and further purified in 
1972 (Ziegler & Mitchell, 1972), it was not until 2008 that enzyme induction by 
xenobiotics was demonstrated (Celius et al., 2008; Celius et al., 2010). In 
these studies, in spite of a very large increase in Fmo3 mRNA level by AhR 
agonist treatment, only a modest increase in protein level and function was 
reported. A gene array analysis performed in our laboratory also 
demonstrated Fmo3 gene induction in the mouse model of APAP 
autoprotection (O'Connor et al., 2014). In this APAP autoprotection mouse 
model, we show a significant increase in Fmo3 protein expression and 
function (Rudraiah et al., 2014). Constitutive Fmo3 expression in a female 
mouse liver is localized in the areas surrounding the periportal region 
(Janmohamed et al., 2004; Rudraiah et al., 2014). Following APAP exposure, 
the Fmo3 protein expression in APAP autoprotected livers is observed in the 
centrilobular regions where APAP-induced damage and/or hepatocellular 
compensatory proliferation is detected. Furthermore, we show that the 
enhanced expression of Fmo3 confers resistance against APAP-induced 
hepatotoxicity in mice (Rudraiah et al., 2014). 
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 In the present study, the effect of various other hepatotoxicants on 
Fmo3 gene expression in male C57BL/6J mouse liver was examined. A 
unifying theme for all hepatotoxicants used in our study is the oxidative 
stress. These models of oxidative stress used are very well studied with 
respect to activation of Nrf2-Keap1 regulatory pathway. This has been 
repeatedly demonstrated in our laboratory and in the literature (Aleksunes et 
al., 2005; Aleksunes et al., 2006; Aleksunes et al., 2006; Bauer et al., 2000; 
Chiu et al., 2002; Goldring et al., 2004; Liu et al., 2013; Randle et al., 2008; 
Tanaka et al., 2009). Thus, we were confident that the treatments selected 
result in oxidative stress and therefore the need for measuring markers of 
oxidative stress for each experimental group of hepatotoxicity was not 
deemed necessary. 
 Coincidentally, all of the hepatotoxicants selected produce cholestasis, 
with the exception of AlOH (Donepudi et al., 2012; Tanaka et al., 2009; 
Weerachayaphorn et al., 2012; Yamazaki et al., 2013). Furthermore, 
perturbation of bile acid homeostasis has been demonstrated to be an early 
event in the pathogenesis of drug induced liver injury (Yamazaki et al., 2013). 
To determine whether accumulation of bile acids is a signaling event 
regulating Fmo3, we measured total hepatic and plasma bile acid levels. 
Consistent with the literature, ANIT and BDL increased plasma and hepatic 
bile acid concentrations. A high CCl4 dose did not significantly alter liver bile 
acid levels, but significantly increased plasma bile acid concentration. APAP 
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tended to increase both hepatic and plasma bile acid concentrations, but this 
is not statistically significant.  
 In general, ANIT and BDL-mediated damage significantly increased 
liver Fmo3 mRNA expression. While CCl4-mediated liver injury significantly 
decreased Fmo3 mRNA expression, no change in expression is evidenced 
with AlOH. Fmo3 mRNA expression in response to ANIT treatment precedes 
serum and hepatic bile acid accumulation and the maximal Fmo3 expression 
(both mRNA and protein) parallels the mild hepatocellular damage observed.  
This observation argues against the concept that hepatic bile acid 
accumulation is a pre-requisite for Fmo3 gene expression changes in the 
ANIT model.  With BDL, unlike ANIT, Fmo3 mRNA induction is associated 
with higher serum and hepatic bile acid levels, but protein level does not 
change.  Since tissues were analyzed 10 days after BDL, we do not have a 
sense of what the temporal relationship is between hepatic bile acid 
accumulation and elevated Fmo3 mRNA induction. This relationship deserves 
further attention based on the discussion of FXR signaling that can be found 
below. 
 Overt ANIT-induced hepatocellular damage at 24 and 48 h decreased 
Fmo3 gene expression and the decease is statistically significant at 48 h 
compared to the 12 h ANIT-treated group. This observation with respect to 
the relationship between plasma ALT level and Fmo3 gene expression is 
consistent with our results with APAP hepatotoxicity. We have demonstrated 
in our APAP autoprotection mouse model that the APAP (400 mg/kg) 
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pretreated group as well as the autoprotected group (APAP pretreatment: 400 
mg/kg, APAP challenge: 600 mg/kg) exhibit average plasma ALT values of 
about 250 IU/L and Fmo3 protein induction. The group that receives a toxic 
APAP dose of 600 mg/kg exhibits much greater average plasma ALT activity 
of about 1600 IU/L, but no Fmo3 gene induction (Rudraiah et al., 2014). 
 One key feature that is consistent with APAP-, BDL- and ANIT-induced 
liver injury and enhanced Fmo3 gene expression is the magnitude in plasma 
ALT elevations. Mild ALT elevation is the common feature for all three models 
where Fmo3 mRNA induction is observed.  Although BDL is a chronic injury 
model, it is well known that the ALT values do not correlate well with the 
severity of liver damage particularly during fibrotic hepatocellular necrosis 
(Kallai et al., 1964). A similar clinical feature is also seen in cases of primary 
biliary cirrhosis (BDL models primary biliary cirrhosis in humans) (Hohenester 
et al., 2009). The lack of Fmo3 protein detection during BDL may be due to 
signal dilution by fibrotic liver tissue. It is also possible that under oxidative 
stress conditions some proteins involved in translation are oxidized in vivo 
inhibiting translation (Shenton et al., 2006). To add to this complexity, in spite 
of lower plasma ALT activity at 24 h (low dose CCl4), and 48 h (both high and 
low dose CCl4) with CCl4, there is down-regulation of Fmo3 gene expression. 
In AlOH-treated livers, lower plasma ALT activity did not show any change in 
Fmo3 gene expression. This is suggestive of an unknown underlying 
mechanism unique to APAP, ANIT, and BDL, which is contributing to Fmo3 
mRNA induction. Studies are necessary to investigate the regional distribution 
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of Fmo3 protein expression during ANIT- and BDL-induced liver injury to 
determine whether the protein expression in these models is localized to the 
portal vein, where ANIT- and BDL-induced hepatotoxicity is confined. 
Collectively, these data suggest that there is a threshold for degree of hepatic 
injury that results in increased Fmo3 mRNA and protein expression. More 
specifically, these data suggest that acute moderate or mild hepatotoxicity is 
optional for Fmo3 induction, while chronic, severe hepatotoxicity is not.  
 As discussed before, all models of hepatic injury used in the current 
study result in hepatic oxidative stress and activate the Nrf2-Keap1 regulatory 
pathway. Importantly, CRE analysis of differentially expressed genes in our 
APAP autoprotection study supported an induction of the Nrf2 pathway 
(O'Connor et al., 2014). Additionally, Celius et al. showed that the 5'-flanking 
region of the mouse Fmo3 contains multiple copies of the ARE (Celius et al., 
2008). Promoter analysis of mouse Fmo3 promoter (7 kb length) using 
MatInspector software (Genomatix, Munich, Germany), also showed an ARE 
at about 3 kb from the transcription start site (data not shown). We also found 
two other binding sites for Bach1, at 600 bp and 2 kb from the Fmo3 
transcription start site (data not shown). Bach1 is a regulatory mediator of 
Nrf2, in that it is a transcription repressor. Bach1 heterodimerizes with small 
Maf proteins in the absence of cellular stress and represses gene expression. 
In the presence of oxidative stress, Bach1 is released from the Maf proteins 
and is replaced by Nrf2 (Kaspar et al., 2009). Thus, using APAP as a model 
toxicant for Nrf2 activation, Fmo3 gene expression was evaluated in Nrf2 KO 
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mice. Compared to APAP-treated wild-type mice, Nrf2 KO mice exhibit 
persistent and significant hepatocellular damage 72 h after APAP 
administration. Nrf2 KO mice are not only more susceptible to APAP-induced 
hepatocellular necrosis, but also fail to recover from injury as rapidly as the 
WT mice. This is consistent with the literature that describes Nrf2 as a master 
regulator of many cytoprotective genes involved in APAP-induced 
hepatotoxicity (Aleksunes et al., 2005; Aleksunes et al., 2006; Bauer et al., 
2000; Chiu et al., 2002; Goldring et al., 2004). Finally, Fmo3 gene induction 
by APAP treatment in Nrf2 null mice suggests that the transcriptional 
regulation of Fmo3 does not involve this transcription factor. The persistent 
mild hepatocellular injury and oxidative stress in Nrf2 KO mice most likely 
activates other signaling mechanisms involved in Fmo3 gene induction.  
 Future studies will investigate the role of other nuclear receptors in 
Fmo3 gene induction. Particularly, farnesoid X receptor (FXR) role in Fmo3 
gene induction during APAP hepatotoxicity is worth investigating. FXR is one 
of the major bile acid sensors in the liver (Chiang, 2002) and plays a 
protective role during cholestasis development. Recently, it is shown that 
activation of FXR induces Fmo3 protein function (Bennett et al., 2013). 
Activation of FXR also provides protection against APAP-induced 
hepatotoxicity (Lee et al., 2010). In addition, we discovered three binding sites 
for farnesoid X receptor-response element (FXRE) at about 1.6, 2.1 and 3.3 
kb from the transcription start site on the mouse Fmo3 promoter (data not 
shown). Although, Pregnane X receptor (PXR) is also a bile acid sensor, no 
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binding sites for PXR were found on promoter analysis and furthermore, PXR 
activation sensitizes APAP-induced hepatotoxicity (Cheng et al., 2009; Guo et 
al., 2004).  
 In conclusion, this study comprehensively characterizes for the first 
time temporal changes in Fmo3 gene expression during different conditions 
known to impart hepatic oxidative stress. In particular, we show that toxic 
ANIT and BDL significantly alter Fmo3 mRNA expression, but only Fmo3 
protein with ANIT. The reason for this discrepancy is not yet clear or easy to 
rationalize. It is possible that Fmo3 is also protective during other chemical-
induced liver injury including ANIT. Even though the exact mechanism of 
Fmo3 gene expression or its role in protecting against toxicant-induced liver 
injury is not yet clear, the observed toxicity threshold for Fmo3 gene 
expression is intriguing. This work advances the lack of knowledge with 
regard to the inducibility of Fmo3 and its potential protective role in drug-
induced liver injury.  
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CHAPTER 4 
Establishment and Characterization of HepaRG Cell Line Over-
Expressing Human Flavin-containing Monooxygenase-3 (FMO3) 
 
4.1 Abstract 
 Flavin-containing monooxygenase (FMO) is a drug metabolizing 
enzyme system similar to cytochrome P450 (CYP). FMO and CYP exhibit 
similar cellular localization and substrate specificity, but a different catalytic 
cycle. FMOs were considered to be non-inducible by xenobiotics, but recently 
we demonstrated liver Fmo3 gene induction and protein expression during 
APAP hepatotoxicity. The role of FMO3 in APAP-induced hepatotoxicity is not 
known. The goal of the present study was to investigate FMO3 gene 
expression, and its role in APAP-induced cytotoxicity in vitro using HepaRG 
cells. HepaRG cells have been recently used as a human in vitro model for 
studying mechanisms of APAP hepatotoxicity. In this study, exposure of 
HepaRG cells to APAP resulted in a significant increase in FMO3 gene 
expression as we see in vivo. To determine the functional significance of 
FMO3 induction during APAP toxicity, we developed a HepaRG cell line over-
expressing human FMO3 (hFMO3-HepaRG). Clonal selection from a 
heterogeneous population of hFMO3-HepaRG cells resulted in two 
homogenous cell lines. Expression of FMO3 in these clones was confirmed 
by qRT-PCR, western blotting and by a catalytic activity assay. Notably, the 
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hFMO3-HepaRG clones had a faster rate of differentiation that was 
dependent on the expression level of FMO3 compared to EV controls. 
Consistent with a faster rate of differentiation in these clones, rifampicin-
induced CYP3A4 expression was also greater. In agreement with our 
postulated role for FMO3 as genetic determinant of APAP toxicity, the low 
hFMO3-HepaRG clone exhibits greater tolerance to APAP-induced (1, 5, 10 
and 15 mM) cytotoxicity. In the high hFMO3-HepaRG clone, LDH leakage is 
significantly lower only at 1 and 5 mM APAP, while at a higher APAP 
concentrations, LDH leakage is significantly greater than in empty vector 
controls. Taken together, our results suggest that changes in FMO3 gene 
expression not only alter HepaRG cell phenotype, evidenced by an 
expression level-dependent greater rate of cell differentiation, but also alter 
susceptibility to APAP-induced cytotoxicity.  
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4.2 Introduction 
 Acetaminophen is one of the most commonly used over-the-counter 
analgesic and antipyretic agent in the U.S. and Great Britain. It was first 
described more than a century ago. However, APAP-poisoning and APAP-
hepatotoxicity was first recognized in 1960s in Great Britain (Davidson & 
Eastham, 1966) and later in the U.S. (McJunkin et al., 1976). APAP usage 
increased after aspirin was implicated in over 80 % of Reye’s syndrome 
cases in children. As APAP usage increased, the incidence of APAP-induced 
hepatotoxicity also increased. In a retrospective study from 1994 to 1996, 
APAP-induced hepatotoxicity comprised 20 % of all cases of acute liver 
failure (ALF) in the U.S. (Schiodt et al., 1999). These numbers increased over 
time and by the early 2000s, nearly 50 % of all ALF cases were due to APAP 
use and misuse. APAP toxicity is still a very prominent cause of liver toxicity, 
accounting for more that 50 % of all ALF from all etiologies (Larson et al., 
2005; Lee, 2010). The potential for drug-related morbidity and mortality, and 
the popularity of this drug, make it a significant human health problem.  
 Until recently, the consensus was that Flavin-containing 
monooxygesnases (FMOs) were not inducible (Cashman & Zhang, 2002; 
Krueger & Williams, 2005). However, recently Celius et al. show that 
activation of the Aryl hydrocarbon (Ah) receptor by 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) induces Fmo3 mRNA in mice, with 
marginal changes detected in protein levels (Celius et al., 2008; Celius et al., 
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2010). Previous work in our laboratory has also documented induction of 
Fmo3 gene expression in an APAP autoprotection mouse model (mice 
pretreated with APAP acquires resistance to APAP re-exposure) (O'Connor et 
al., 2014; Rudraiah et al., 2014).  Furthermore, we also demonstrated an 
association between Fmo3 expression and protection against APAP-induced 
hepatotoxicity (Rudraiah et al., 2014). More specifically, female mice express 
much greater Fmo3 protein levels in liver compared to their male 
counterparts. In fact, Fmo3 protein expression in normal male mouse liver is 
undetectable by immunochemical techniques (Rudraiah et al., 2014). 
Coincidentally, female mice are highly resistant to APAP hepatotoxicity (Dai 
et al., 2006). Taking advantage of this sex-dependent difference in liver Fmo3 
expression in C57BL/6J mice, we demonstrated that administration of the 
FMO inhibitor methimazole (MMI) renders female mice susceptible to APAP-
induced hepatotoxicity (Rudraiah et al., 2014). Results from FMO3-over-
expressing human hepatocyte cell line (HC-04) also supports the conclusion 
that Fmo3 is important for development of resistance to APAP-induced 
hepatotoxicity. 
 The human liver, similar to our APAP autoprotection mouse model, can 
adapt to APAP-induced hepatotoxicity (Shayiq et al., 1999; Watkins et al., 
2006). In these studies, individuals developed tolerance to hepatotoxicity 
following repeated exposure to supratherapeutic doses of APAP. Although 
the clinical data suggest that the human liver can adapt to APAP-induced 
hepatotoxicity similar to that seen in our APAP autoprotection mouse model, 
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the mechanism for this adaptation is not known. Unlike C57BL/6J mouse liver 
where Fmo3 expression is negligible, FMO3 is the predominant FMO enzyme 
in the adult human liver with levels comparable to CYP3A4 (Koukouritaki et 
al., 2002). Furthermore, inducibility of FMO3 in the human liver has not been 
reported.  
 The HepaRG cell line, derived from a hepatoma in a female patient, is 
a recently developed in vitro system for studying hepatotoxicants. HepaRG 
cells are bipotent progenitors, that differentiate into hepatocyte-like cells and 
biliary epithelial-like cells (Cerec et al., 2007; Parent et al., 2004). HepaRG 
expresses a more normal spectrum of drug metabolizing enzymes similar to 
primary human hepatocytes and human liver tissues, unlike other hepatoma 
cell lines such as HepG2 (Hart et al., 2010). HepG2 cells express very low 
cytochrome P450 (CYP) levels compared to primary human hepatocytes or 
human liver, particularly those involved in APAP metabolism. McGill et al. 
have demonstrated that many of the mechanistic features of APAP-induced 
hepatotoxicity in mouse hepatocytes and HepaRG cells are very similar. In 
addition, APAP-induced cytotoxicity as well as key mechanistic events 
occurring in HepaRG cells are consistent to that seen in mouse hepatocytes 
(McGill et al., 2011). Thus, the goal of the current study was to investigate 
FMO3 gene expression in HepaRG cells and to determine the functional 
significance of FMO3 over-expression during APAP-induced cytotoxicity.  
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4.3 Materials and Methods 
Chemicals 
 All chemicals were obtained from Sigma-Aldrich (St Louis, MO) and 
were of reagent grade or better.  
Cell Culture and Treatment 
 HepaRG cells, growth supplement and differentiation medium 
supplement were obtained from Biopredic International (Saint-Gregoire, 
France). Cells were maintained in Williams E medium supplemented with 1X 
glutamax, 0.05 mM riboflavin, growth or differentiation supplement and 1 % 
antibiotic-antimycotic (100 units/mL penicillin G sodium, 100 µg/mL 
streptomycin sulfate, and 0.25 µg/mL amphotericin B) in a 5 % CO2 and 
humidified environment (95 % relative humidity) at 37°C. HepaRG cell line 
differentiation was performed according to manufacturer’s protocol and is 
presented as a flowchart in Figure 4.1. Briefly, HepaRG cells were grown at 
high density in growth medium for 14 d. Cell differentiation was induced by 
maintaining cells in the differentiation medium for an additional 14 to 21 d. 
The medium was renewed every 3 d. The cells were maintained for up to four 
weeks after differentiation for use.  
 For all treatments, HepaRG cells were seeded at 4x105 cells/well in a 
24-well plate. For rifampicin treatment, cells were cultured in induction 
medium (Biopredic International) containing 10 µM rifampicin (diluted from 
1000X rifampicin stock in DMSO) for 24 h. Cells were harvested in TRIzol 
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reagent for RNA isolation. For APAP treatment, culture media was replaced 
with tox medium (Biopredic International, Saint-Gregoire, France) containing 
APAP (concentrations ranging from 1 mM to 15 mM). Cells were harvested 
for measuring LDH leakage, RNA- or microsomal-protein isolation 24 h later. 
For MMI treatment, cells were incubated in tox medium containing 1 mM MMI 
for 30 min at 37 °C. Following incubation with MMI, culture medium containing 
5 mM APAP was added to wells. Cytotoxicity was measured using the LDH 
assay kit, 24 h later. All experiments were performed in triplicates and 
repeated at least three times. 
Preparation of Microsomal Fractions for Western Blot Analysis 
 Microsomes were isolated from cells as described previously 
(Rudraiah et al., 2014). Protein concentration was determined by the method 
of Lowry using Bio-Rad protein assay reagents (Bio-Rad Laboratories, 
Hercules, CA). Microsomal proteins (10 μg) were electrophoretically resolved 
using 10 % polyacrylamide gels and transferred onto PVDF-Plus membrane 
(Micron Separations, Westboro, MA). A rabbit anti-human FMO3 primary 
antibody (BD Gentest, NJ) at a 1:500 dilution was used to detect FMO3, with 
β-Actin as loading control. Blots were then incubated with horseradish 
peroxidase (HRP) conjugated secondary antibodies against rabbit IgG 
(Sigma-Aldrich, St Louis, MO). Protein-antibody complexes were detected 
using a chemiluminescent kit (Thermo Scientific, IL) with visualization using 
GeneMate blue autoradiography film (Bioexpress, Kaysville, UT).  
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RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR) 
 TRIzol reagent (Life Technologies, Carlsbad, CA) was used to extract 
total RNA from cells and cDNA was made using the M-MLV RT kit 
(Invitrogen, Carlsbad, CA). mRNA expression was quantified by the ΔΔCT 
method and normalized to the housekeeping gene, β-actin. Primer pairs were 
synthesized by Integrated DNA Technologies (Coralville, IA), and the primer 
sequences are presented in Table 1. Amplification was performed using an 
Applied Biosystems 7500 Fast Real-Time PCR System. Amplification was 
carried out in a 20 μL reaction volume containing 8 μL of diluted cDNA, Fast 
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and 1 
μM of each primer.   
Lentiviral Vector Construction, Transduction and Clonal Selection 
 The FMO3-T2A-luc lentiviral transfer vector was constructed as 
described previously (Rudraiah et al., 2014). The replication-defective virus 
was generated in HEK 293T cells and concentrated as previously described 
(Rudraiah et al., 2014). HepaRG cells were seeded to confluency prior to 
transduction in HepaRG growth medium in a 24 well plate. The cells were 
then infected with a series of volumes of untitered concentrate (40 μL, 20 μL, 
and 10 μL per well) for three days. Prior to, during, and after viral 
transduction, cells were maintained in HepaRG growth medium containing 
0.05 mM riboflavin. Media was changed every 3 days. Clonal selection from 
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heterogeneous hFMO3-HepaRG cells was performed by the method of 
dilution. Differentiation of selected clones was performed according to 
manufacturer’s protocol described previously in this section.  
Enzyme Assay 
 FMO3 enzyme activity assay was performed using methimazole (MMI) 
as substrate as described previously (Rudraiah et al., 2014). Briefly, MMI 
metabolism was determined spectrophotometrically by measuring the rate of 
MMI S-oxygenation via the reaction of the oxidized product with nitro-5-
thiobenzoate (TNB) to generate 5,5’-dithiobis(2-nitrobenzoate) (DTNB). The 
incubation mixture consisted of NADPH generating system and 100 to 150 
μg/mL microsomal protein in sodium phosphate buffer (pH 9.0). Reactions 
were initiated by the addition of different amounts of MMI. The range of MMI 
concentrations were between 1.25 and 800 μM. Specific activity (µM/min/mg) 
was determined using the molar extinction coefficient of NADPH (28.2 mM-
1cm-1).  
LDH Leakage 
 Percent lactate dehydrogenase (LDH) leakage was determined via the 
Tox-7 kit (Sigma-Aldrich, St. Louis, MO) as a measure of cytotoxicity following 
APAP treatment. The assay was performed according to manufacturer’s 
instructions.  
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FMO3 Knockdown by shRNA  
 FMO3 short hairpin RNA (FMO3 shRNA) (sc-72256-SH) and 
scrambled shRNA (sc-108060) plasmids were obtained from Santa Cruz 
Biotechnology. Differentiated EV-HepaRG and hFMO3-HepaRG clones were 
plated at 40 to 80 % confluency 24 h prior to tansfection. FMO3 shRNA and 
scrambled shRNA plasmid transfection was performed using TransIT-TKO® 
Transfection Reagent (Mirus, Madison, WI) according to manufacturer’s 
instructions. Following transfection, cells were harvested at 72 h to isolate 
RNA and protein. Stable shRNA knockdown of FMO3 was verified by qRT-
PCR and western blot analysis for FMO3 mRNA and protein expression, 
respectively. All experiments were performed in triplicates and repeated at 
least three times. Representative results are reported.  
Statistical Analysis 
 Results are expressed as mean ± standard error (SE). Data were 
analyzed using the Student’s t-test or ANOVA followed by a post-hoc test. 
While Student’s t-test was used to compare means of two different treatment 
groups, ANOVA was used to compare the means of more than two means of 
different treatment groups that are normally distributed with a common 
variance. All statistical analysis was performed using GraphPad Prism version 
4.00 for Macintosh (GraphPad Software, Inc., San Diego, CA). Differences 
were considered significant at p<0.05.   
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Table 4.1. Primer Sequences for Quantitative RT-PCR 
Gene Primer Sequences 
Forward: 5'- TGG TTA TGG AGG CTG CAT CT -3' ABCC2 
(MRP2) Reverse: 5'- CAT ACA GGC CCT GAA GAG GA -3' 
Forward: 5'- GAC CCA CAG GTA GAT GCA GG -3' ABCC3 
(MRP3) Reverse: 5'- AGC TCG GCT CCA AGT TCT G -3' 
Forward: 5'- CCT TGC AAC TCC TCT CCA AG -3' ABCC4 
(MRP4) Reverse: 5'- ATC TGC TCA CGC GTG TTC TT -3' 
Forward: 5'- CTT CGT AAA CCA GTG GCA GG -3' 
CYP1A2 
Reverse: 5'- AGG GCT TGT TAA TGG CAG TG -3' 
Forward: 5'- GAC CAC CAG CAC AAC TCT GA -3' CYP2E1 
 Reverse: 5'- CCC AAT CAC CCT GTC AAT TT -3' 
Forward: 5'- TTT TGT CCT ACC ATA AGG GCT TT -3' 
CYP3A4 
Reverse: 5'- CAC AGG CTG TTG ACC ATC AT -3' 
Forward: 5'- TTG TAA ATG CTA GCC CTG CC -3' 
FMO3 
Reverse: 5'- CTG TCT GGA AGA GGG GCT G -3' 
Forward: 5'- CAA GGA CGT TCT CAA GTG GG -3' 
GCLC 
Reverse: 5'- CTT TCT CCC CAG ACA GGA CC -3' 
Forward: 5'- CTG AAG GAC TTC ATC TCC CG -3' 
GSTM1 
Reverse: 5'- CCC AGA CAG CCA TCT TTG AG -3' 
Forward: 5'- GTT GGT GGA ATC AAC TGC CT -3' 
UGT1A1 
Reverse: 5'- TTG ATC CCA AAG AGA AAA CCA -3' 
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4.4 Results 
CYP3A4 Transcript Constitutive and Inducible Expression Profiles in HepaRG 
Cells 
 To examine the constitutive and inducible CYP3A4 mRNA expression 
in HepaRG cells, undifferentiated (early and late) and differentiated, HepaRG 
cells were treated with 10 µM rifampicin or vehicle for 24 h. CYP3A4 mRNA 
levels were quantified by qRT-PCR. The results in Figure 4.2 show that 
CYP3A4 mRNA levels with vehicle treatment increased by 2.8±0.5-and 
6.3±0.8-fold, in late-undifferentiated and differentiated HepaRG cells, 
respectively, compared to the early-undifferentiated HepaRG cells. Following 
treatment with rifampicin, CYP3A4 mRNA expression increased by 12.5±1.1-, 
56.6±2.3-, and 172.4±8.9-fold in early-undifferentiated, late-undifferentiated 
and differentiated HepaRG cells, respectively, in comparison with vehicle 
treated early-undifferentiated HepaRG cells.  
FMO3 Gene Expression Following APAP Treatment in HepaRG Cells 
 To evaluate the FMO3 gene expression after APAP treatment in 
HepaRG cells, differentiated HepaRG cells were treated with 1, 2.5 or 5 mM 
APAP or vehicle for 24, 48 and 72 h. APAP-induced cytotoxicity was 
measured by measuring percent LDH leakage into the culture media. The 
results are shown in Figure 4.3A. The percent LDH leakage into the medium 
did not change significantly with 1 mM APAP treatment at 24, 48 or 72 h. 
While percent LDH release with 2.5 mM APAP increased significantly at 24 
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and 48 h by 7.5±0.2 and 8.7±0.1 %, respectively, the values are not 
statistically significant at 72 h compared to respective control treatment. At all 
time-points tested (24, 48 and 72 h), 5 mM APAP treatment significantly 
increased the amount of LDH release in HepaRG cells to 8.5±0.3, 14.6±0.2, 
and 20.7±0.7 %, respectively. Then, the temporal FMO3 transcript expression 
after APAP treatment was evaluated. FMO3 mRNA expression in HepaRG 
cells exposed to APAP is presented in Figure 4.3B. FMO3 mRNA levels 
increased significantly by 2±0.35-, 2.1±0.3-, and 2±0.34- fold change in 
response to 1, 2.5 and 5 mM APAP, respectively, at 24 h. While FMO3 mRNA 
transcript levels peaked with 1 mM APAP treatment at 48 h by 3±0.4-fold 
change, the levels are not statistically significant at 72 h. No change is FMO3 
mRNA expression is seen with all three doses at 72 h. To investigate if the 
increase in FMO3 transcripts translates into protein, we performed western 
blotting. Representative blots and densitometric analysis of blots are shown in 
Figure 4.3C. FMO3 protein is abundantly expressed in HepaRG cells (vehicle 
controls). Following treatment with 5 mM APAP, FMO3 protein levels 
increased significantly by 1.5±0.05- and 1.4±0.1-fold change at 24 and 48 h, 
respectively, compared to vehicle control. FMO3 protein levels decreased 
significantly at 72 h with 1, 2.5 and 5 mM APAP treatment compared to 
vehicle control. These data demonstrate that a single dose APAP treatment 
results in a significant increase in FMO3 protein levels in the human 
hepatoma cell line, HepaRG cells. 
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Establishment of Human Hepatoma Cell Line (HepaRG) Over-expressing 
Human FMO3 (hFMO3-HepaRG) 
  We developed a HepaRG cell line over-expressing human FMO3 to 
evaluate the functional significance of FMO3 over-expression during APAP-
induced cytotoxicity. The FMO3 expression vector we used previously 
(Rudraiah et al., 2014) to over-express FMO3 in the human hepatocyte cell 
line (HC-04) was used again to over-express FMO3 in HepaRG cells. The 
expression vector is a bicistronic vector driven by the ubiquitin-C promoter, 
which allowed co-expression of the FMO3 and luciferase (LUC) genes in 
transduced HepaRG cells. Twelve clones were picked from a heterogenous 
population of hFMO3-HepaRG cells. Out of twelve clones selected, two 
clones were maintained for further studies. The clones expressed a 152±13- 
and 1031±12.6-fold change in luciferase activity, compared to the empty 
vector control (EV-HepaRG) (Figure 4.4A). For convenience, these two 
hFMO3-HepaRG clones are termed the Low-hFMO3-HepaRG and High-
hFMO3-HepaRG cell line, respectively. FMO3 mRNA expression is shown in 
Figure 4.4B. FMO3 mRNA levels increased by 6.5±0.8- and 25±0.9-fold 
change in Low- and High-hFMO3-HepaRG cell line, respectively, compared 
with EV control. FMO3 protein expression was confirmed by performing 
western blotting and from FMO3 enzyme activity assay using microsomal 
fractions isolated from EV and both FMO3-over-expressing HepaRG clones. 
Representative blots, densitometric analysis of western blot and the specific 
activity of over-expressed FMO3 protein are shown in Figure 4.4C, 4.4D and 
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4.4E, respectively. Fmo3 protein levels increased by 3.2±0.1- and 5±0.04-fold 
in Low-, and High-FMO3 expressing HepaRG cells, respectively. Consistent 
with western blotting results, the specific activity of over-expressed FMO3 
protein also increased to 98±1.5, and 150±8.7 μM/min/mg in Low-, and High-
FMO3 expressing HepaRG cells, respectively, compared to EV-HepaRG 
control (64.4±5.2 μM/min/mg).  
Phenotypic Characteristics of hFMO3-HepaRG Cells in Culture 
 Representative phase-contrast micrographs of hFMO3-HepaRG Cells 
in culture are shown in Figure 4.5. hFMO3-HepaRG cells exhibit a strikingly 
faster rate of differentiation (formation of colonies of granular epithelial cells) 
compared to empty vector control cells. This is evident by the appearance of 
colonies of granular epithelial cells in the High-hFMO3-HepaRG clone as 
early as 14 d while cells are still in growth medium. (Figure 4.5C).  Empty 
vector and Low-hFMO3-HepaRG also differentiate but at slower rates. At all 
stages of differentiation, there is a consistent, expression level-dependent 
increase in rate of differentiation of hFMO3-HepaRG cells.  
Transcript Expression of Transporters, Bioactivation- and Detoxification-
Enzymes for APAP in hFMO3-HepaRG Cells 
 Untreated hFMO3-HepaRG cell lines were characterized with respect 
to the expression of genes critical in APAP bioactivation, transporters and 
detoxification pathways by qRT-PCR. Results are shown in Figure 4.6. No 
significant change in CYP1A2 expression is seen in both hFMO3-HepaRG 
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cell lines compared to EV controls. However, CYP2E1 mRNA levels 
increased by 5.3±0.1- and 14.2±0.2-fold change in Low- and High-hFMO3-
HepaRG cell line, respectively. Among all bioactivation gene expression 
tested, the increase in CYP3A4 mRNA is highest by a fold change of 11±0.4 
and 53±2.2 in Low- and High-hFMO3-HepaRG cell line, respectively, 
compared to EV control. The expression of phase II enzyme, UDP 
glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) also increased 
significantly by 2.7±0.3-fold change in High-FMO3 expressing clone while no 
change in expression was evidenced in the Low-FMO3 expressing clone.  
The expression of Glutamate-cysteine ligase (GCLC) and glutathione S-
transferase µ1 (GSTM1) showed a decreasing trend in both clones. This 
decrease is statistically significant only with GCLC in the High-FMO3 
expressing HepaRG cells. While the expression of ATP-binding cassette, 
sub-family C/multidrug resistance-associated protein (ABCC/MRP) 
particularly MRP3 and MRP4 tended to decrease with increasing FMO3 
expression, this was not statistically significant. MRP2 expression on the 
other hand increased significantly in high-FMO3 expressing clone by 
3.3±0.14-fold change compared to EV control. 
CYP3A4 Transcript Constitutive and Inducible Expression Profiles in hFMO3-
HepaRG Cells 
 To determine the CYP3A4 transcript constitutive and inducible 
expression in hFMO3-HepaRG cells, undifferentiated (early and late) and 
differentiated hFMO3-HepaRG cells were treated with 10 µM rifampicin or 
	   161	  
vehicle for 24 h. CYP3A4 mRNA levels were quantified by qRT-PCR. mRNA 
levels are presented as graphs (4.7A and 4.7B) and tabulated in Figure 4.7C.  
The results in Figure 4.7A show CYP3A4 constitutive mRNA levels at 
undifferentiated (early and late) and differentiated stages. CYP3A4 mRNA 
expression is significantly higher in High-hFMO3-HepaRG cells at both late-
undifferentiated and differentiated stages. Following treatment with rifampicin, 
CYP3A4 mRNA expression further increases significantly by 140.7±22- and 
884.9±48.1-fold change in late-undifferentiated and differentiated in High-
hFMO3-HepaRG cells, respectively, compared to respective EV-HepaRG 
controls (Figure 4.7B). These results are consistent with the faster rate of 
differentiation phenotype observed in hFMO3-HepaRG cell lines. Collectively, 
these data suggest that there is a correlation between FMO3 expression and 
differentiation in HepaRG cells that over-express human FMO3 protein and 
function.  
Effect of FMO3 Over-expression on APAP-induced Cytotoxicity in HepaRG 
Cells  
 The basal LDH leakage in vehicle treated High-hFMO3-HepaRG clone 
is significantly lower (6 %) than the EV-HepaRG cells (15 %) (Figure 4.8A). In 
Figure 4.8B, the basal LDH leakage in significantly lower in both the Low- and 
the High-hFMO3-HepaRG clones (13 % and 6 %) compared to EV controls 
(20 %). This suggests that FMO3 over-expression contributes to a 
characteristic cellular ability to resist stress. 
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  To evaluate the functional significance of FMO3 over-expression 
during APAP-induced cytotoxicity, EV-HepaRG and hFMO3-HepaRG cells 
were treated with 1, 5, 10 and 15 mM APAP for 24 h. The percent LDH 
leakage into the media in response to these four concentrations of APAP in 
Low-FMO3 expressing HepaRG cells is significantly lower (13, 16, 23 and 24 
%) compared to empty vector control (18, 22, 27 and 28 %). The percent LDH 
leakage in High-FMO3 expressing cells following 1 and 5 mM APAP 
treatment is significantly lower (8 and 11 %) than in EV cells, while higher 
LDH values (33 %) are seen at 15 mM APAP than in EV cells treated with the 
same concentration of APAP (Figure 4.8A). Taken together, these data 
suggest that over-expression of FMO3 protects against APAP-induced 
cytotoxicity in the Low-hFMO3-HepaRG clone. By contrast, High-hFMO3-
HepaRG cells are protected against lower APAP concentrations, but APAP 
cytotoxicity is aggravated at higher APAP concentrations with high FMO3 
expression.  
 The amount of LDH leakage (%) into the media does not change with 
only MMI treatment, compared with vehicle treated EV- and hFMO3-HepaRG 
cell lines. The percent LDH leakage in response to 5 mM APAP treatment 
increased significantly to 25 % in EV-HepaRG cells compared with vehicle 
treated EV-HepaRG cells (20 %). While no change in LDH leakage was 
observed in Low-hFMO3-HepaRG cells in response to APAP, percent LDH 
leakage increased in High-hFMO3-HepaRG cells to 11 % compared with 
vehicle treated High-hFMO3-HepaRG cells (8 %). The percent LDH leakage 
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in both Low- and High-hFMO3-HepaRG clones after APAP is significantly 
lower compared to APAP treated EV controls (Figure 4.8B). Following 
pretreatment with 1 mM MMI, APAP-induced cytotoxicity increased to 17 % in 
Low-FMO3 expressing cells and to 16 % in High-FMO3 expressing clone 
compared to only APAP-treated Low- and High-hFMO3-HepaRG clones. No 
change in LDH leakage is observed in MMI pretreated, APAP-treated EV cells 
compared with only APAP-treated EV cells. This data suggests that inhibition 
of FMO3 activity by MMI in Low-, and High-FMO3 expressing clones resulted 
in rescue of sensitivity to APAP only in Low-FMO3 expressing cell line 
compared to EV controls.  
Effect of Short Hairpin RNA Interference (FMO3-shRNA) on FMO3 mRNA 
and Protein Expression in EV and FMO3 Over-expressing HepaRG Cell Lines 
 To knockdown FMO3 gene expression in EV, Low-, and High-FMO3 
expressing HepaRG cells, differentiated clones were transfected with FMO3-
shRNA or scrambled-shRNA for 72 h. qRT-PCR and western blot analysis of 
FMO3 was performed 72 h after transfection (Figure 4.9). FMO3 mRNA 
expression decreased significantly to 0.25-, 0.5- and 0.67-fold change which 
represents a 75, 46.2 and 33.7 % decrease, respectively, in EV-, Low- and 
High-hFMO3-HepaRG cells, compared to their respective scrambled-shRNA 
transfected cells (Figure 4.9A). Representative western blots are shown in 
Figure 4.9B and densitometric analysis of western blot is shown in Figure 
4.9C. FMO3 protein expression in EV-HepaRG cells following FMO3-shRNA 
transfection decreased significantly to 0.18-fold change which represents a 
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82.4 % decrease, compared to scrambled-shRNA. In Low- and High-hFMO3-
HepaRG clones, FMO3 protein expression also decreased significantly to 
0.25- and 0.44-fold change, which represents a 74.8 and 56.3 % decrease, 
respectively, compared to scrambled-shRNA transfected controls (Figure 
4.9C). These data shows that the FMO3 knockdown using shRNA 
interference in hFMO3-HepaRG and EV-HepaRG clones was successful. 
Effect of FMO3 Knockdown on APAP-induced Cytotoxicity in hFMO3-
HepaRG Cells 
 To determine whether FMO3 knockdown in hFMO3-HepaRG cells 
restores their susceptibility to APAP-induced cytotoxicity, FMO3-shRNA and 
scrambled-shRNA transfected cells were treated with 5 mM APAP for 24 h. In 
response to 5 mM APAP treatment, the percent LDH leakage into the medium 
increased significantly to 33 % in EV-HepaRG cells compared with control 
treated EV-HepaRG cells (26 %) (Figure 4.10). APAP treatment also 
increased percent LDH leakage in Low- and High-hFMO3-HepaRG clones to 
31 and 30 %, respectively, compared to vehicle treated controls (25 % in 
Low- and 23 % in High-hFMO3-HepaRG cells). Even though the percent LDH 
leakage increased in hFMO3-HepaRG clones, the values were significantly 
lower only in the High-hFMO3 expressing clone compared with 5 mM APAP 
treated EV-HepaRG cells. Although, the cytotoxicity trend in response to 
APAP treatment is similar to that seen in Figure 4.8A, the overall percent LDH 
leakage is higher due to sub-confluent number of differentiated cells used in 
this study.  
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 Transfection of scrambled-shRNA or FMO3-shRNA further increased 
the percent LDH leakage in all three EV- and hFMO3-HepaRG cell lines. No 
significant change in LDH leakage in scrambled-shRNA transfected, APAP 
treated cells is observed in comparison with scrambled-shRNA transfected 
cells. Furthermore, percent LDH leakage in FMO3-shRNA transfected cells 
exposed to APAP increased in Low- and High-hFMO3 HepaRG cells 
compared to scrambled shRNA transfected APAP treated cells.  Together 
these data suggests that FMO3 knockdown in Low- and High-hFMO3-
HepaRG cells restores their susceptibility to APAP-induced cytotoxicity. 
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Figure 4.1 
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Figure 4.1 HepaRG cell line differentiation protocol flowchart. 
Undifferentiated HepaRG cells are maintained in growth medium from Day 0 
(HepaRG Undifferentiated early) to Day 14 (HepaRG Undifferentiated late).  
On Day 0, HepaRG cells appear elongated with clear cytoplasm. During 
proliferation period cells appear as a homogenous cell population with an 
epithelial phenotype showing no regular structural organization. When the 
cells reach confluency, they undergo progressive morphological changes 
acquiring a granular cytoplasm. From Day 15 to Day 23, cells are maintained 
in differentiation medium diluted by half with growth medium. From day 24 
onwards, cells are maintained in only differentiation medium. Between Day 28 
and Day 35, cells appear differentiated into two subpopulations (HepaRG 
Differentiated):  hepatocyte-like cells  and  biliary epithelial-like cells.     
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Figure 4.2 
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Figure 4.2 Quantitative RT-PCR analysis of CYP3A4 transcripts following 
Rifampicin treatment in undifferentiated (early and late) and differentiated 
HepaRG cells. RNA was isolated from cells treated with rifampicin (10μM) or 
vehicle for 24 h. mRNA expression was measured by qRT-PCR using human 
primers specific for CYP3A4. Gene expression was normalized to the 
housekeeping gene β-Actin. CYP3A4 mRNA expression is presented as 
mean Fold Change ± SE. Two-way ANOVA was performed followed by the 
Bonferroni’s post-test. Asterisks (*) represent a statistical difference (p < 0.05) 
between control and rifampicin treatment. 
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Figure 4.3 
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Figure 4.3 Effect of APAP treatment on cytotoxicity and FMO3 gene 
expression in HepaRG cells. Differentiated HepaRG cells were treated with 1, 
2.5, and 5 mM APAP or control. At 24, 48, and 72h after treatment, percent 
LDH leakage into the medium was measured using a commercial kit. The 
data are presented as mean LDH leakage (%) ± SE (A). RNA was isolated 
from cells at 24, 48 and 72 h after APAP treatment or vehicle. FMO3 mRNA 
expression was measured by qRT-PCR using human-specific FMO3 primers. 
Gene expression was normalized to the housekeeping gene β-Actin. FMO3 
mRNA expression is shown as mean Fold Change ± SE (B). Western blot for 
FMO3 was performed using 10 µg microsomal protein isolated from HepaRG 
cells treated with APAP or vehicle. Rabbit anti-human FMO3 primary antibody 
was used to detect FMO3 protein expression. Equal protein loading was 
confirmed by detection of β-actin. The data are presented as blots as well as 
mean FMO3 protein expression (Fold Change) ± SE. Two-way ANOVA was 
performed followed by the Bonferroni’s post-test. Asterisks (*) represent a 
statistical difference (p < 0.05) between control and APAP treatment. 
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Figure 4.4 
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Figure 4.4 Establishment of HepaRG cells over-expressing human FMO3 
(hFMO3-HepaRG). Lentiviral vector construction and transduction are 
described in Materials and Methods. Luciferase activity was measured to 
determine the efficiency of transduction in hFMO3-HepaRG clones (A). 
Luciferase activity is presented as mean luciferase activity/mg protein (Fold 
Change) ± SE. FMO3 mRNA expression in EV and FMO3 over-expressing 
HepaRG clones. The data are presented as mean Fold Change ± SE (B). 
Western blot for FMO3 in EV and hFMO3-HepaRG clones. Rabbit anti-human 
FMO3 primary antibody was used to detect FMO3 protein expression. The 
data are presented as blots (C) as well as mean FMO3 protein expression 
(Fold Change) ± SE (D). Microsomes isolated from EV and hFMO3 over-
expressing clones were used to measure FMO3 activity using methimazole 
as substrate. Data are presented as mean Specific Activity (μM/min/mg) ± 
SE. One-way ANOVA was performed followed by the Dunnett’s post-test. 
Asterisks (*) represent a statistical difference (p< 0.05) compared to EV 
controls. 
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Figure 4.5 
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Figure 4.5 Phase-contrast micrographs of HepaRG cells over-expressing 
human FMO3 (hFMO3-HepaRG). Empty vector and hFMO3 over-expressing 
HepaRG clones were grown and differentiated as described in Materials and 
Methods and Figure 1. Representative micrographs on Day 14 (A, B, C), Day 
23 (D, E, F), Day 35 (G, H, I) and Day 45 (J, K, L) are shown. Scale bar: 400 
µm.  
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Figure 4.6 
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Figure 4.6 Expression profiles of genes involved in acetaminophen 
bioactivation, detoxification, and transport in HepaRG cells over-expressing 
human FMO3 (hFMO3-HepaRG). RNA isolated from untreated empty vector- 
and hFMO3-HepaRG clones was reverse transcribed to cDNA. The cDNA 
samples were analyzed by qRT-PCR using human-specific primers and the 
gene expression was normalized to the housekeeping gene β-Actin. Gene 
expression of acetaminophen bioactivating enzymes (CYP1A2, CYP2E1, and 
CYP3A4), detoxifying enzyme (UGT1A1), glutathione homeostasis enzymes 
(GCLC and GSTM1), and efflux transporters (MRP2, MRP3 and MRP4) were 
analyzed. mRNA expression are presented as mean Fold Change ± SE. One-
way ANOVA was performed followed by the Dunnett’s  post-test. Asterisks (*) 
represent a statistical difference (p < 0.05) compared to EV controls.  
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Figure 4.7 
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Figure 4.7 Relative CYP3A4 mRNA expression following Rifampicin 
treatment in empty vector and hFMO3-HepaRG clones. RNA was extracted 
from cells following rifampicin (10 μM) treatment or control, and cDNA was 
prepared using a commercial MMLV-RT kit. The cDNA samples were 
analyzed for CYP3A4 mRNA levels by quantitative RT-PCR. CYP3A4 gene 
expression was normalized to housekeeping gene β-Actin. mRNA expression 
after control (A) and rifampicin (B) treatment are presented as mean Fold 
Change ± SE. CYP3A4 mRNA expression profiles in hFMO3-HepaRG Cells 
is shown in Table (C). Two-way ANOVA was performed followed by the 
Bonferroni’s post-test. Asterisks (*) represent a statistical difference (p < 0.05) 
from respective EV-HepaRG cells.  
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Figure 4.8  
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Figure 4.8 Significance of FMO3 over-expression During APAP-induced 
cytotoxicity in HepaRG cells. Empty vector, Low-, and High-FMO3 expressing 
clones were treated with APAP concentrations from 1 mM to 15 mM. Percent 
LDH leakage into the medium was measured 24 h later, using a commercial 
kit. The data are presented as mean LDH leakage (%) ± SE (A). Two-way 
ANOVA was performed followed by the Bonferroni’s post-test. Asterisks (*) 
represent a significant difference (p< 0.05) compared to respective vehicle 
control group and pound (#) represent a significant change (p<0.05) 
compared to respective EV controls. (B) To inhibit FMO3, EV, Low-, and 
High-FMO3 expressing clones were incubated with MMI (1 mM) for 30 min 
before APAP (15 mM) treatment. Percent LDH leakage into the medium was 
measured 24 h after APAP treatment. The data are presented as mean LDH 
leakage (%) ± SE. Asterisks (*) represent a significant difference (p< 0.05) 
compared to the respective vehicle treated clone, and pound (#) represent a 
significant difference (p<0.05) compared to respective 5 mM APAP treated  
clone. 
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Figure 4.9 
 
 
	   183	  
 
 
 
 
Figure 4.9 FMO3 mRNA and protein expression after short hairpin RNA 
interference in EV and FMO3 over-expressing HepaRG clones. qRT-PCR 
analysis of FMO3 transcripts 72 h after FMO3-shRNA or scrambled-shRNA 
transfection in EV, Low-, and High-FMO3 expressing clones. The data are 
presented as mean Fold Change ± SE (A). Western blots for FMO3 were 
performed using microsomes isolated from scrambled- or FMO3-shRNA 
transfected EV and FMO3 over-expressing HepaRG clones. Recombinant 
human FMO3 protein was used as a positive control indicated by “+” sign. 
The data are presented as blots (B) and as mean FMO3 protein expression 
(Fold Change) ± SE (C). Two-way ANOVA was performed followed by the 
Bonferroni’s post-test. Asterisks (*) represent a significant decrease 
compared to scrambled-shRNA transfected control.  
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Figure 4.10 
 
 
	   185	  
 
 
 
 
Figure 4.10 Effect of FMO3 knockdown on APAP-induced cytotoxicity in 
FMO3 over-expressing HepaRG clones. Empty vector, Low-, and High-FMO3 
expressing cell lines were transfected with scrambled- or FMO3-shRNA for 72 
h. Cells were treated with 5 mM APAP for 24 h. Percent LDH leakage into the 
medium was measured. The data are presented as mean LDH leakage (%) ± 
SE. Two-way ANOVA was performed followed by the Bonferroni’s post-test. 
Asterisks (*) represent a significant decrease (p< 0.05) compared to 
respective EV-HepaRG cells and pound (#) represent a significant increase 
compared to respective APAP treated scrambled sh-RNA transfected clone. 
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4.5 Discussion 
 Primary human hepatocytes are the most pertinent model for studying 
xenobiotic metabolism and toxicity, including APAP-induced hepatotoxicity. 
However, they have major drawbacks in that the availability of these cells is 
limited, isolation procedures are complicated, they are expensive and due to 
inter-individual variability, the drug response can vary significantly from one 
batch of hepatocytes to the next (Madan et al., 2003). The lifespan of primary 
human hepatocytes is short and they undergo changes in CYP expression 
levels (primarily loss) over time in culture. To overcome these limitations, 
immortalized liver-derived cell lines were introduced as an alternative model 
for studying in vitro metabolism and cytotoxicity (Gerets et al., 2012). 
Because of their unlimited availability and phenotypic stability, hepatoma cell 
lines like HepG2 cells have been used extensively in toxicity studies. They 
express very low CYP levels compared to primary human hepatocytes or 
human liver, especially those isoforms that are involved in the metabolism of 
APAP (Rodriguez-Antona et al., 2002). Their low metabolic capacity makes 
them useful for toxicity testing of parent molecules and less suitable for 
metabolite toxicity testing. HepaRG, a human hepatoma cell line, is a recently 
developed cellular model that expresses a more normal spectrum of drug 
metabolizing enzymes. The mechanistic features of APAP-induced 
hepatotoxicity in HepaRG cells are similar to that reported for mouse 
hepatocytes and mouse liver in vivo (McGill et al., 2011). Recently we 
demonstrated FMO3 gene induction in an acetaminophen resistance mouse 
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model termed APAP autoprotection. Although the phenomenon of APAP 
autoprotection is also seen in patients exposed to supratherapeutic doses of 
APAP, the mechanism is not known. Thus, the goal of the present study was 
to investigate FMO3 gene induction in HepaRG cells, an in vitro model of 
human hepatocytes much closer to the in vivo situation, and to also determine 
the functional significance of FMO3 over-expression during APAP-induced 
cytotoxicity.   
 Primary human hepatocytes express high cytochrome P450 (CYP) 
levels and exhibit higher responsiveness to CYP inducers, such as 
phenobarbital, beta-naphthoflavone and rifampicin. Constitutive and inducible 
CYP3A4 mRNA expression in HepaRG cells is widely used to assess 
metabolic and/or differentiation status (Aninat et al., 2006; Gerets et al., 2012; 
Hart et al., 2010). Thus, HepaRG cell’s responsiveness to rifampicin was 
evaluated at different growth stages. At confluence, as well as, with addition 
of differentiation medium, HepaRG cells differentiate into hepatocyte- and 
biliary epithelial-like cells (Gripon et al., 2002; Hart et al., 2010). Consistent 
with the literature, HepaRG cells in culture progressively differentiate which is 
evident from their responsiveness to rifampicin on Day 14 and Day 35. Then, 
differentiated HepaRG cells were exposed to APAP concentrations ranging 
from 1 to 5 mM. While 1 mM APAP treatment did not significantly increase 
LDH release from cells at any of the time-points tested, 2.5 mM APAP 
increased LDH leakage at 24 and 48 h. By 72 h, no difference in LDH leakage 
was detected compared to vehicle treated controls. This is suggestive of mild 
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cellular injury caused by 2.5 mM APAP that resolves by 72 h. On the contrary, 
the cellular injury by 5 mM APAP is progressive and does not resolve by 72 h. 
FMO3 mRNA levels increase at 24 h with all three doses of APAP and at 48 
h, the increase is statistically significant only with 1 mM APAP. Even though 
mRNA increase is seen with 1 and 2.5 mM APAP, the FMO3 protein 
expression does not change. On the contrary, 5 mM APAP results in 
significant increase in FMO3 protein levels at 24 and 48 h, but the levels are 
significantly lower at 72 h. This observation with respect to the relationship 
between degree of toxicity and FMO3 gene expression, where FMO3 gene 
expression decreases during overt toxicity and mild toxicity induces FMO3 
gene expression, is consistent with our previous results in vivo with various 
hepatoxicants in mice (Rudraiah et al., 2014; Rudraiah et al., 2014).  
 The decrease in FMO3 protein expression at 72 h may be due to 
production of H2O2. Even though FMOs form a relatively stable 
hydroperoxyflavin intermediate and does not contribute to production of H2O2, 
during absence of NADPH, peroxyflavin can decompose to hydrogen 
peroxide resulting in significant loss of enzyme activity (Cashman, 1999).  
Collectively, it is notable that FMO3 gene expression is inducible by APAP-
induced cytotoxicity in HepaRG cells. Although the change in FMO3 protein 
expression is only by a fold-change of 1.5, the constitutive FMO3 protein 
expression in HepaRG cells is very high (comparable to CYP3A4 expression). 
A fold-change of 1.5, can be very large and physiologically significant. 
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 To further investigate the importance of FMO3 over-expression during 
APAP-induced cytotoxicity, we successfully established an over-expression 
system. The FMO3 over-expressing HepaRG cell lines exhibit a striking 
expression level-dependent faster rate of differentiation compared to empty 
vector control cells. To examine any possible difference in gene expression 
profiles that might contribute to APAP-induced cytotoxicity, genes involved in 
acetaminophen-bioactivation, -detoxification, and efflux transporters were 
screened. Interestingly, an FMO3 level-dependent increase in expression of 
CYP2E1, CYP3A4, UGT1A1 and MRP2 genes and a decrease in GCLC, are 
seen. Most striking are the gene expression changes for CYPs, particularly 
CYP3A4. Cashman et al. reported a concomitant increase in FMO3, FMO4 
and CYP2E1 functional activity in rats on total parenteral nutrition and choline 
(Cashman et al., 2004), but a correlation or interdependence between the two 
was not investigated. Currently there are no reports in the literature that show 
a correlation with FMO3 gene expression and CYP activity. The mechanism 
of such a regulation is also not known and warrants further investigation.  
 To examine whether the observed phenotype of faster differentiation in 
hFMO3-HepaRG cells is consistent with its responsiveness to rifampicin 
treatment, FMO3-over-expressing HepaRG cells were exposed to rifampicin 
and CYP3A4 mRNA levels were quantified. Consistent with the observed 
phenotype of greater differentiation state, CYP3A4 induction is significantly 
higher in FMO3-over-expressing cell lines compared to empty vector control. 
This suggests that the HepaRG cells over-expressing FMO3 are 
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differentiating at a faster rate compared to control cell line and that they 
respond more robustly to enzyme induction treatment. The mechanism by 
which FMO3 over-expression is driving cellular differentiation is not known. 
 Furthermore, the percent LDH leakage into the media in Low-hFMO3-
HepaRG cells in response to APAP treatment is significantly lower compared 
to empty vector control. In High-hFMO3-HepaRG cells, the amount of LDH 
leakage by APAP is significantly lower at lower APAP concentrations, but at 
higher APAP concentrations, the LDH leakage is significantly greater. This 
trend where low FMO3-over-expression being protective and high FMO3-
over-expression combined with toxic APAP dose being more toxic is also 
seen with FMO3-over-expressing hepatocyte cell line (HC-04) (Rudraiah et 
al., 2014). Taken together, these data suggest that over-expression of FMO3 
significantly alters susceptibility to APAP-induced cytotoxicity. It should also 
be noted that the High-hFMO3-HepaRG cells express significantly higher 
CYPs that metabolize APAP. The toxicity noticed may be due to over 
production of toxic metabolite NAPQI or due to production of H2O2. Examining 
gene expression and metabolite profiles using transcriptomics and 
metabolomic approaches in these cell lines could help identify signaling 
molecules and pathways involved in cellular differentiation driven by FMO3.  
 FMO3 inhibition by MMI has been demonstrated in our lab (Rudraiah  
et al., 2014). Inhibition of FMO3 activity by MMI resulted in rescue of 
sensitivity to APAP toxicity. However, since MMI is not a specific FMO3 
inhibitor, we used RNA interference to knockdown over-expressed FMO3 in 
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FMO3-over-expressing cell lines. Transfection of sh-FMO3 resulted in a 
significant decrease in FMO3 protein expression in EV- and FMO3-over-
expressing cell lines. These transfection experiments and APAP treatment 
were performed in a 50 to 60 % cell confluent conditions but APAP dose 
response in Figure 8 was performed at a high density (100 % confluent 
conditions). Because of the lower confluency as well as toxicity resulting from 
transfection procedure itself, cells exhibit higher basal LDH leakage into the 
media compared to experiments performed using 100 % confluent conditions. 
Although the knockdown of FMO3 in hFMO3-HepaRG cells did restore the 
susceptibility to APAP-induced cytotoxicity exhibited by the EV cells with 
normal FMO3 levels, the scrambled-RNA transfected cells exhibit higher 
toxicity compared to only APAP  treated EV- and hFMO3-HepaRG cell lines. 
Finally, FMO3 knockdown in hFMO3-HepaRG cells were capable of 
differentiating at a rate similar to non-knockdown hFMO3-HepaRG clones 
(data not shown). Furthermore, western blotting of differentiated knockdown-
hFMO3-HepaRG cells, failed to show low FMO3 expression compared to 
differentiated scrambled-shRNA transfected hFMO3-HepaRG cells (data not 
shown). Although FMO3 knockdown was successful, the lack of a selection 
marker in the sh-FMO3 plasmid prevented us to control the cells repopulating 
the plate after knockdown. Development of a knockdown clone can address 
this problem.   
 In summary, we show FMO3 gene induction by APAP-induced 
cytotoxicity in HepaRG cells. This is the first report demonstrating xenobiotic 
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mediated FMO3 gene induction in a human hepatoma cell line. Even though 
the mechanism of induction or the role of FMO3 in APAP-induced 
hepatotoxicity/cytotoxicity is not clearly known, there are two potential 
hypotheses for its potential role during toxicant exposure. One involving a role 
for cyteamine in maintaining the cellular thiol:disulphide potential in a cell 
(Ziegler et al., 1979) and the other is the possible regulation of immune cells  
by an FMO3 metabolite (Bennett et al., 2013; Z. Wang et al., 2011). Strikingly, 
data presented in this manuscript demonstrates a third novel dimension to 
FMO3 function during toxicant exposure. Our data shows that FMO3 may be 
involved in driving cellular differentiation. Although this calls for further 
investigation, the potential role of FMO3 in cellular proliferation and 
differentiation is consistent with the considerable lag time in gene and protein 
induction seen in our mouse model of APAP autoprotection (Rudraiah et al., 
2014), where protein peaks at 72 h after a single dose APAP treatment. This 
time frame is consistent with stages of repair and regeneration with APAP 
toxicity.  
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CHAPTER 5 
Human Hepatic Flavin-containing Monooxygenase-3 (FMO3) Gene 
Expression is Not Regulated by Nuclear Factor, Erythroid 2- Like 2 
(NRF2/NFE2L2) Under Oxidative Stress Conditions 
 
5.1 Abstract 
 The flavin-containing monooxygenases  (FMOs) are important for the 
oxidation of a variety of endogenous compounds and xenobiotics. The 
hepatic expression of FMO3 is highly variable and until recently, it was 
thought to be uninducible. In this study, human FMO3 gene regulation by the 
oxidative stress transcription factor, nuclear factor (erythroid-derived 2)-like 2 
(NRF2) was examined. Constitutive FMO3 gene expression is repressed in 
HepG2 cells, thus this cell can be a good model for FMO3 gene regulation 
studies. Over-expression of NRF2 in HepG2 cells increased NRF2 target 
gene expression, heme oxygenase-1 (HMOX1) and NAD(P)H:quinone 
oxidoreductase-1 (NQO1), but did not alter FMO3 gene expression. Co-
transfection studies with NRF2 or its cytosolic regulatory protein, Kelch-like 
ECH-associated protein 1 (KEAP1), expression vectors, along with FMO3 
promoter luciferase reporter constructs of various lengths (5 Kb or 6 Kb), did 
not change FMO3 reporter gene activity significantly. Furthermore, treatment 
with tert-butyl hydroperoxide (tBHP) or tert-butyl hydroquinone (tBHQ) did not 
alter FMO3 reporter construct activity. In summary, in vitro results suggest 
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that the transcriptional regulation of FMO3 might not involve the NRF2-
KEAP1 regulatory pathway.  
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5.2 Introduction 
 Flavin-containing monooxygenases (FMOs) are enzymes that catalyze 
oxidation of a variety of nitrogen-, sulphur- and phosphorous-containing 
xenobiotics to their respective oxides. In human liver, constitutive FMO3 
expression and developmental expression patterns have been extensively 
studied (Klick & Hines, 2007; Klick et al., 2008; Shimizu et al., 2008). Briefly, 
Klick and Hines demonstrated that binding of transcription factors such as 
nuclear factor Y (NFY), upstream stimulatory factor 1 (USF1), YYI and an 
unidentified GC box to the regulatory domains upstream of the transcription 
start site are important for regulating constitutive FMO3 transcription (Klick & 
Hines, 2007). The pre-B-cell leukemia factor 2 (Pbx2) as a heterodimer with 
an unidentified homeobox (Hox) isoform contributes to FMO3 developmental- 
and tissue-specific regulation (Klick & Hines, 2007). Another factor, CCAAT 
enhancer-binding protein β (C/EBPβ), binding more distal to the transcription 
start site, is important for the FMO3 developmental expression pattern (Klick 
et al., 2008). Finally, Shimuzu et al. (2008) reported that HNF-4 and NF-Y 
modulates FMO3 gene expression in the Japanese population. Because 
xenobiotic-induced FMO3 gene expression was not identified, transcriptional 
regulation during toxicant exposure is not well characterized. 
 Acetaminophen (APAP)-induced hepatotoxicity results in Fmo3 over-
expression in mice (Rudraiah et al., 2014). Additionally, we also showed that 
toxic alpha-naphthyl isothiocyanate (ANIT) treatment and bile duct ligation 
(BDL) induced Fmo3 gene expression (Rudraiah et al., 2014). Because all 
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hepatotoxicants that induce Fmo3 also induce oxidative stress, the goal of the 
current study was to investigate whether oxidative stress transcription factor 
nuclear factor (erythroid-derived 2)-like 2 (NRF2) might regulate FMO3 gene 
expression. FMO3 Constitutive expression is repressed in HepG2 cells 
making this cell line useful for studying FMO3 regulation using recombinant 
FMO3 promoter-directed reporter constructs. Thus, all in vitro studies were 
performed in HepG2 cells. Reporter constructs containing FMO3 promoter 
sequences of various lengths (5 Kb or 6 Kb) directing luciferase expression 
were used in the current study. Co-transfection studies with FMO3 promoter 
luciferase reporter constructs and NRF2 or its cytosolic retainer Kelch-like 
ECH-associated protein 1 (KEAP1) did not significantly alter luciferase 
reporter gene activity. Subsequent promoter analysis using MatInspector 
software (Genomatix, Munich, Germany), did not identify any antioxidant 
response element (ARE) sites on the reporter constructs used in the current 
study. These results suggest that the transcriptional regulation of FMO3 might 
not involve NRF2-KEAP1 regulatory pathway. 
5.3 Material and Methods 
Chemicals  
 Tert-butyl hydroperoxide and tert-butyl hydroquinone were purchased 
from Sigma-Aldrich (St Louis, MO). All other reagents were of reagent grade 
or better and commercially available.  
Cell Culture and Transient Transfection Reporter Gene Assay 
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 HepG2 cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10 mM glucose, 10 % fetal bovine serum and 1 
% antibiotic-antimycotic (100 units/mL penicillin G sodium, 100 µg/mL 
streptomycin sulfate, and 0.25 µg/mL amphotericin B) in a 5 % CO2 and 
humidified environment (95 % relative humidity) at 37°C. Expression plasmids 
containing variable lengths of FMO3 promoter sequences (5905bp:pRNH970 
or 4908bp:pRNH1013) directing luciferase expression were prepared using a 
Genome Walker Kit (BD Biosciences) as described previously (Klick & Hines, 
2007). Expression plasmid p3XFLAG-myc-CMV-26 (EV26) was obtained from 
Sigma-Aldrich (St Louis, MO). NRF2 or KEAP1 ORF (Open Biosystems, 
Waltham, MA) was cloned into EV26. For transient transfection, HepG2 cells 
were seeded in a 12-well plate at approximately 30 % confluence. The 
following day, transient transfection (NRF2 or KEAP1 expression plasmids 
prepared in our lab) or co-transfections (FMO3 promoter luciferase reporter 
constructs and transcription factor expression plasmids) was performed using 
Lipofectamine (Invitrogen) according to the manufacturer’s manual. Cells 
were harvested for RNA isolation or to determine luciferase activity using the 
luciferase assay system (Promega) according to the manufacturer’s protocol. 
For tert-butyl hydroperoxide (tBHP) and tert-butyl hydroquinone (tBHQ) 
treatment culture media (complete DMEM) was replaced with media 
containing 100 μM tBHP or 100 μM tBHQ 6 h after transfection.  Cells were 
harvested 42 h after treatment to determine luciferase activity. If not otherwise 
indicated, the amount of lipofectamine used was 2.5 μL/well, the amount of 
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transfected plasmids was 0.3 μg/well for transcription factors and 0.5 μg/well 
for reporter genes.  
RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR) 
 TRIzol reagent (Life Technologies, Carlsbad, CA) was used to extract 
total RNA from cells transiently transfected with expression plasmids 
containing NRF2 or KEAP1. cDNA was prepared using the M-MLV RT kit 
(Invitrogen, Carlsbad, CA). NRF2, KEAP1, HMOX1, NQO1 and FMO3 mRNA 
expression was quantified by the ΔΔCT method and normalized to the 
housekeeping gene, β-actin. Primer pairs were synthesized by Integrated 
DNA Technologies (Coralville, IA) and are presented in Table 1. Amplification 
was performed using an Applied Biosystems 7500 Fast Real-Time PCR 
System. Amplification was carried out in a 20 μL reaction volume containing 8 
μL diluted cDNA, Fast SYBR Green PCR Master Mix (Applied Biosystems, 
Foster City, CA) and 1 μM of each primer.   
Isolation of Nuclear Fraction from HepG2 Cells 
 HepG2 cells were plated at 8x105 cells per dish in a 60 mm dish 
overnight. The following day, cells were treated with 100 μM tBHP in serum 
free DMEM for 2 h.  After 2 h, cells were removed from the incubator, scraped 
and collected in 1 mL cold PBS and transferred into microcentrifuge tubes. 
The cell suspension was then centrifuged at 12000 g for 1 min to collect the 
cells. Cell pellets were resuspended in 400 μL cold hypotonic buffer [10 mM 
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HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and 0.2 mM 
phenylmethylsulfonylfluoride (PMSF)] and incubated for 20 min on ice, 
vortexed for 10s and then centrifuged at 1000 g for 10 min at 4°C. The 
resulting pellet was again resuspended in hypertonic buffer (20 mM HEPES, 
pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, 0.5 mM DTT, 25 % 
glycerol and 0.2 mM PMSF) and incubated on ice for 20 min for high-salt 
extraction. Samples were vortexed for 10s and centrifuged at 1000 g for 10 
min. The supernatant fraction containing nuclear proteins was measured for 
protein concentration.  
Western Blot Analysis 
 For western blot analysis of NRF2, 40 μg nuclear protein was mixed 
with Laemmli’s buffer, incubated at 90°C for 10 min, and electrophoretically 
resolved using 10 % SDS polyacrylamide gels and transblotted onto PVDF-
Plus membrane (Micron Separations, Westboro, MA). A custom rabbit anti-
Human NRF2 primary antibody (Cell Signaling Technology, Inc. Danvers, 
MA) was used to detect NRF2 with TFIIB as a loading control. Blots were 
then incubated with HRP conjugated secondary antibodies against rabbit IgG 
(Sigma-Aldrich, St Louis, MO). Protein-antibody complexes were detected 
using a chemiluminescent kit (Thermo Scientific, IL) with visualization using 
GeneMate blue autoradiography film (Bioexpress, Kaysville, UT).  
LDH Leakage 
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 Percent lactate dehydrogenase (LDH) leakage was determined via the 
Tox-7 kit (Sigma-Aldrich, St. Louis, MO) as a measure of cytotoxicity following 
tBHP treatment. The assay was performed according to manufacturer’s 
instructions.  
Statistical Analysis 
 Results are expressed as mean ± standard error (SE). Data were 
analyzed using the student’s t-test, one-way ANOVA with Dunnett’s post-hoc 
test or two-way ANOVA followed by the Bonferroni’s post-hoc test. All 
statistical analysis was performed using GraphPad Prism version 4.00 for 
Macintosh (GraphPad Software, Inc., San Diego, CA). A p value of <0.05 was 
considered statistically significant.   
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Table 5.1 Primer Sequences for Quantitative RT-PCR 
Gene Primer Sequences 
Forward: 5'- TTG TAA ATG CTA GCC CTG CC -3' 
FMO3 
Reverse: 5'- CTG TCT GGA AGA GGG GCT G -3' 
Forward: 5'- GCC AGC AAC AAA GTG CAA G -3' 
HMOX1 
Reverse: 5'- GAG TGT AAG GAC CCA TCG GA -3' 
Forward: 5'- TGA CAA GCT TAT GCA GCC AGA TCC CAG G -3' 
KEAP1 
Reverse: 5'- GTG AGG ATC CTC AAC AGG TAC AGT TCT GCT GGT -3' 
Forward: 5'- GGA CTG CAC CAG AGC CAT -3' 
NQO1 
Reverse: 5'- TCC TTT CTT CTT CAA AGC CG -3' 
Forward: 5'- GCT CAT ACT CTT TCC GTC GC -3' 
NRF2 
Reverse: 5'- ATC ATG ATG GAC TTG GAG CTG -3' 
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5.4 Results 
NRF2 and KEAP1 Over-expression Did Not Significantly Alter FMO3 mRNA 
Expression in HepG2 Cells 
 To examine the possible role of the NRF2-KEAP1 regulatory pathway 
in controlling FMO3 gene expression, FMO3 mRNA levels were quantified in 
cells over-expressing NRF2 or its cytosolic regulatory protein, KEAP1. The 
results in Figure 5.1 show that transfection with the NRF2 expression vector 
results in a 2.7±0.2-fold change in NRF2 mRNA levels compared to empty 
vector-transfected cells. Transfection with KEAP1 expression vector results in 
a 1.4±0.15-fold change in KEAP1 mRNA levels compared to empty vector 
controls. Over-expression of NRF2 results in significantly higher expression of 
the NRF2 target genes, NQO1 and HMOX1, by 3.1±0.7-fold and 3.4±0.4-fold, 
respectively, compared to the empty vector. No significant change in FMO3 
mRNA expression is observed with NRF2 over-expression. In addition, no 
significant change in NQO1, HMOX1 and FMO3 mRNA expression is seen 
with KEAP1 over-expression  (Figure 5.1). 
A Subtoxic Dose of tBHP Results in NRF2 Nuclear Translocation and 
Expression of NRF2 Target Genes in HepG2 Cells 
 In response to a 100 µM tBHP treatment for 24 h, the percent LDH 
leakage from HepG2 cells did not change (Figure 5.2A). Treatment with a 
subtoxic dose of tBHP (100 µM) for 2 h results in an increase in NRF2 nuclear 
localization (Figure 5.2B).  The increased nuclear localization of NRF2 is 
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associated with significant increases in the expression of the NRF2 target 
genes, HMOX1 and NQO1 by 1.8±0.3- and 1.7±0.06-fold, respectively, 
compared to vehicle treated controls (Figure 5.2C and 5.2D). 
Effect of NRF2 or KEAP1 Over-expression on FMO3-directed Reporter Gene 
Activity 
 To determine whether the transcription factor, NRF2, activates FMO3 
gene expression, co-transfection studies with NRF2 or KEAP1 expression 
vectors and FMO3 promoter luciferase reporter constructs (pRNH1013 and 
pRNH970) were performed. Co-transfection of reporter genes with NRF2 or 
KEAP1 did not significantly alter FMO3-directed reporter gene activity (Figure 
5.3A). Furthermore, NRF2 or KEAP1 over-expression studies also were 
carried out using a subtoxic dose of the pro-oxidant and Nrf2 activator, tBHP. 
Results are shown in Figure 5.3B. No significant change in reporter gene 
activity is seen with KEAP1 co-transfection. However, tBHP treatment 
combined with NRF2 expression plasmid and FMO3 promoter luciferase 
reporter construct co-transfection, significantly decreased luciferase activity.  
Effect of Pro-oxidant-induced NRF2-KEAP1 Regulatory Pathway Activation 
on FMO3-directed Reporter Gene Activity 
 FMO3 promoter luciferase reporter constructs (pRNH1013 & 
pRNH970) or empty vector were transiently expressed in HepG2 cells and 
exposed to tBHP or tBHQ. No significant change in reporter gene activity is 
observed after treatment (Figure 5.4). 
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Figure 5.1 
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Figure 5.1 Effect of NRF2 and KEAP1 over-expression on FMO3 mRNA 
levels in HepG2 cells. The oxidative stress responsive transcription factor, 
NRF2, or its cytosolic regulatory protein, KEAP1, were transiently expressed 
in HepG2 cells. RNA was isolated from cells 48 h after transfection. cDNA 
was made using a commercial MMLV-RT kit and the cDNA samples were 
analyzed by quantitative RT-PCR using human NRF2, KEAP1, NQO1, 
HMOX1 and FMO3 specific primers. mRNA levels were normalized to the 
housekeeping gene, β-Actin. NRF2, KEAP1, HMOX1, NQO1 and FMO3 
mRNA expression are presented as mean fold change ± SE. Each 
experiment was done in triplicate and repeated at least three times, and 
representative experimental results are shown. One-way ANOVA followed by 
Dunnett’s post-hoc test was used for data analysis. Asterisks (*) represent a 
statistical difference (p < 0.05) from empty vector (EV26) transfected group.  
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Figure 5.2 
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Figure 5.2 Effect of tBHP treatment on cytotoxicity and NRF2-KEAP1 
regulatory pathway in HepG2 cells. (A) HepG2 cells were treated with tBHP 
(100 μM) or vehicle for 2 h. Cytotoxicity with 100 μM tBHP was measured by 
measuring LDH activity in the medium 2 and 24 h after treatment. The data 
are presented as LDH leakage (%) ± SE. (B) Western blots for NRF2 were 
performed using nuclear fractions from tBHP- and vehicle-treated HepG2 
cells. RNA was isolated from HepG2 cells 24 h after treatment with tBHP. 
cDNA samples were analyzed by quantitative RT-PCR for NRF2 target genes 
HMOX1 (C) and NQO1 (D). Gene expression was normalized to the 
housekeeping gene β-Actin. NQO1 and HMOX1 mRNA expression are 
presented as mean fold change ± SE. Each experiment was done in triplicate 
and repeated at least three times, and representative experimental results are 
shown. Student’s t-test was used for data analysis. Asterisks (*) represent a 
statistical difference (p < 0.05) from control treated group.  
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Figure 5.3 
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Figure 5.3 Effect of NRF2 or KEAP1 over-expression on FMO3-directed 
reporter gene activity. Transcription factor, NRF2, or its cytosolic regulatory 
protein, KEAP1, were transiently co-expressed with the FMO3 promoter 
luciferase reporter constructs 5kb-length (pRNH1013), 6kb-length (pRNH970) 
or the parent plasmid, pGL3 basic, in HepG2 cells. (A) Luciferase activity was 
measured 48 h after transfection, using a commercial kit. Luciferase activity 
was normalized to total protein and data are presented as mean fold change 
± SE. (B) HepG2 cells were treated with the pro-oxidant, tBHP (100 μM), or 
vehicle 24 h after transfection for 6 h. Luciferase activity was measured 42 h 
after tBHP treatment. Luciferase activity was normalized to total protein and 
presented as mean fold change ± SE. Each experiment was done in triplicate 
and repeated at least three times, and representative experimental results are 
shown. Two-way ANOVA was performed followed by the Bonferroni’s post-
test. Asterisks (*) represent a statistical difference (p < 0.05) from the 
respective empty vector (EV26) transfected group. 
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Figure 5.4 
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Figure 5.4 Effect of tBHP and tBHQ on FMO3-directed reporter gene activity. 
FMO3 promoter luciferase reporter constructs (pRNH1013 & pRNH970) or 
the parent plasmid, pGL3 basic were transiently transfected into HepG2 cells. 
The transfected cells were treated with the pro-oxidant tBHP (100 μM), tBHQ 
(100 μM) or vehicle 48 h after transfection for 6 h.  Luciferase activity was 
measured 42 h following treatment with tBHP or tBHQ. Luciferase activity was 
normalized to total protein and presented as mean fold change ± SE. Each 
experiment was done in triplicate and repeated at least three times, and 
representative experimental results are shown. Two-way ANOVA was 
performed followed by the Bonferroni’s post-test. Statistical comparisons 
revealed no significant differences among the data sets.  
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5.5 Discussion 
 Mammalian FMOs have long been considered non-inducible by 
xenobiotics (Cashman & Zhang, 2002; Krueger & Williams, 2005). Thus, the 
transcriptional regulation of FMO involving stress activated transcription 
factors has not been studied. Recently, Celius et al. (2008, 2010) showed that 
activation of the Aryl hydrocarbon (Ah) receptor by 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) induced Fmo3 mRNA expression in mice. 
The authors also showed that increased Fmo3 mRNA levels in response to 3-
methylcholanthrene (3MC) and benzo(a)pyrene (BaP) treatment, but not by 
TCDD, in Hepa-1 cells was mediated by p53 binding to a response element in 
the Fmo3 promoter region (Celius et al., 2010). A gene array analysis 
performed in our laboratory also identified increased Fmo3 gene expression 
after APAP treatment (O'Connor et al., 2014). We have also demonstrated 
enhanced Fmo3 gene expression after treatment with other hepatotoxicants 
such as alpha-naphthyl isothiocyanate and after bile duct ligation (Rudraiah et 
al., 2014; Rudraiah et al., 2014). Given that all three of these latter treatments 
results in oxidative stress, the goal of the present study was to determine 
whether FMO3 regulation under oxidative stress conditions might involve 
NRF2-KEAP1 regulatory pathway activation, which is known to mediate many 
oxidative-stress induced changes in gene expression. 
 Over-expression of NRF2 induced expression of its known target 
genes, HMOX1 and NQO1 (Aleksunes et al., 2006; Aleksunes & Manautou, 
2007; Aleksunes et al., 2008). With over-expression of KEAP1 we anticipated 
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seeing a significant decrease in HMOX1 and NQO1 expression, but no such 
changes were observed. HMOX1 has also been shown to be regulated by 
hypoxia-inducible factor-1α (HIF-1α) and JNK-1 (Yeligar et al., 2010). 
Similarly, AhR has been shown to regulate NQO1 (Wang et al., 2013; Yeligar 
et al., 2010). It is possible that during over-expression of KEAP1, transcription 
factors other than Nrf2 play a role in maintaining expression of HMOX1 and 
NQO1. Over-expression of NRF2 or KEAP1 did not significantly alter FMO3 
gene expression, suggesting that FMO3 gene regulation does not involve 
NRF2-KEAP1. However, Klick et al. demonstrated that treatment of HepG2 
cells with 5-aza-2’-deoxycytidine (DNA methyl transferase inhibitor) resulted 
in detectable FMO3 expression, consistent with DNA methylation being a 
major mechanism repressing HepG2 FMO3 expression (Klick et al., 2008). 
The DNA methylation-mediated suppression of HepG2 FMO3 may well have 
prevented any NRF2-mediated effects on this gene.  
 To further investigate possible NRF2-mediated FMO3 gene regulation, 
co-transfection studies using two FMO3 promoter luciferase reporter 
constructs (pRNH1013 and pRNH970) were performed. Co-transfection of 
NRF2 or KEAP1 expression vectors along with the FMO3 reporter constructs 
did not significantly alter reporter gene activity. However, co-transfection of 
the NRF2 expression vector and the FMO3 reporter constructs, in addition to 
activation of NRF2 nuclear translocation by a treatment with a subtoxic dose 
of tBHP, did reduce reporter gene activity significantly. Although, this is 
suggestive of a potential NRF2 suppressive effect on FMO3 gene 
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transcription, a 6 kb promoter analysis using MatInspector software 
(Genomatix, Munich, Germany), did not identify any antioxidant response 
element (ARE) site on FMO3 promoter. The decrease in reporter gene activity 
might be due to an indirect mechanism during oxidative stress conditions that 
may or may not involve NRF2. The one other major possibility worth 
evaluating is the activator protein-1 mediated regulation of FMO3. Oxidative 
stress is known to alter signaling through c-Jun N-terminal Kinase  (JNK) and 
related pathways, thus activating AP-1 (Elsby et al., 2003; Enomoto et al., 
2001; Li & Jaiswal, 1992). In addition, promoter analysis discovered four 
binding sites for AP-1 at about 0.7, 0.9, 4.9 and 5.7 kb from the transcription 
start site on the human FMO3 promoter (data not shown).  
 FMO3 reporter construct over-expression along with NRF2 activation 
by tBHP or tBHQ treatment also failed to alter reporter gene activity. The 
tBHP dose used in this study increased NRF2 nuclear translocation and 
expression of the known NRF2 target genes, HMOX1 and NQO1. 
Collectively, these data suggest that FMO3 transcriptional regulation does not 
involve the NRF2-KEAP1 signaling pathway.  
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CHAPTER 6 
Summary 
 Flavin-containing monooxygenase-3 (Fmo3) is a drug-metabolizing 
enzyme involved in oxygenation of a wide variety of endogenous substances 
and xenobiotics (Krueger & Williams, 2005). The importance of mammalian 
FMO in xenobiotic metabolism is known, but its physiological function(s) are 
poorly understood. Among all FMOs in humans, FMO3 is most studied 
because mutant alleles contribute to a disease known as trimethylaminuria or 
fish-odor syndrome. Until recently, Fmo3 gene inducibility by xenobiotics was 
not known. Recent studies with Ah receptor agonists demonstrated increased 
Fmo3 gene expression in mice livers (Celius et al., 2008; Celius et al., 2010). 
A gene array analysis performed previously in our laboratory also 
demonstrated increases in liver Fmo3 gene expression in the mouse model of 
APAP autoprotection (O'Connor et al., 2014). Given the prevalence of APAP-
hepatotoxicity and the human health impact associated with the misuse of this 
popular over-the-counter and prescription medication, a further understanding 
of the mechanism(s) involved in such protection and the identification of new 
genetic determinants of APAP toxicity is of considerable significance. The 
work presented in this dissertation examines Fmo3 gene expression and 
regulation during oxidative stress conditions. Our studies provide the first 
comprehensive analysis of Fmo3 gene and protein expression changes, as 
well as catalytic enzyme activity, in response to treatment with a xenobiotic.  
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The functional significance of Fmo3 over-expression to APAP toxicity was 
also investigated employing both in vitro and in vivo methods.  
 In Chapter 2, we examined Fmo3 mRNA and protein expression 
during APAP-induced liver injury. The significance of FMO3 over-expression 
was also investigated to establish a causal relationship between the Fmo3 
gene expression and APAP hepatotoxicity. It is demonstrated in Chapter 2 
that Fmo3 mRNA expression in response to a single dose of APAP is 
accompanied by marginal increases in Fmo3 protein expression and catalytic 
activity. In contrast to what was observed with a single mildly hepatotoxic 
dose of APAP, both liver Fmo3 mRNA and protein expression are significantly 
higher in mice treated with the APAP autoprotection regimen (pre- and post-
APAP treatment). Fmo3 gene expression alteration was further confirmed by 
examining protein expression by western blotting, immunohistochemistry as 
well as enzymatic assay. Consistent with the protein expression analysis by 
western blotting, Fmo3 catalytic activity and centrilobular zonal expression 
are also significantly greater in the APAP autoprotection group. One of the 
most striking finding in this study is the highly confined distribution of the 
Fmo3 protein around the central vein after APAP in the APAP autoprotected 
livers. Together, these studies suggest that the regulation of Fmo3 gene 
expression (transcriptional and/or translational) is different under the 
conditions of treatment with a single APAP dose versus an autoprotection 
treatment regimen.  
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 The functional significance of Fmo3 over-expression during APAP 
hepatotoxicity was evaluated both in vivo and in vitro. Female mice express 
higher basal Fmo3 levels in liver than male mice (Cherrington et al., 1998; 
Hines, 2006; Janmohamed et al., 2004), and are much more resistant to 
APAP hepatotoxicity compared to males (Dai et al., 2006). MMI inhibition of 
Fmo3 renders female mice highly susceptible to APAP-induced hepatotoxicity 
without altering the magnitude of liver injury produced by APAP in male mice. 
Results from hepatocyte cell line (HC-04) over-expressing FMO3 
demonstrate that enhanced expression of FMO3 confers resistance against 
APAP-induced cytotoxicity. Together, our studies in Chapter 2 indicate that 
Fmo3 gene is inducible following hepatotoxic APAP treatment in mice and 
that FMO3 over-expression is protective against APAP-induced cytotoxicity in 
cultured liver cells. These data provide the foundation for subsequent studies 
aimed at unveiling the function(s) that make Fmo3 a novel genetic 
determinant of APAP toxicity. 
 The purpose of the next set of studies presented in Chapter 3 was to 
investigate Fmo3 gene induction in other mouse models of hepatic injury. 
Hepatotoxicants used in this study include ANIT, CCl4 and AlOH. In addition, 
BDL was used as our fourth model since it is a widely accepted surgical 
intervention producing cholestatic liver injury. Since a common feature of all 
these forms of liver injury is oxidative stress, the potential role of the 
transcription factor Nrf2 in altering Fmo3 gene expression was also 
examined. We show that toxic ANIT and BDL significantly alter Fmo3 mRNA 
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expression. CCl4-mediated liver injury significantly decreased Fmo3 mRNA 
expression and no change in expression is evidenced with AlOH. We also 
observed a toxicity threshold for Fmo3 gene expression in APAP, ANIT and 
BDL livers. Mild to moderate injury in all three models appears to be optimal 
for Fmo3 mRNA induction, while no change and/or reduction in Fmo3 
expression is seen with more pronounced injury. While both cholestasis 
models, toxic ANIT and BDL, significantly alter Fmo3 mRNA expression, 
Fmo3 protein increase is observed only with ANIT. It is possible that under 
more pronounced oxidative stress conditions (as seen in cases of greater 
magnitude of hepatotoxicity) some proteins involved in gene translation are 
oxidized in vivo inhibiting translation (Shenton et al., 2006). The possibility of 
translational inhibition during BDL should not be overlooked.  
 In addition, Fmo3 gene induction is still observed in Nrf2 knockout 
mice in response to APAP treatment, indicating that the transcriptional 
regulation of Fmo3 does not involve Nrf2 signaling. It is also possible that the 
hepatocellular injury that persists at 72 h in Nrf2 KO mice most likely activates 
other signaling mechanisms mediating Fmo3 gene induction. To determine 
whether accumulation of bile acids is a signaling event regulating Fmo3, total 
hepatic and plasma bile acid levels were measured with all hepatotoxicants. 
Consistent with the literature, ANIT and BDL increased plasma and hepatic 
bile acid concentrations. A high CCl4 dose did not significantly alter liver bile 
acid levels, but significantly increased plasma bile acid concentration. APAP 
tended to increase both hepatic and plasma bile acid concentrations, but this 
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is not statistically significant. No change in plasma and hepatic bile acid levels 
were observed with AlOH treatment. Because, ANIT, BDL and APAP that 
induced Fmo3 gene expression also increased hepatic and plasma bile acid 
levels, future studies to address the mouse liver Fmo3 gene regulation should 
investigate the role of nuclear receptor farnesoid X receptor (FXR) in Fmo3 
gene induction. FXR is one of the major bile acid sensors in the liver (Chiang, 
2002) and plays a protective role during cholestasis development. Recently, it 
has also been shown that activation of FXR induces Fmo3 protein function in 
mice (Bennett et al., 2013). Furthermore, activation of FXR can protect 
against APAP-induced hepatotoxicity (Lee et al., 2010). In support of all this, 
we discovered using Matinspector three binding sites for farnesoid X 
receptor-response element (FXRE) on the mouse Fmo3 promoter.  
 Similar to our APAP autoprotection mouse model, human liver can 
adapt to APAP-induced hepatotoxicity (Shayiq et al., 1999; Watkins et al., 
2006). Thus, the goal of Chapter 4 was to investigate FMO3 gene induction 
in a human hepatoma cell line, HepaRG cells. HepaRG cell line is a recently 
developed cellular model that expresses a more normal spectrum of drug 
metabolizing enzymes comparable to human hepatocytes. The mechanistic 
features of APAP-induced hepatotoxicity in HepaRG cells are similar to that 
reported for mouse primary hepatocytes and mouse liver in vivo (McGill et al., 
2011). Experiments in Chapter 4 demonstrate FMO3 gene induction during 
APAP-induced cytotoxicity. This is the first report showing induction of FMO3 
by a xenobiotic treatment in human hepatocytes.  
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 Furthermore, to study the functional significance of FMO3 over-
expression during APAP-induced cytotoxicity, HepaRG cells over-expressing 
FMO3, as an alternative in vitro system, were developed. As described 
previously in this dissertation (Chapter 2), we had already established the 
hepatocyte cell line HC-04 over-expressing human FMO3 (hFMO3-HC-04). 
HepaRG cells differ from HC-04 cells in that the constitutive FMO3 
expression is very high, which is comparable to adult human liver. FMO3 
over-expression in HepaRG cells was assumed to model FMO3 over-
expression during APAP treatment in human liver/hepatocytes. Consistent 
with results from hFMO3-HC-04 cells, the results from hFMO3-HepaRG cells 
also show that FMO3 over-expression alters susceptibility to APAP-induced 
hepatotoxicity. Most importantly and highly intriguing, our data with the 
HepaRG cells show that FMO3 may play an important role in cellular 
differentiation. The potential role for FMO3 in cellular differentiation is 
consistent with the latent profile of Fmo3 protein expression changes we 
observed in vivo in our APAP autoprotection mouse model (Chapter 2). It 
remains to be determined the mechanism underlying the faster rate of cell 
differentiation driven by FMO3 over-expression in HepaRG cells. Future 
studies that could aid in not only characterizing the functions of Fmo3 that 
make it a genetic determinant of APAP hepatotoxicity, but also its potential 
role in speeding cell differentiation are planned employing transcriptomics, 
proteomics and possibly RNA-seq approaches. The goal of these proposed 
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studies is to identify signaling pathway(s) and cellular events associated with 
FMO3 function that may be relevant to the main findings of this dissertation. 
 Toxic APAP, ANIT and BDL induce Fmo3 gene expression in mice. A 
common event for all hepatotoxicants that induce Fmo3 in mice is oxidative 
stress, and activation of Nrf2-Keap1 regulatory pathway. NRF2 target gene 
NQO1 induction is also reported in human liver samples obtained from 
patients during transplantation following APAP overdose (Aleksunes et al., 
2006). The results in Chapter 3 with Nrf2 null mice show that Fmo3 is not 
regulated by transcription factor Nrf2 but FMO3 gene regulation and promoter 
sequences differ between humans and mice. Thus, the experiments in 
Chapter 5 were aimed to investigate whether NRF2 regulates human FMO3 
gene expression. Constitutive FMO3 expression is repressed in HepG2 cells 
(Klick et al., 2008). Thus, HepG2 cells were used for all experiments in this 
study. Co-transfection studies with FMO3 promoter luciferase reporter 
constructs (5 kb or 6 kb) and NRF2 or its cytosolic retainer Kelch-like ECH-
associated protein 1 (KEAP1) did not significantly alter luciferase reporter 
gene activity. Subsequent promoter analysis using Matinspector did not 
identify any antioxidant response element (ARE) sites on reporter constructs 
used in the current study. Based on these results we concluded that the 
transcriptional regulation of FMO3 might not involve NRF2-KEAP1 regulatory 
pathway.  
Although, investigating FMO3-driven HepaRG differentiation is a 
potential subject of future innovative research, the possible involvement of 
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FMO in maintaining cellular thiol:disulphide ratios deserves consideration also 
and should not be overlooked. The relationship between cellular 
thiol:disulphide ratios and the regulation of metabolic reactions is very well 
documented (Barron, 1953). Cysteamine is a substrate for FMO3 oxygenation 
and oxygenation of cysteamine during APAP hepatotoxicity may serve to help 
control the overall thiol:disulphide redox state of the cell. This in turn may 
modulate cellular metabolism and/or activate signal transduction pathway 
leading to altered susceptibility to APAP (or protection). Thus, strengthening 
cellular defenses and heightened toxicant tolerability. It is also possible that 
oxygenation of cysteamine to cystamine by Fmo3 and transport out of the cell 
also may represent a detoxication mechanism and/or protective event, 
because cysteamine is toxic to cells at concentrations as low as 39 µM 
through the transition metal-dependent formation of hydrogen peroxide 
(Jeitner & Lawrence, 2001). To investigate whether oxygenation of 
cysteamine to cystamine by Fmo3 is important during APAP hepatotoxicity, 
follow-up studies will measure the total hepatic cysteamine and cystamine 
concentrations in the mouse model of APAP autoprotection. Together, this 
work not only supports the usefulness, but also validates the use of 
transcriptomic analysis for identifying genetic determinants of diseases and 
adverse reactions to chemicals (e.g. chemical-induced hepatotoxicity). Both 
the in vitro and in vivo approaches used in this study represent valuable tools 
for investigating the involvement of FMO3 during APAP-induced hepatic 
injury.  
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